意见反馈 手机随时随地看行情
  • 公司公告

公司公告

华东医药:2021年半年度报告(英文版)2021-09-04  

                                          The Half Year Report 2021 of Huadong Medicine Co., Ltd




Huadong Medicine Co., Ltd.

  The Half Year Report 2021




        August 2021




                                                                      1
                                             The Half Year Report 2021 of Huadong Medicine Co., Ltd




        Section I. Important Declaration, Contents and Definitions


     The Board of Directors, Board of Supervisors, directors, supervisors and

senior management of Huadong Medicine Co., Ltd. (hereinafter referred to as

the “Company”) hereby guarantee that the information presented in this half

year report is authentic, accurate and complete and free of any false records,

misleading statements or material omissions, and shall undertake individual and

joint legal liabilities.

     Lv Liang, the Company’s legal representative and the officer in charge of

accounting, and Qiu Renbo, head of accounting department (accounting

supervisor) hereby declare and guarantee that the financial statements in this

half year report are authentic, accurate and complete.

     All directors have attended the Board of Directors meeting to review this

half year report.

     The future plans, development strategies and other forward-looking

statements in this half year report shall not be considered as substantial

commitment of the Company to investor. Investors and related parties should

maintain sufficient risk awareness, and should understand the difference

between plans, forecasts and promises. Investors are kindly reminded to pay

attention to possible investment risks.

     The Company faced various risks in its operations, involving industry


                                                                                                 2
                                               The Half Year Report 2021 of Huadong Medicine Co., Ltd



policies, markets, R&D of new drugs, product price reduction, etc. For details,

refer to “X. Risks and Countermeasures” in “Section III. Discussion and

Analysis of the Management”. We thank all investors for paying attention to the

Company’s operations, and we hope that you can be aware of investment risks.

     The company does not plan to distribute cash dividends, no bonus share

will be issued; and no capital reserve will be converted to increase the share

capital.

     According to “Stock Listing Rules of the Shenzhen Stock Exchange”, if

listed companies have both Chinese or other language version of public notice,

they should ensure the content of both versions are the same. In the case of

discrepancy, the original version in Chinese shall prevail.




                                                                                                   3
                                                                  The Half Year Report 2021 of Huadong Medicine Co., Ltd




                                                   Contents




Section I. Important Declaration, Contents and Definitions ......................................... 2

Section II. Company Profile and Key Financial Indicators .......................................... 8

Section III. Discussion and Analysis of the Management........................................... 11

Section IV. Corporate Governance .............................................................................. 45

Section V. Environmental and Social Responsibility .................................................. 46

Section VI. Important Matters ..................................................................................... 59

Section VII. Share Change and Shareholders ............................................................. 84

Section VIII. Preferred Shares..................................................................................... 89

Section IX. Information about Bonds ......................................................................... 90

Section X. Financial Report ........................................................................................ 91




                                                                                                                      4
                                                The Half Year Report 2021 of Huadong Medicine Co., Ltd




                   Documents Available for Reference




     I. Financial Statements carrying the signatures and stamps of the Company

Principal, the Chief Financial Officer and the person in charge of accounting firm;

     II. Original copies of all documents and the announcements thereof disclosed in

the reporting period on the designated newspaper.




                                                                                                    5
                                                                  The Half Year Report 2021 of Huadong Medicine Co., Ltd




                                                 Definitions


                     Term                  refers to                                 Definition

CSRC                                       refers to China Securities Regulatory Commission

SSE                                        refers to Shenzhen Stock Exchange

Huadong Medicine/the Company/our Company   refers to Huadong Medicine Co., Ltd.

CGE                                        refers to China Grand Enterprises, Inc.

Huadong Medicine Group                     refers to Hangzhou Huadong Medicine Group Co., Ltd.

Zhongmei Huadong                           refers to Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

Jiangdong Company                          refers to Hangzhou Zhongmei Huadong Pharmaceutical Jiangdong Co., Ltd.

Jiuyang Bio                                refers to Jiangsu Jiuyang Biopharm Co., Ltd.

Xi’an Bohua                               refers to Huadong Medicine (Xi’an) Bohua Pharmaceutical Co., Ltd.

Jiuyuan Gene                               refers to Hangzhou Jiuyuan Gene Engineering Co., Ltd.

Doer Biologics                             refers to Zhejiang Doer Biologics Corporation

Huadong Ningbo Company                     refers to Huadong Ningbo Medicine Co., Ltd.

Chongqing Peg-Bio                          refers to Chongqing Peg-Bio Biopharm Co., Ltd.

Qyuns Therapeutics                         refers to Qyuns Therapeutics Co., Ltd.

Nuoling Biomedical                         refers to Nuoling Biomedical Technology (Beijing) Co., Ltd.

Yuanda Investment Management               refers to Shanghai Yuanda Investment Management Co., Ltd.

Fuguang Chengdu                            refers to Fuguang Chengdu Equity Investment Management Co., Ltd.

Hangzhou High-Tech                         refers to Hangzhou High-Tech Venture Capital Management Co., Ltd.

Yuanda Huachuang                           refers to Beijing Yuanda Huachuang Investment Co., Ltd.

Hangzhou Heda                              refers to Hangzhou Heda Industrial Fund Investment Co., Ltd.

Pharmaceutical Industry Fund/Fuguang
                                           refers to Hangzhou Fuguang Hongxin Equity Investment Partnership (L.P.)
Hongxin

Sinclair                                   refers to Sinclair Pharma Limited

vTv Company                                refers to vTv Therapeutics LLC

R2                                         refers to R2 Technologies,Inc.

MediBeacon                                 refers to MediBeacon Inc.

ImmunoGen                                  refers to ImmunoGen, Inc.

Provention Bio                             refers to Provention Bio, Inc.

RAPT                                       refers to RAPT Therapeutics,Inc.


                                                                                                                      6
                                                                    The Half Year Report 2021 of Huadong Medicine Co., Ltd


Kylane                                     refers to Kylane Laboratoires SA

High Tech                                  refers to High Technology Products, S.L.U.

LG                                         refers to LG Chem Ltd

Jetema                                     refers to Jetema. Co,.ltd

Exscientia                                 refers to Exscientia Ltd.

GMP                                        refers to Good Manufacturing Practice

CGMP                                       refers to Current Good Manufacture Practices

GSP                                        refers to Good Supply Practice

BE                                         refers to Bioequivalence

                                                       Center for Drug Evaluation (of National Medical Products
CDE                                        refers to
                                                       Administration)

MAH                                        refers to Marketing Authorization Holder

FDA                                        refers to (U.S.) Food and Drug Administration

NMPA                                       refers to National Medical Products Administration

NDA                                        refers to New Drug Application

ANDA                                       refers to Abbreviated New Drug Application

                                                       International Council for Harmonisation (of Technical Requirements
ICH                                        refers to
                                                       for Pharmaceuticals for Human Use)

IND                                        refers to Investigational New Drug

PK/PD                                      refers to pharmacokinetics/pharmacodynamics

CMC                                        refers to Chemistry, Manufacturing and Control

CMO                                        refers to Contract Manufacturing Organization

CDMO                                       refers to Contract Development and Manufacturing Organization

PMA                                        refers to Premarket Application

QA                                         refers to Quality Assurance (department)

                                                       Catalogue     of       Drugs   for    Basic    National     Medical
Catalogue of Drugs for Insurance(2020)   refers to
                                                       Insurance/Employment Injury Insurance/Birth Insurance(2020)

ADC                                        refers to Antibody-Drug Conjugate

EHS                                        refers to Environment、Health、Safety

                                                       Drugs that can only be purchased and used according to prescriptions
Prescription Drugs                         refers to
                                                       issued by physicians

OTC                                        refers to Over The Counter

MRCT                                       refers to International Multi-center Clinical Trial

RWS/RWR                                    refers to Real World Study/Real World Research




                                                                                                                              7
                                                                            The Half Year Report 2021 of Huadong Medicine Co., Ltd




            Section II. Company Profile and Key Financial Indicators

I. Company information

Stock name (abbreviation)       Huadong Medicine                          Stock code                     000963

Stock listed on                 Shenzhen Stock Exchange

Company name in Chinese         华东医药股份有限公司

Company name in Chinese
                                华东医药
(abbreviation, if any)

Company name in English (if
                                HUADONG MEDICINE CO., LTD
any)

Company name in English
                                HUADONG MEDICINE
(abbreviation, if any)

Legal representative            Lv Liang


II. Contact persons and contact information

                                                 Secretary of the Board of Directors            Securities Affairs Representative

Name                                         Chen Bo                                       /

Contact address                              866 Moganshan Road, Hangzhou                  /

Tel.                                         0571-89903300                                 /

Fax                                          0571-89903300                                 /

Email address                                hz000963@126.com                              /


III. Other information

1. Company’s contact information

Whether there is any change in the Company’s registered address, office address, zip code, company website or company email
address during the reporting period.
□ Applicable     √ N/A
There is no change in the Company’s registered address, office address, zip code, company website or company email address during
the reporting period. For details, please refer to 2020 Annual Report.


2. Information disclosure and place of the report

Whether there is alteration in information disclosure and place of the report during the reporting period.
□ Applicable     √ N/A


                                                                                                                                    8
                                                                              The Half Year Report 2021 of Huadong Medicine Co., Ltd


The media selected by the Company for information disclosure, the website designated by CSRC for publication of the half year
report, and the location of preparation of the Company’s half year report have not changed during the reporting period. For details,
please refer to the 2020 Annual Report.


IV. Key accounting data and financial indicators

Whether the Company needs to perform a retroactive adjustment or restatement of previous accounting data
□Yes    √No

                                                                                                                  Change of the current
                                                Current reporting period         Same period last year          reporting period over the
                                                                                                                same period last year(%)

Operating revenue (yuan)                                 17,179,437,902.61                16,660,934,157.64                          3.11%

Net profit attributable to shareholders of
                                                          1,300,346,324.85                 1,731,184,721.25                       -24.89%
listed companies (yuan)
Net profit attributable to shareholders of
listed companies after deducting                          1,193,980,887.18                 1,406,723,973.10                       -15.12%
non-recurring gains/losses (yuan)
Net cash flow from operating activities
                                                          1,738,512,372.11                 1,255,542,667.29                        38.47%
(yuan)

Basic earnings per share (yuan/share)                                0.7431                           0.9894                      -24.89%

Diluted earnings per share (yuan/share)                              0.7431                           0.9894                      -24.89%

Weighted average return on equity (ROE)                              8.54%                           13.12%                         -4.58%

                                                                                                                Change of the end of the
                                               End of the current reporting
                                                                                       End of last year         current reporting period
                                                          period
                                                                                                               over the end of last year(%)

Total assets (yuan)                                      26,108,178,089.87                24,201,348,154.75                         7.88%

Net assets attributable to shareholders of
                                                         15,567,274,148.76                14,619,821,308.60                         6.48%
listed companies (yuan)

Share capital of the Company as of the trading day before disclosure

Share capital of the Company as of the trading day before
                                                                                                                             1,749,809,548
disclosure (share)

Fully diluted earnings per share calculated on the basis of the latest Share capital

Dividends paid on preferred shares                                                                                                     0.00

Perpetual bond interest paid (yuan)                                                                                                    0.00

Fully diluted earnings per share calculated on the basis of the
                                                                                                                                    0.7431
latest Share capital (yuan/share)




                                                                                                                                              9
                                                                           The Half Year Report 2021 of Huadong Medicine Co., Ltd


V. Differences in accounting data under domestic and overseas accounting standards

1. Differences in net profit and net assets disclosed in financial statements under international and Chinese
accounting standards

□ Applicable   √ N/A
There are no differences in net profit and net assets disclosed in financial statements under international and Chinese accounting
standards.


2. Differences in net profit and net assets disclosed in financial statements under overseas and Chinese
accounting standards

□ Applicable   √ N/A
There are no differences in net profit and net assets disclosed in financial statements under overseas and Chinese accounting
standards.


VI. Items and amounts of non-recurring gains/losses

√ Applicable   □ N/A
                                                                                                                          Unit: RMB yuan

                               Item                                           Amount                                Note

Gains/losses on disposal of non-current assets (including the
                                                                                      -110,119.08
written-off part of the accrued assets impairment reserve)

Government grants included in current gains/losses (excluding                                        Mainly due to the confirmation of
those closely related to operating activities and measured                        138,308,095.20 government grants by
according to unified national standards)                                                             subsidiaries in the current period.

Receivables subject to separate impairment test and reversal of
                                                                                    5,388,185.00
reserve for impairment of contract assets

Other non-operating revenue or expenditure expect
                                                                                    -4,916,566.97
above-mentioned items

Minus: Amount affected by income tax                                               22,095,294.54

     Amount affected by rights and interests of minority
                                                                                   10,208,861.94
stakeholders (after tax)

Total                                                                             106,365,437.67                     --

If the Company recognizes an item as a non-recurring gain/loss based on the “Interpretative Announcement No. 1 on Information
Disclosure Criteria for Public Companies – Non-Recurring Profit/Loss” or recognizes an item satisfying the definition of
non-recurring gain/loss in the announcement as a recurring gain/loss, reasons should be specified.
□ Applicable   √ N/A
No such case during the reporting period.




                                                                                                                                       10
                                                           The Half Year Report 2021 of Huadong Medicine Co., Ltd




           Section III. Discussion and Analysis of the Management

I. Main business of the company during the reporting period

     1. Main business of the company
     Huadong Medicine Co., Ltd. (stock code: 000963), founded in 1993 and headquartered in
Hangzhou, Zhejiang Province, was listed on Shenzhen Stock Exchange in December 1999. After
more than 20 years of development, its business covers the whole pharmaceutical industrial chain.
With the pharmaceutical industry as its core, the Company expands its medicine business and
aesthetic medicine industry. It has developed into a large comprehensive listed pharmaceutical
company integrating R&D, production and sales of medicine.
     The pharmaceutical industry of the Company focuses on R&D, production and sales of
specialist medication, chronic disease medication and medication for special purposes. The Company
has formed core product pipelines in such fields as chronic kidney diseases, transplantation immunity,
internal secretion and gastrointestinal system, and owns a number of first-line clinical medications
with market advantages in China. Meanwhile, through independent development, external
introduction and project cooperation, the Company focuses on the R&D layout of innovative drugs
and generic drugs with high technical barriers in the three core fields of anti-tumor, internal secretion
and autoimmunity. The Company continues to carry out international product registration,
international certification, consistency evaluation, etc., and continues to achieve results, forming an
international pharmaceutical industry system.
     The Company has four business segments, including Traditional Chinese Medicine (TCM) and
Western Medicine, medical devices, ginseng, antler and other herbs, and health industry, covering
pharmaceutical wholesale, pharmaceutical retail, third-party pharmaceutical logistics characterized
by cold chain, pharmaceutical e-commerce, hospital value-added service, and featured mega health
industry, providing customers with integrated solutions.
     Committed to the R&D, production and sales of a series of advanced international aesthetic
brands and high-end aesthetic medicine products, the Company’s aesthetic medicine business
targets the global high-end aesthetic medicine market and focuses on the R&D, production and
sales of the latest products and devices in facial micro-plastic surgery and skin management.
Sinclair, a wholly-owned subsidiary of the Company that is headquartered in the United Kingdom,
has production bases in France and the Netherlands, and promotes and sells long-effect microsphere
fillers for injection, hyaluronic acid, as well as face thread lift products in the global market.

                                                                                                              11
                                                           The Half Year Report 2021 of Huadong Medicine Co., Ltd


Sinclair is the global operation platform of the Company for aesthetic medicine business. The
aesthetic medicine sector also includes High Tech (Spain), an overseas wholly-owned subsidiary,
R2 (USA) and Kylane (Switzerland), two partially-owned subsidiaries, and Huadong Ningbo
Medicine Co., Ltd., a domestic holding subsidiary.
     2. Overview of the Company’s operations during the reporting period
     2021 is not only the first year of China’s “14th Five-Year Plan” period, but also a year of
transition, in which China’s pharmaceutical industry has entered a new stage of development and the
market pattern has changed dramatically. In the post-pandemic period, China’s economy maintains
its recovery momentum and is driving the unleashing of the potential of domestic demand. However,
as the COVID-19 pandemic breaks out repeatedly, the global economic situation is complex and
severe, and the international situation is still subject to many unstable and uncertain factors.
     2021 is still an extraordinary year for the Company, with overflowing huge difficulties and
pressure. With the gradual national and local normalization of volume-based procurement of drugs,
the quantity and category of drugs have been gradually expanded and are being advanced in depth.
The backward forcing effect of medical insurance policies has become increasingly pronounced, and
the reform of the medical insurance payment mechanism has been accelerating. In the context of
medical insurance cost control and clinical value first, DRG/DIP has been extensively piloted at the
same time, and the assessment of rational drug use by medical institutions has been put on the agenda.
Therefore, hospitals’ sales model of drugs and competitive landscape will also undergo major
changes. The pharmaceutical market and pharmaceutical enterprises are still facing a huge policy
shock. In July 2021, the Center for Drug Evaluation of National Medical Products Administration
issued the draft for comments of the Guidelines for Clinical Value-based Clinical Research and
Development of Anti-tumor Drugs, which caused widespread concern in the industry. The concept of
“Clinical value-based” will become a significant factor in innovative drug R&D strategies in the
future.
     In the first half of 2021, despite the dual challenges of industry policy and market competition,
the Company continued to follow the trend, actively pursued changes, and focused on innovation. It
implemented its strategic planning around its annual business objectives, and made great efforts to
overcome the staged impact of the price reduction of some products, maintaining the stable
development of overall operations. Furthermore, it achieved new breakthroughs in the three major
sectors of the pharmaceutical industry, pharmaceutical commerce, and aesthetic medicine business,
laying a solid foundation for the realization of the annual business objectives.
     During the reporting period, the Company achieved an operating income of RMB17.179
billion, up 3.11% year on year; the net profit attributable to the shareholders of the listed company

                                                                                                              12
                                                           The Half Year Report 2021 of Huadong Medicine Co., Ltd


was RMB1.3 billion, down 24.89% year on year, and the net profit attributable to the shareholders
of the listed company after deducting non-recurring gains/losses was RMB1.194 billion, down
15.12% year on year. During the reporting period, Hangzhou Zhongmei Huadong Pharmaceutical
Co., Ltd., the core subsidiary of the Company achieved an operating income of RMB5.424 billion,
down 10.85% year on year, and its net profit was RMB1.192 billion, down 13.49% year on year; in
the second quarter, due to the impact of product price reduction, the operating income of Zhongmei
Huadong decreased by 5.35% year on year (the first quarter down 14.58% year on year), its net
profit decreased by 11.67% year on year (the first quarter down 14.6% year on year), and the
decline narrowed significantly compared with the first quarter. In the first half of this year, the sales
volume and market share of Acarbose products of Zhongmei Huadong kept rising year on year, and
its transplantation immunity and cardiovascular products maintained rapid growth. In the second
half of the year, the Company will deepen its implementation of innovation and transformation, and
strive to achieve the business indicators of the pharmaceutical industry in 2021 to meet and exceed
the goals of last year. During the reporting period, Huadong Pharmaceutical Distribution Company
continued to show a gradual recovery in its overall business; the growth in the first quarter was
relatively rapid due to the low year-on-year base, and the growth in the second quarter stabilized.
During the reporting period, the operating income was RMB11.765 billion, up 9.34% year on year;
     In the aesthetic medicine business, the Company continued to maintain recovery, with an
overall operating income of RMB565 million during the reporting period, up 46.25% year on year.
The overseas aesthetic medicine business maintained rapid growth despite the repeated outbreak of
the COVID-19 pandemic. During the reporting period, Sinclair (the UK) showed a clear recovery in
its overall business. As orders from the international market increased significantly, and the sales of
high-end hyaluronic acid filler MaiLi series newly launched in the European market and Korean
Lanluma (poly-L-lactic acid (PLLA) collagen stimulant) on commission were better than expected,
Sinclair achieved a year-on-year growth of 111.28% in its operation income (including the newly
acquired Spanish company High Tech), in which Sinclair’s own income rose by 74%. It is expected
to maintain the current operating trend in the second half of the year. In the second half of the year,
the Company will continue to accelerate the progress of clinical registration of other core aesthetic
medicine products at home and abroad. In addition, following the official launching of
polycaprolactone microsphere facial filler Ellansé for injection, the Company’s core aesthetic
medicine product, in the Chinese mainland market in August, Glacial Spa (F0), a cold-touch
cosmetic instrument from R2 Company (the USA), is expected to officially enter the Chinese
mainland market in the third quarter, which is expected to drive new performance growth in the
Company’s aesthetic medicine business.

                                                                                                              13
                                                           The Half Year Report 2021 of Huadong Medicine Co., Ltd


     The main reasons for the year-on-year decrease in the Company’s net profit during the reporting
period were as follows: (1) The income and gross profit of some products of Zhongmei Huadong
slightly decreased year on year due to the price reduction after the implementation of the national
centralized procurement and National Drug Reimbursement List (NDRL) price negotiations; (2) The
Company’s non-recurring gains and losses in the first quarter of 2020 were RMB290 million,
including a net income of GBP30.65 million from the transfer of regional product distribution rights
by Sinclair to Galderma, which greatly increased the Company’s overall income in the first quarter of
2020. No such matters occurred during the reporting period, and other non-recurring gains and losses
totaled RMB106 million, resulting in a further decrease in the net profit attributable to shareholders of
the listed company year on year.
     (1) Pharmaceutical industry
     During the reporting period, under the continuous influence of the normalization of centralized
drug procurement and the increasing fluctuation of demand caused by market competition, the
Company practiced the value-oriented lean manufacturing concept and adhered to technological
innovation and the agile production mode to cope with market competition and changes. In terms of
production, the Company explored its potential internally, and made multi-dimensional and
multi-level efforts to promote lean management from aspects of process optimization, technology
improvement, process innovation, flexible employment, supplier development, and bidding and
purchasing negotiations, effectively improving product quality and labor efficiency per capita and
reducing production costs. Externally, it continued to promote product transfer and outsourcing, and
expanded production capacity. With the capacity release in the new workshop of international R&D
and manufacturing center for preparations, the production capacity has been further guaranteed and
expanded, which also laid the foundation for the international development of preparation products.
     In the first half of 2021, for the core purposes of changing the concept and realizing the
transformation from cost center to profit center, the Company launched the reform of production
system and CMC system. It mobilized various departments by formulating targeted incentive
programs. Taking the acceleration of the development of industrial microbiology-based strategic
planning as a breakthrough, the Company made progress in project commercialization, and made
great breakthroughs in the export of high-end bulk drugs CMO and CDMO. On this basis, it further
increased investment, in hope of quickly building industrial chain in the field of industrial
microbiology, occupying the high ground in the industry, and achieving industrialization. The
project of Huadong Medicine Biomedical Science and Technology Park has officially commenced,
and the construction is pushed forward as planned. In terms of EHS tasks, the Company
implemented the whole staff EHS responsibility system and the concept of process risk control

                                                                                                              14
                                                         The Half Year Report 2021 of Huadong Medicine Co., Ltd


around R&D, production and industrial park construction, and improved its EHS management and
control capabilities through the building of both tiered risk management and control system and
hidden risk screening and management system.
     During the reporting period, Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
continued to take effective countermeasures regarding national centralized drug procurement
projects, centralized procurement by inter-provincial alliances, provincial- and city-level centralized
procurement, GPO projects, etc. On the premise of actively anticipating policy, it fully analyzed its
own capabilities and advantages, and set up the concept of development based on strategy,
improving its all-round marketing capabilities. It continued to adhere to the marketing strategy of
“equal attention to out-of-hospital market and in-hospital market, and equal attention to the medical
insurance market and the self-paying market, equal attention to online and offline markets, and
vigorous expansion of the county-level and primary-level markets”, attached great importance to
patient education, kept reforming and adjusting the marketing structure, accelerated the formation
of the full-time sales force, increased the coverage of the primary-level and blank markets, and
expanded the out-of-hospital promotion teams. The Company accelerated the hospital development
and sales volume increase of the varieties that were newly approved for launching. It continued to
boost the development and coverage of Acarbose Tablets in the out-of-hospital market and Acarbose
Chewable Tablets in the in-hospital market, maintain the stock market, strive for the margin market,
and cover the blank market. Although the impact of price reduction of such products as Bailing
Capsule and Pantoprazole continued, bringing phased pressure to the Company’s revenue growth,
the situation has stabilized. It is expected that the impact of product price reduction on the Company
in the second half of the year will fade away, and the overall revenue of the pharmaceutical industry
is expected to stabilize and recover. The Company will deepen its implementation of innovation and
transformation, make great efforts to mitigate the impact of lower product prices, and strive to
achieve the business indicators of the pharmaceutical industry in 2021 to meet and even exceed the
goals set last year.
     During the reporting period, the Company continuously improved its product pipelines, kept
up with the forefront of global R&D, spared no effort to deploy global innovative drugs with
foresight based on clinical value, differentiation and technology, rapidly supplemented the
innovative product pipelines, and consolidated the generic drug product pipeline in the chronic
disease field that has formed a competitive advantage in the market, rapidly establishing and
enriching product clusters and echelons. The Company made great progress in the quantity and
quality of its own R&D projects and introduced projects: (1) The Company invested RMB487.5
million to acquire 75% of Hangzhou Doer Biologics’ shares and became its controlling shareholder.

                                                                                                            15
                                                          The Half Year Report 2021 of Huadong Medicine Co., Ltd


Doer Biologics, an R&D enterprise with multiple independent intellectual property rights and a
unique protein engineering technology platform, specializes in the development of innovative
biological drugs. It focuses on the development of multi-domain-based multi-specific innovative
fusion proteins, antibody drugs and peptide drugs to meet unmet clinical needs in the fields of
oncology, metabolism, ophthalmology, etc. It has an excellent R&D team of 50 professionals. (2) In
the field of autoimmunity, in February 2021, the Company introduced HDM3002 (PRV-3279), a
product under development by Provention Bio (USA), which is used to treat systemic lupus
erythematosus (SLE) and bispecific antibody that prevents or reduces the immunogenicity of gene
therapy. The phase II international multi-center clinical research for the product is being carried out.
At present, pre-IND materials have been submitted in China. (3) In the field of diabetes, in June
2021, the Company introduced the product SCO-094 of SCOHIA PHARMA, Inc. (Japan) under the
development in clinical phase I, which is a global innovative dual agonist of GLP-1R and GIPR
targets for the treatment of such diseases as type 2 diabetes, obesity and non-alcoholic
steatohepatitis (NASH). Through the investment layout in the above fields, the Company has
preliminarily formed its R&D ecosystem. While optimizing the innovation system, the Company
strengthened the introduction of advanced clinical medicine talents and the development of
organizational structure, accelerated the progress of clinical projects and implementation. All those
efforts made achievements.
     (For details of the R&D pipelines and related work, refer to the R&D related content in this
chapter.)
     During the reporting period, Pantoprazole Injection (trade name: Pan Li Su) from the
wholly-owned subsidiary of the Company, Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.,
won the bid in the fourth batch of national drug centralized procurement, and Decitabine for
injection (trade name: Xiang Ke) won the bid in the fifth batch of national drug centralized
procurement, which will help consolidate and expand the market share, establish the Company’s
high-quality brand, enhance market reputation and influence, and has a positive impact on the
Company’s market expansion for follow-up products in the digestion and anti-tumor fields.
     (2) Pharmaceutical commerce
     During the reporting period, the Company’s pharmaceutical commerce accelerated the
innovation-driven corporate development, adhered to the concept of “good products always stand
for the first productivity”, consolidated the traditional pharmaceutical commerce, reshaped its core
competitiveness, surpassed its peers with innovation, and continued to build itself into a leading
service provider in the pharmaceutical industry in Zhejiang Province.
     It properly carried out the introduction of new products and cooperation with suppliers, and

                                                                                                             16
                                                         The Half Year Report 2021 of Huadong Medicine Co., Ltd


made great efforts to build a province-wide market expansion network, form a promotion team for
the in-hospital and private hospital markets, enrich product lines, and foster new profit models. In
terms of innovation drive, the Company sought breakthroughs from four directions: market
expansion, e-commerce business, cold chain logistics and characteristic mega health industry. It
changed the operational thinking, optimized the in-hospital market, and made arrangements for the
out-of-hospital market. At the same time, the Company properly carried out access services,
expanded the provincial market of high-value products such as narcotic and psychotropic drugs,
medical devices, ginseng, antler and other medicinal materials. All subsidiaries set up specialized
sales teams, giving play to the synergy between the headquarter and subsidiaries, and conducted
two-way assessments. The Company laid out the out-of-hospital market, focusing on the expansion
of OTC business, including pharmacies near hospitals, social pharmacies, Internet medical
cooperation, online order delivery, etc. It actively participated in the digital reform of medical and
health services in Zhejiang Province, provided support to open up the full channel of “Internet +
diagnosis and treatment”, and took the lead in completing the first medicine delivery services of
“Internet + Medical Service” for many provincial hospitals. It continued to undertake medicine
delivery services for chronic illness long-term prescriptions from dozens of community service
centers in Hangzhou; the Internet out-of-hospital delivery business in Shaoxing, Huzhou, Jiaxing,
Wenzhou, Ningbo, Jinhua, Lishui and other regions was also rapidly expanding.
     It also accelerated the development of e-commerce business, upgraded its own platform, and
promoted B2C/B2B/O2O/H2C and other modes of business through third-party channels. Relying
on its independent B2B e-commerce platform and supported by modern pharmaceutical logistics
and distribution system, the Company provided distribution services of drugs, medical devices and
other products for the second and third terminals in Zhejiang Province and even the whole country.
It entered the 2021-2022 list of key cultivating e-commerce platforms in Zhejiang Province. During
the reporting period, Huadong Medicine Supply Chain Management (Hangzhou) Co., Ltd., a
wholly-owned subsidiary, was awarded the first express business license of a pharmaceutical cold
chain enterprise in Zhejiang Province issued by Zhejiang Provincial Postal Administration, setting a
benchmark for enterprises in the field; it also obtained the qualification of third-party vaccine
storage and transportation service from Zhejiang Provincial Center for Disease Control and
Prevention, becoming the exclusive service provider in the province to provide safe and specialized
storage and distribution guarantee for the vaccination in the whole province against COVID-19. In
addition, it has completed the planned tasks for the first half of the year in an efficient and timely
manner, boosting the universal vaccination to combat the COVID-19 pandemic.
     In March 2021, the wholly-owned subsidiary of the Company located in Chengdu officially

                                                                                                            17
                                                         The Half Year Report 2021 of Huadong Medicine Co., Ltd


obtained the Internet hospital license — Practice License for Medical Institutions, and officially
commenced the construction of the “Internet platform” of Huadong Medicine.
     (3) Aesthetic medicine business
     The aesthetic product portfolio of Huadong Medicine’s aesthetic medicine business covers the
mainstream non-surgical aesthetic medicine fields such as facial fillers, body shaping, catgut
embedding and energy source devices. The Company has formed a comprehensive product cluster
integrating full product portfolios of differentiated sodium hyaluronate, collagen stimulator,
botulinum toxin type A, catgut embedding and implanting, and energy source devices, achieving a
comprehensive layout of the “non-invasive + minimally invasive” aesthetic medicine industrial
chain. Huadong Medicine’s aesthetic medicine business focuses on the breakthrough and innovation
in the field of aesthetics, and is committed to providing comprehensive and scientific aesthetic
products. The sector is equipped with independent R&D departments, including four global R&D
centers, namely, wholly-owned subsidiaries Sinclair (UK) and High Tech (Spain), and
partially-owned companies R2 (USA) and Kylane (Switzerland), and five production bases in the
Netherlands, France, the United States, Switzerland and Bulgaria, with the core products launched
in more than 60 countries and regions.
     During the reporting period, Sinclair (UK), a wholly-owned subsidiary of the Company,
acquired 100% equity in High Tech, a Spanish company engaged in energy source aesthetic
medicine devices. Since then, the latter officially became a major part of the Company’s landscape
of global aesthetic medicine business and is included in the consolidated statements of Sinclair and
the Company. Sinclair and High Tech have started to work together on market and business
collaboration and integration; the Company is formulating the launching plans for High Tech’s five
products on sale overseas and four innovative products under R&D, and plans to start the
registration of core products in China in 2021.
     During the reporting period, Ellansé, a polycaprolactone microsphere facial filler for injection,
the core product of Sinclair, obtained the Medical Device Registration Certificate issued by the
National Medical Products Administration (NMPA) in April 2021, and will be officially marketed in
Chinese mainland in August. The Company established a wholly-owned subsidiary, Sinclair
Aesthetics (Shanghai) Medical Technology Co., Ltd., to undertake the sales and promotion of
Ellansé. At present, the latter has assigned a full-time brand manager and set up an independent
direct selling team for the product Ellansé. Meanwhile, the preparations for brand and marketing
communication, the training and education of the first aesthetic medicine institutions and physicians
are being carried out as planned. After launching, 100 hospitals will be the first to use the product,
and it is expected to gradually expand to 300-500 domestic hospitals next year. The Company hopes

                                                                                                            18
                                                         The Half Year Report 2021 of Huadong Medicine Co., Ltd


to lead the Chinese aesthetic medicine industry into the era of regeneration by virtue of the natural,
safe and lasting effect of Ellansé. It will also make efforts in the domestic terminal market of
aesthetic medicine, and carry out both online and offline marketing to diversify the marketing
matrix, so that the sales volume can be rapidly expanded after being launched in China.
     Moreover, the Company introduced a cold-touch cosmetic instrument from R2 Company,
Glacial SpaTM (F0, life cosmetology version of a frozen freckle-removing medical device), has
obtained a marketing approval in Korea and Taiwan of China, and the Management Certification for
Non-medical Devices from NMPA. The product is mainly designed to solve skin tone problems,
including uneven skin tone, dark yellow and darkened skin, dull skin, sensitive and reddish skin,
severe local pigmentation, etc. The Company is sparing no effort to prepare for the launch of the
product in China, and it is expected to be officially marketed in China in the third quarter of 2021.
Cooperation intentions have been reached with some beauty institutions.
     During the reporting period, the Company continued to accelerate the progress of clinical
registration of other core aesthetic medicine products at home and abroad, and made positive
progress. Silhouette Instalift, a catgut embedding product of Sinclair, was successfully filed with
China Human Genetic Resources Administration Office, Ministry of Science and Technology of the
People’s Republic of China, and officially entered into a registered clinical research, with the
subjects being enrolled smoothly. Sinclair’s Perfectha series product containing lidocaine and High
Tech’s Cooltech Define obtained the CE Certification from EU, respectively. Glacial Rx (F1), a
frozen freckle-removing medical device developed by R2 (USA) was classified as a Class II
Medical Device by Zhejiang Medical Products Administration on July 5, and its registration in
China is promoted in an orderly manner. The product was approved for import by Hainan Province
and will soon be launched in the hospitals in the Hainan Boao Lecheng International Medical
Tourism Pilot Area. The product has successively obtained marketing licenses in Korea and
Singapore in the Asia-Pacific region, and applied for marking in Indonesia and Malaysia.
     In addition to actively promoting the clinical registration of domestic aesthetic medicine
products, the Company is actively following up the latest policies issued by the National
Development and Reform Commission on supporting the development of high-end aesthetic
medicine industry in Hainan, and a number of aesthetic medicine products of its aesthetic medicine
subsidiaries that have been registered, certified and launched in the mainstream markets or regions
such as the United States and the EU conform to the standards of the policy. The Company is
preparing for the registration and launch of those products in Hainan, including Ellansé type M,
cryolipolysis energy source product, a new high-end lidocaine-containing hyaluronic acid filler
MaiLi series product, etc. It will accelerate the approval and launch of those products in China by

                                                                                                            19
                                                                         The Half Year Report 2021 of Huadong Medicine Co., Ltd


conducting real-world research.
   Market
                   Main Products                  Intended Use                             Registration and Launch
Classification

                 YVOIRE hyaluronic
                                                   Facial filler                              Launched in China
                        acid
                                             Used for subcutaneous            Launched in the Chinese mainland in August 2021
                      Ellansé          implantation to correct moderate       Obtained registration certification or marketing
                                           to severe nasolabial folds            access in more than 60 countries or regions

                                          Designed for mid-face tissue
                                                                                          Certified by FDA, the USA
                 Catgut-embedding       lifting surgery, temporarily fixing
                                                                               Obtained registration certification or marketing
                 SilhouetteInstalift    and lifting the dermis under the
                                                                                 access in more than 60 countries or regions
                                                     cheeks

                    MaiLi series                   Facial filler                   CE certification of EU, launched in Europe

  Minimally                                                                    Obtained registration certification or marketing
   Invasive                                                                      access in more than 60 countries or regions
                  Perfectha series                 Facial filler
                                                                                Perfectha series product containing lidocaine
                                                                                   obtained the CE certification from the EU

                 Kylane’s two key
                                              Facial and body filler                              Under R&D
                   R&D products


                  Botulinum Toxin
                                                Wrinkle removal                In the process of registration and launch in China
                 (kreotoxin type A)

                      Lanluma
                   (PLLA collagen             Facial and body filler               CE certification of EU, launched in Europe
                     stimulant)

                                        To eliminate benign pigmented
                                         lesions of the skin, and relieve
                                                                                                USA FDA 510(k)
                  F1 (Glacial   RxTM)   pain, swelling, inflammation and
                                                                               In the process of registration and launch in China
                                            hematoma through low
                                                  temperature

                         F2                  Whole body whitening                                 Under R&D

                                                                              Approved for launch in the United States and Korea

 Noninvasive                                                                           Filed for launch in Taiwan, China
                  Glacial SpaTM (F0)    Skin whitening and brightening
                                                                               To be launched in the Chinese market in the third
                                                                                                quarter of 2021

                      Cooltech          Body shaping and fat reduction                     CE certification from EU

                                                                              CE certification from EU, and TGA certification from
                  Cooltech Define       Body shaping and fat reduction
                                                                                                   Australia

                       Crystile         Body shaping and fat reduction                        Launched overseas

                     Primelase                    Hair removal                 Obtained registration certification or marketing



                                                                                                                                20
                                                                  The Half Year Report 2021 of Huadong Medicine Co., Ltd


                                                                         access in more than 11 countries or regions


                Primelase Pro               Hair removal               In the process of global registration and launch

                                                                       Obtained registration certification or marketing
                   Elysion                  Hair removal
                                                                         access in more than 7 countries or regions

                 Define 2.0         Skin tightening and shaping                     Under R&D overseas

                 Define 3.0         Skin tightening and shaping                     Under R&D overseas

                   Titania          Skin tightening and shaping                     Under R&D overseas

                      Fig. Launch and R&D of the Company’s Main Aesthetic Medicine Products

     (4) Other matters
    In January 2021, the Company entered into an agreement with Shanghai Yuanda Investment
Management Co., Ltd. and Hangzhou High-tech Venture Capital Management Co., Ltd. and jointly
set up Hangzhou Fuguang Hongxin Equity Investment Partnership (L.P.) (referred to as “Fuguang
Hongxin Pharmaceutical Industry Fund”). The Pharmaceutical Industry Fund was established with a
total scale of RMB200 million, of which RMB98 million is contributed by the Company with its
own funds and the Company is a limited partner of the Pharmaceutical Industry Fund. The
Pharmaceutical Industry Fund mainly invests in startup and early projects in the fields of aesthetic
medicine, endocrinology, anti-rejection regarding organ transplantation, alimentary canal, tumor,
nephrology, immunology, etc. As of the disclosure date of this report, the Pharmaceutical Industry
Fund had completed the initial fund raising, finished the industrial and commercial registration
procedures, and completed the filing with AMAC on April 2, 2021. After its establishment,
Fuguang Hongxin Pharmaceutical Industry Fund jointly invested in Nuoling Biomedical
Technology (Beijing) Co., Ltd., an innovative enterprise focusing on the R&D of a new generation
of polymer ADC drugs, with Zhongmei Huadong in April 2021, holding 5.97% and 4.48% of the
shares of Nuoling Biomedical, respectively.
    Also in April 2021, Zhongmei Huadong, a wholly-owned subsidiary of the Company, reached
a cooperation agreement with Zhejiang Provincial Natural Science Foundation Committee (referred
to as “Foundation Committee”) and jointly set up the Joint Innovation and Development Fund of
Zhejiang Provincial Natural Science Foundation and Huadong Medicine. It became the first
enterprise in Zhejiang Province to cooperate with the Foundation Committee. Projects funded by
the Joint Innovation and Development Fund fall into three categories: major projects, key projects
and exploratory projects. The major projects focus on three core fields, namely, metabolic disease,
tumor and immunity, which are highly compatible with the key fields of the Company’s R&D
layout. The establishment of the Joint Innovation and Development Fund is conducive to attracting
and gathering superior scientific research forces inside and outside the province, carry out basic

                                                                                                                       21
                                                          The Half Year Report 2021 of Huadong Medicine Co., Ltd


research and applied basic research, create an open and cooperative development model, and speed
up innovation and research process of the Company.
     During the reporting period, the Company had been listed on the Fortune China 500 selected
by FortuneChina.com for the 10th consecutive year and Top 100 Pharma Companies in China in
2020, reelected one of Top 10 Industrial Enterprises in Chemical-Pharmaceutical Industry in 2020,
and was granted many honors and awards, including the “Best Board of Directors”, “Best Investor
Relations” and “Best Board Secretary” of the 12th China Listed Company Investor Relations
Tianma Award, China’s Top 10 Enterprises for Biomedical Business Development in 2020, etc.,
which fully shows the market recognition and affirmation of Huadong Medicine’s comprehensive
competitive strength, efficient operation, corporate governance level and ability to create value.
     In the first half of 2021, despite many obstacles and challenges, the Company unswervingly
promoted the development goal of innovation and transformation, and maintained a stable and
positive development trend, fully demonstrating its strong development resilience. Looking forward
to the second half of 2021, the external situation facing the Company is still grim, the COVID-19
pandemic is still fraught with repetitiveness and uncertainty, and the competition and policy
challenges in the pharmaceutical industry are becoming more prominent, resulting in the continuous
great development pressure on the Company’s three major business sectors. The road of
development is full of hardships, so we must cheer up and strive to be strong. Since the heavy
responsibility lies on our shoulders, we must be bold in moving forward. In the second half of 2021,
the Company will continue to promote innovation and reform, formulate the development goals of
the seventh Three-Year Plan, make great efforts to build its R&D ecosystem, continue to intensify
efforts to carry out innovation and R&D, continuously enhance the international capability of the
pharmaceutical industry system, improve the efficiency of new drug R&D, and promote the global
strategic layout of the aesthetic medicine business. At the same time, all cadres and employees shall
work hard for the second half of 2021, show courage to face difficulties in R&D and production,
marketing, talent introduction, quality management and other aspects, uphold a pioneering spirit,
and make unremitting efforts toward the annual business goals, to achieve the Company’s annual
high-quality development.


II. Analysis of core competitiveness

     1. Open innovative drug R&D System and continuous improvement of innovation
capability
     After years of development, the Company has established its independent R&D system, a global


                                                                                                             22
                                                        The Half Year Report 2021 of Huadong Medicine Co., Ltd


new drug R&D center as well as a global R&D strategic collaboration ecosystem centered on
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., and cooperated with world-renowned
colleges at home and abroad, research institutes, innovative R&D companies, professional
technology platforms and so on in new drug R&D projects. The Company continuously has increased
R&D investment, made an overall planning for the global innovative products in the three core areas
of anti-tumor, internal secretion and autoimmunity, and carried out cooperation with the world’s
leading AI drug discovery company Exscientia and XtalPi in anti-tumor drug R&D. Through
independent R&D, external cooperation and product license-in, the Company has continuously
enriched the product pipelines in core areas, formed a good development trend of continuous clinical
promotion and marketing of innovative products, and provided new momentum for medium- and
long-term growth.

     2. Comprehensive capability in international business development

    The Company actively promotes global expansion. Through the acquisition of the equity of UK
Sinclair and Spanish High Teach engaged in aesthetic medicine, the Company has realized the global
layout of aesthetic medicine sales network. Through strategic and equity collaboration with R2 (US),
Medibeacon (US), ImmunoGen (US), Provention Bio (US), Kylane (Switzerland), LG (South Korea),
Jetema (South Korea) and so on, the Company supplemented and enriched the commercial
development rights of innovative drugs and high-end aesthetic medicine products at home and abroad.
The Company also accelerated the international registration of products. Its online chemical raw
medicines have been certified by the Food and Drug Administration (FDA) or EU and other
authoritative authentication in markets; its Pantoprazole Sodium Lyophilized Powder for Injection
has been temporarily approved by the FDA; and its Acarbose Tablets gained market access to the
United States and the European Union Austria. The Company is the first Chinese medicine enterprise
to achieve these results. In addition, the Company actively develops international logistics and
purchasing suppliers to realize the internationalization of purchasing ability. It has promoted the
internationalization level of CMO/CDMO business and integrate it into the global innovative drug
R&D industry chain.
     3. Abundant product pipelines for specialized departments and chronic diseases and
overall competitive advantage in the field of diabetes medication
    Over the years, the Company has been deeply engaged in medication for specialized
departments, chronic diseases and special drugs, and has built a good brand effect and solid market
foundation in such fields as chronic kidney diseases, transplantation immunity, internal secretion,
and digestive system, and has maintained a leading market share of similar products in China. The

                                                                                                           23
                                                         The Half Year Report 2021 of Huadong Medicine Co., Ltd


Company has formed a comprehensive pipeline of innovative drugs and differentiated generic drugs
in the diabetes clinical mainstream therapeutic target. In the field of organ transplantation, it also
realized full coverage of clinical first-line immunosuppressive drugs. The Company has established
a global first-in-class distribution of new drugs in the three core areas of anti-tumor, internal
secretion and autoimmunity, forming a differentiated advantage. At present, 24 core marketed
products of the Company have been included in the 2020 Catalog of Medicines Covered by the
National Medical Insurance System.




     4. Leading professional pharmaceutical care team and extensive market network in
China

     The pharmaceutical industry of the Company has a professional pharmaceutical care team of
6,000 people, takes the promotion of clinical value and academic results as the core, and promotes a
multi-channel marketing model that combines general hospitals, primary medical institutions, retail
and third terminals, and Internet online. It has gradually formed effective coverage through multiple
channels and has a good competitive advantage.
     The business of the Company has been deeply rooted in the market of Zhejiang Province for
many years, with complete commercial formats and rich distribution varieties, and has
comprehensive competitive advantages in policy affairs, market access and network coverage. It has
fully covered the customers from public medical institutions, key private medical institutions and
retail pharmacies in Zhejiang Province, and maintained the leading order satisfaction rate. The
Company has established business cooperation with 90% of the mainstream pharmaceutical

                                                                                                            24
                                                         The Half Year Report 2021 of Huadong Medicine Co., Ltd


enterprises at home and abroad. The Company has a complete cold chain logistics distribution
service system and professional capabilities, and its cold chain logistics distribution business is in
the lead in China. The Company has obtained the first express business license of pharmaceutical
cold chain enterprise in Zhejiang Province, and got the exclusive qualification of third-party storing
and transporting vaccine from Zhejiang Provincial Center for Disease Control and Prevention.
     5. High end international aesthetic medicine product pipeline covering mainstream
non-surgical fields

    In 2018, through the successful acquisition of Sinclair in UK, the Company strategically
entered the aesthetic medicine industry, effectively completed the integration of products and
businesses in less than three years, and realized the full layout of the non-invasive and minimally
invasive aesthetic medicine industry chain. In the fields of facial fillers, body shaping, catgut
embedding, energy source devices and so on, we have a number of patented products with global
rights and also have an international aesthetic medicine operation and BD team. Focusing on the
global high-end aesthetic medicine market, further integrating R&D resources and capabilities, and
relying on the four global R&D centers of Sinclair in the UK, High Tech in Spain, R2 in the United
States and Kylane in Switzerland, and five global production bases in the Netherlands, France, the
United States, Switzerland and Bulgaria, the Company has formed its international aesthetic
medicine business integrating R&D, production, and marketing, and set up a global aesthetic
medicine marketing network, which has covered more than 60 countries and regions in the world.
     6. Prudent and pragmatic operation style and shareholder return

     The Company values management innovation, and strives to meet the demand of market
competition by improving its quality of operation. High quality products, excellent
commercialization ability, compliant and efficient marketing services, differentiated market
positioning, innovative R&D layout and completed talent planning all boost the long-term and
stable development of the Company. Since its listing, the Company has maintained steady growth in
performance for 21 years. Since 2007, the Company has kept the return on equity (ROE) above
20% for 14 years consecutively, leading A-share listed companies and the medicine industry. Since
its listing 21 years ago, the Company has paid dividends for 18 times, with a total value of
RMB4.577 billion, far exceeding the RMB250 million raised in its IPO. The Company has brought
continuous and stable returns of investment to shareholders.


                                                                                                            25
                                                                            The Half Year Report 2021 of Huadong Medicine Co., Ltd


III. Analysis of main business

Please refer to the relevant content of "I. Main business of the company during the reporting period".
Year-on-year changes in major financial data
                                                                                                                       Unit: RMB yuan

                                                                                 Year-on-year percentage
                           Current reporting period     Same period last year                                   Cause of changes
                                                                                     increase/decrease

Operating revenue                 17,179,437,902.61          16,660,934,157.64                      3.11%

Operating cost                    11,589,419,896.59          10,681,089,643.50                      8.50%

Selling expenses                   2,978,753,751.45           3,109,911,383.02                     -4.22%

Administrative expenses              534,683,411.33             506,362,613.35                      5.59%

                                                                                                            Mainly due to the
                                                                                                            increase of interest
Financial expenses                      9,789,580.87             17,531,072.80                    -44.16% income and the
                                                                                                            year-on-year decrease of
                                                                                                            financing cost

Income tax expenses                  240,728,486.55             334,125,800.82                    -27.95%

R&D investment                       437,556,684.96             479,685,981.21                     -8.78%

                                                                                                            Mainly due to the
                                                                                                            increase of capital return
Net cash flows from
                                   1,738,512,372.11           1,255,542,667.29                     38.47% and the decrease of
operating activities
                                                                                                            operating expenses in the
                                                                                                            current period

                                                                                                            Mainly due to the
                                                                                                            increase of equity
Net cash flows from
                                  -1,297,044,289.24            -374,008,436.39                    252.78% investment and
investing activities
                                                                                                            construction assets in the
                                                                                                            current period

                                                                                                            Mainly due to the
Net cash flows from
                                    -366,906,114.30            -743,357,031.90                     50.55% increase of loans in the
financing activities
                                                                                                            current period

                                                                                                            Mainly due to the
                                                                                                            increase of the amount of
Net increase in cash and
                                      74,138,062.91             179,100,260.58                    -58.61% cash flow paid for
cash equivalents
                                                                                                            investing activities in the
                                                                                                            current period

                                                                                                            Mainly due to the
Accounts receivable                                                                                         increase of banker’s
                                     530,122,144.99             828,659,217.25                    -36.03%
financing                                                                                                   acceptance discount in
                                                                                                            the current period



                                                                                                                                      26
                                                                           The Half Year Report 2021 of Huadong Medicine Co., Ltd


                                                                                                             Mainly due to the
Other receivables                    114,697,517.74               87,269,489.82                   31.43% increase of suspense
                                                                                                             accounts receivable

                                                                                                             Mainly due to the
Other current assets                  44,928,681.66               85,654,691.58                  -47.55% decrease of pending input
                                                                                                             tax in the current period

                                                                                                             Mainly due to the
                                                                                                             acquisition of Doer
Goodwill                           2,100,106,651.09           1,469,617,262.10                    42.90%
                                                                                                             Biologics and High Tech
                                                                                                             in the current period

                                                                                                             Mainly due to the
Notes payable                        979,859,751.59             554,336,058.71                    76.76% increase of bill payments
                                                                                                             in the current period

                                                                                                             Mainly due to the
                                                                                                             decrease of advance drug
Contract liabilities                  53,923,017.30               94,384,629.77                  -42.87%
                                                                                                             payments in the current
                                                                                                             period

                                                                                                             Mainly due to the
Non-current liabilities                                                                                      decrease of long-term
                                      43,273,480.68               67,813,886.68                  -36.19%
due within one year                                                                                          payables due within one
                                                                                                             year

                                                                                                             Mainly due to the
Long-term borrowing                  477,876,860.08             151,611,367.86                   215.20% increase of subsidiaries’
                                                                                                             long-term borrowing

                                                                                                             Mainly due to the
                                                                                                             increase in contingent
                                                                                                             and deferred
Long-term payables                   157,449,847.67               26,812,354.90                  487.23% consideration resulting
                                                                                                             from the acquisition of
                                                                                                             external companies by
                                                                                                             the subsidiaries

Significant changes in the company's profit composition or source of profit during the reporting period
□ Applicable   √ N/A
There was no major change in the company's profit composition or source of profit during the reporting period.
Composition of operating revenue
                                                                                                                       Unit: RMB yuan

                              The current reporting period                    Same period last year                   Year-on-year
                                                Proportion in                                Proportion in             percentage
                             Amount                                      Amount
                                              operating revenue                            operating revenue        increase/decrease

Total operating           17,179,437,902.61                  100%     16,660,934,157.64                   100%                     3.11%



                                                                                                                                         27
                                                                                  The Half Year Report 2021 of Huadong Medicine Co., Ltd


revenue

By sector

Business                     11,765,327,916.99                68.48%         10,760,596,159.30               64.59%                     9.34%

Manufacturing                 5,599,557,312.42                32.59%          6,238,364,356.65               37.44%                 -10.24%

aesthetic medicine
                                565,046,106.58                   3.29%         386,369,300.00                  2.25%                46.25%
[Note]

International
                                276,081,206.58                   1.61%         130,673,336.90                  0.78%               111.28%
aesthetic medicine

Offset (inter-sectoral
                               -461,528,533.38                                 -468,699,695.21
offset)

By product

By region

Domestic sales               16,879,853,037.00                98.26%         16,505,022,711.72               99.06%                     2.27%

Overseas sales                  299,584,865.61                   1.74%         155,911,445.92                  0.94%                92.15%

[Note] The aesthetic medicine business of the Company includes both the domestic and the international aesthetic medicine business.
There is a little overlap between the income statistics of the domestic aesthetic medicine business and that of the pharmaceutical
commerce and the pharmaceutical manufacturing industry. In order to truly reflect the Company’s business reality, the data is counted
separately.
Sectors, products or regions that account for more than 10% of the Company’s operating revenue or operating profit
√ Applicable     □ N/A
                                                                                                                             Unit: RMB yuan

                                                                                     Year-on-year                            Year-on-year
                                                                                                         Year-on-year
                                                                                      percentage                              percentage
                                                                  Gross profit                            percentage
                      Operating revenue      Operating cost                        increase/decrease                       increase/decrease
                                                                      rate                             increase/decrease
                                                                                      in operating                          in gross profit
                                                                                                       in operating cost
                                                                                        revenue                                  rate

By sector

Business              11,765,327,916.99 10,897,355,721.16                7.38%                9.34%               9.57%              -0.20%

Manufacturing            5,599,557,312.42 1,069,513,577.27               80.90%             -10.24%              -2.69%              -1.48%

International
aesthetic                  276,081,206.58        88,544,271.23           67.93%             111.28%             82.21%                  5.12%
medicine

Offset
(inter-sectoral            -461,528,533.38   -465,993,673.07
offset)

By region

Domestic sales        16,879,853,037.00 11,485,297,284.73                31.96%               2.27%               8.76%              -4.06%

Overseas sales             299,584,865.61     104,122,611.86             65.24%              92.15%             66.59%                  5.33%


                                                                                                                                              28
                                                                                   The Half Year Report 2021 of Huadong Medicine Co., Ltd


If the statistical specifications of the Company’s main business data have been adjusted during the reporting period, the Company’s
main business data of the most recent period should be adjusted according to the specifications at the end of the reporting period.
□ Applicable     √ N/A
Explanation of the reason why the relevant data has changed by more than 30% year-on-year.
□ Applicable     √ N/A


IV. Analysis of non-main business

√ Applicable    □ N/A
                                                                                                                             Unit: RMB yuan

                                                        Proportion in total
                                 Amount                                                 Note on reasons             Sustainable or not
                                                              profit

                                                                               Mainly due to the increase of
                                                                               bill discount interest and
Investment income                  -54,458,950.28                      -3.44% losses of partially-owned        No
                                                                               enterprises in the current
                                                                               period

                                                                               Mainly due to the
                                                                               government subsidies
Other income                       137,364,653.52                      8.68%                                   No
                                                                               recognized in the current
                                                                               period


V. Analysis of assets and liabilities

1. Major changes in asset composition

                                                                                                                             Unit: RMB yuan

                      End of the current reporting
                                                                End of last year
                                  period
                                                                                             Change of
                                           Proportion                         Proportion                       Note on major changes
                                                                                            proportion
                            Amount          in total         Amount            in total
                                             assets                             assets

Monetary funds       3,269,314,047.58         12.52% 3,198,080,997.82            13.21%         -0.69%

Accounts
                     6,871,300,450.79         26.32% 6,137,675,568.82            25.36%          0.96%
receivable

Contract assets                                0.00%                               0.00%         0.00%

Inventories          4,130,364,327.93         15.82% 4,067,635,254.80            16.81%         -0.99%

Real estate
properties for             17,191,977.46       0.07%        17,792,735.95          0.07%         0.00%
investment




                                                                                                                                         29
                                                                            The Half Year Report 2021 of Huadong Medicine Co., Ltd


Long-term equity
                        947,007,338.50          3.63%   850,072,053.02     3.51%           0.12%
investments

Fixed assets          2,668,749,549.01        10.22% 2,420,366,582.92      10.00%          0.22%

                                                                                                   Mainly due to the transfer of part of
Constructions in
                      2,000,163,547.28          7.66% 2,240,201,926.65     9.26%          -1.60% products under construction to fixed
progress
                                                                                                   assets

Right-of-use
                        128,934,858.91          0.49%                      0.00%           0.49%
assets

Short-term
                      1,386,401,620.12          5.31% 1,416,932,884.87     5.85%          -0.54%
borrowing

Contract
                           53,923,017.30        0.21%    94,384,629.77     0.39%          -0.18%
liabilities

Long-term                                                                                          Mainly due to the increase of
                        477,876,860.08          1.83%   151,611,367.86     0.63%           1.20%
borrowing                                                                                          Sinclair’s long-term borrowing

Lease liability            82,245,770.91        0.32%                                      0.32%


2. Major overseas assets

√ Applicable     □ N/A

                                                                                                            Proportion of     Whether
                                  Assets size                                 Control
   Specific                                                                                                    overseas     there are any
                   Reason for        (Ten                      Operating    measures to
  content of                                       Location                                 Profit or loss assets in the     significant
                    formation      thousand                      mode       ensure assets
    assets                                                                                                   Company’s     impairment
                                     yuan)                                     safety
                                                                                                              net assets        risks

                                                                           Control of
                                                                           the Board of
                                                                           Directors and
                                                                           examination
                                                                           & approval
                                                                           of major
                                                                           decisions;
Sinclair
                  Acquisition                                 Independent daily             Loss during
Pharma                           15925.85        UK                                                                9.83% No
                  of equity                                   accounting   supervision      the period
Limited
                                                                           of financial
                                                                           matters;
                                                                           entrusting
                                                                           external
                                                                           intermediarie
                                                                           s to conduct
                                                                           audits

Note: In April 2019, the Company entered into strategic cooperation with R2 Dermatology, a US company specializing in medical


                                                                                                                                           30
                                                                                     The Half Year Report 2021 of Huadong Medicine Co., Ltd


devices and technology development related to dark spot removal and skin whitening using freezing technology in the field of
aesthetic medicine, and invested 30 million US dollars for equity investment in R2 and became its shareholder. As of the date of this
disclosure, the company's wholly-owned subsidiary Hangzhou Huasheng Investment Management Co., Ltd. has completed all
payment for equity investment, with a shareholding ratio of 27.75%. In July 2019, the Company entered into strategic cooperation
with MediBeacon, a US company dedicated to the development of contrast agents and equipment in such medical fields as renal
function and gastrointestinal function assessment, and invested 30 million US dollars for equity investment. As of the date of this
report, the company's wholly-owned subsidiary Hangzhou Huasheng Investment Management Co., Ltd. has contributed 15 million
US dollars, or 4.3% of its shares.


3. Assets and liabilities measured at fair value

√ Applicable    □ N/A
                                                                                                                               Unit: RMB yuan

                                                                                       Amou
                                                                          Impairmen
                                                         Cumulative                      nt
                                       Change in fair                     t accrued
                                                        changes in fair                purcha Amount sold                          Closing
     Item         Opening balance value for the                           during the                           Other Changes
                                                        value included                 sed in in this period                       balance
                                       current period                      current
                                                          in equity                     this
                                                                           period
                                                                                       period

Financial
Assets

Including:
Investment in
                   225,453,120.05 15,091,655.18          7,534,147.03                           1,668,836.76    3,119,799.71 235,756,138.76
other equity
instruments

Total of the
                   225,453,120.05 15,091,655.18          7,534,147.03                           1,668,836.76    3,119,799.71 235,756,138.76
above

Financial
                                0.00             0.00             0.00                                  0.00                             0.00
Liabilities

Other changes
During the reporting period, whether the company’s main asset measurement attributes have changed significantly
□ Yes   √ No


4. Limitation of asset rights at the end of the reporting period


                    Item                          Book value at the end of the period                      Reason for limitation

         Cash and bank balance                                37,768,911.41                                     Cash deposit
                 Fixed assets                                 23,619,173.02                          Mortgage guarantee for borrowing
                    Total                                     61,388,084.43




                                                                                                                                             31
                                                                                         The Half Year Report 2021 of Huadong Medicine Co., Ltd


VI. Investment

1. Overview

√ Applicable □ N/A

 Investment amount in the reporting period         Investment amount in the same period of
                                                                                                                         Percentage change
                     (yuan)                                           last year (yuan)

                              1,485,053,641.17                                       722,699,019.70                                                 105.48%


2. Significant equity investments acquired during the reporting period

√ Applicable □ N/A
                                                                                                                                           Unit: RMB yuan

                                                                                                                 Profit or
                                                                                             Progre
                                                                                                                 loss of
                                                                          Term               ss as of                        Involve                Disclos
 Name       Main     Way of Invest Shareh                                                               Project investm                  Disclosu
                                                  Capital Partner           of     Product        the                          d in                      ure
      of   busines invest      ment      olding                                                           ed      ent in                 re date
                                                  source        (s)       invest    type     balanc                          litigatio               index
investee         s     ment amount        ratio                                                         income     the                   (if any)
                                                                          ment               e sheet                         n or not               (if any)
                                                                                                                 current
                                                                                              date
                                                                                                                  period

                                                           Fuguan                            The
                                                           g                                 Pharm
                                                           Chengd                            aceutic
                                                           u                                 al
                                                           Equity                            Industr
                                                           Invest                            y Fund
Hangzh
                                                           ment                              had
ou
                                                           Manag                             comple
Fuguan
           Equity                                          ement                             ted the
g
           investm                                         Co.,                              initial
Hongxi                                                                                                                                              http://w
           ent;      Newly                                 Ltd.,                             fund
n                              98,000,            Own                    Long-t                                  -996,32                 January ww.cnin
           venture establis              49.00%            Hangzh                  Equity raising,        0.00               No
Equity                         000.00             funds                  erm                                         9.16                08, 2021 fo.com.
           capital hed                                     ou                                finishe
Investm                                                                                                                                             cn
           investm                                         High-T                            d the
ent
           ent                                             ech                               industr
Partners
                                                           Venture                           ial and
hip
                                                           Capital                           comme
(L.P.)
                                                           Manag                             rcial
                                                           ement                             registr
                                                           Co.,                              ation
                                                           Ltd.,                             proced
                                                           Hangzh                            ures,
                                                           ou                                and


                                                                                                                                                               32
                                                                                        The Half Year Report 2021 of Huadong Medicine Co., Ltd


                                                             Heda                          comple
                                                             Industri                      ted the
                                                             al Fund                       filing
                                                             Invest                        with
                                                             ment                          AMA
                                                             Co.,                          C on
                                                             Ltd.,                         April
                                                             and                           2,
                                                             Shangh                        2021.
                                                             ai
                                                             Yuanda
                                                             Invest
                                                             ment
                                                             Manag
                                                             ement
                                                             Co.,
                                                             Ltd.

Zhejian
                                                                                           Compl
g Doer                                                                                                                                     http://w
          pharma               487,50                                                      eted
Biologi              Acquisi                       Own                  Long-t                              -3,566,1             April     ww.cnin
          ceutical             0,000.0 75.00%                /                   Equity equity       0.00              No
cs                   tion                          funds                erm                                   78.14              28, 2021 fo.com.
          R&D                       0                                                      invest
Corpora                                                                                                                                    cn
                                                                                           ment
tion

          R&D,
          product
          ion and
          sales of
High      non-inv                                                                          Equity
                                                   Own
Technol asive                                                                              deliver                                         http://w
                               499,60              funds/e                                                                       Februar
ogy       EBD        Acquisi             100.00                         Long-t             y has            10,954,2                       ww.cnin
                               3,000.0             xternal /                     Equity              0.00              No        y 18,
Product (energy tion                           %                        erm                been               59.92                        fo.com.
                               0[Note]             financi                                                                       2021
s,        source                                                                           comple                                          cn
                                                   ng
S.L.U.    type)                                                                            ted
          medical
          aestheti
          c
          devices

                               1,085,1
                                                                                                            6,391,75
Total         --        --     03,000.    --            --        --      --       --           --   0.00                   --      --          --
                                                                                                                2.62
                                   00

Note: Conversion is based on the central parity of the Euro to RMB exchange rate on June 30, 2021, which is 7.6862.




                                                                                                                                                     33
                                                                                            The Half Year Report 2021 of Huadong Medicine Co., Ltd


3. Significant non-equity investments in progress during the reporting period

√Applicable    □N/A
                                                                                                                                          Unit: RMB yuan

                                                                    Cumulat
                                                                                                                             Reasons
                                                                       ive                                        Cumula
                                                                                                                              for not
                                                         Investme actual                                            tive
                                              Industry                                                                       meeting
                                  Investme                  nt      investme                                       income
                                              involved                                                                         the                 Disclos
                    Way of          nt in                amount         nt                     Project Projecte realized                Disclos
                                               in the                            Capital                                     planned                 ure
 Project name      investme         fixed                 during     amount                    progres       d     by the               ure date
                                              investme                           source                                      schedul                index
                        nt        assets or                the       by the                         s     income end of                 (if any)
                                                 nt                                                                           e and                (if any)
                                    not                  reporting end of                                            the
                                               project                                                                       projecte
                                                          period       the                                        reportin
                                                                                                                                d
                                                                    reporting                                     g period
                                                                                                                             income
                                                                     period

Huadong
Medicine
                                              Pharmac                                                                                              http://w
Biomedical
                   Self-built                 eutical    25,972,9 1,742,30 Own                                                          March      ww.cni
Science and                       Yes                                                          95.00%        /        /      N/A
                   project                    manufac       20.50 4,827.30 funds                                                        9, 2017 nfo.com
Technology
                                              turing                                                                                               .cn
Park Project
Phase II

Huadong                                                                                                                                            http://w
                                              Pharmac                                                                                   April
Medicine Life Self-built                                 17,735,2 18,871,4 Own                                                                     ww.cni
                                  Yes         eutical                                          24.00%        /        /      N/A        21,
Science            project                                  78.06       41.26 funds                                                                nfo.com
                                              R&D                                                                                       2021
Industrial Park                                                                                                                                    .cn

                                                         43,708,1 1,761,17
Total                   --              --       --                                    --           --       --      --         --            --         --
                                                            98.56 6,268.56


4. Investment in financial assets

(1) Securities Investment

√ Applicable     □ N/A

                                                                   Gain/los Accumu
                                                          Book
                                                                    s from      lative       Purchas
                                              Account value at                                           Selling Gain/los Book
                                                                      fair       fair           e
                        Stock       Initial      ing       the                                           amount s during value at
Type of    Stock                                                     value      value        amount                                     Account Capital
                      abbrevia investm measure beginni                                                   in the    the       the end
  stock    code                                                     changes changes           in the                                    ing item source
                           tion    ent cost     ment      ng of                                          current reportin    of the
                                                                     in the included current
                                               model       the                                           period g period period
                                                                    current       in          period
                                                         period
                                                                    period      equity



                                                                                                                                                              34
                                                                        The Half Year Report 2021 of Huadong Medicine Co., Ltd


                                                                                                                 Other
Domesti                                 Fair                                                                     equity
c and                         20,207, value      23,582, 15,091, 7,534,1             4,788,6           33,885, instrum Own
           RAPT     RAPT                                                      0.00              0.00
overseas                      400.00 measure     877.56   655.18   47.03              36.47            896.27 ent           funds
stock                                   ment                                                                     investm
                                                                                                                 ent

                              20,207,            23,582, 15,091, 7,534,1             4,788,6           33,885,
Total                                       --                                0.00              0.00                   --      --
                              400.00             877.56   655.18   47.03              36.47            896.27

Date of announcement of
the Board of Directors on
                            N/A
securities investment
approval

Date of announcement of
the Board of Shareholders
                            N/A
on securities investment
approval (if any)

Note: In 2018, Huadong Medicine Investment Holding (Hong Kong) Co., Ltd., a subsidiary of the Company, invested USD 3 million
to purchase 218,102 preferred shares of RAPT Therapeutics, Inc. in C-2 series. RAPT Therapeutics, Inc. (stock code: RAPT) was
listed on the NASDAQ Stock Exchange on October 30, 2019. Up to now, Huadong Medicine Investment Holding (Hong Kong) Co.,
Ltd. holds 165,002 RAPT shares after reducing some of its shares, accounting for 0.575% of the total shares of RAPT Therapeutics,
Inc.


(2) Derivatives investment

□ Applicable   √ N/A
No such case during the reporting period.


VII. Major assets and equity sales

1. Major assets sales

□ Applicable   √ N/A
No such case during the reporting period.


2. Major equity sales

□ Applicable   √ N/A


VIII. Analysis of wholly-partially owned and shareholding companies

√ Applicable   □ N/A
Main subsidiaries and the shareholding companies that have an impact on the Company’s net profit of more than 10%
                                                                                                                   Unit: RMB yuan


                                                                                                                                    35
                                                                               The Half Year Report 2021 of Huadong Medicine Co., Ltd


  Company            Company                      Registered                                       Operating       Operating
                                Main business                   Total assets    Net assets                                       Net profit
    name              type                            capital                                       revenue         profit

                               Production and
                               management
Hangzhou                       of Traditional
Zhongmei                       Chinese and
                                                                10,842,477,3 7,154,596,77 5,424,176,08 1,351,726, 1,192,375,260.
Huadong          Subsidiary    Western raw       872,308,130
                                                                       02.54           1.52               9.31        436.61                  78
Pharmaceutic                   medicines and
al Co., Ltd.                   preparations,
                               and health care
                               products

Huadong                        Sales of
Ningbo                         biological                       1,002,680,43 614,591,609. 569,093,932. 68,384,569
                 Subsidiary                      5,000,000                                                                     50,333,683.31
Medicine                       products as                              3.29                26                01         .49
Co., Ltd.                      proxy

                               Wholesale of
                               TCM
                               materials,
Huadong
                               TCM
Medicine                                                        1,297,079,12 255,691,676. 1,294,102,66 34,340,365
                 Subsidiary    decoction         61,300,000                                                                    24,584,261.31
Wenzhou                                                                 0.10                70            2.82           .65
                               pieces,
Co., Ltd.
                               chemical
                               preparations,
                               etc.

Huadong
Medicine
                               Warehousing
Supply Chain                                                    283,569,835. 135,556,348. 84,045,782.2 10,619,118
                 Subsidiary    and storage       50,729,863                                                                      6,166,445.05
Management                                                                84                55                 1         .24
                               services
(Hangzhou)
Co., Ltd.

                               R&D,
                               production and
Sinclair
                 Sub-subsidiar sales of          219,962,963. 1,592,584,83 474,560,100. 276,081,206. -47,618,96
Pharma                                                                                                                         -52,918,540.05
                 y             aesthetic         92                     4.52                47                58        1.79
Limited
                               medicine
                               products

Acquisition and disposal of subsidiaries during the reporting period
√ Applicable     □ N/A

                                                  Methods of acquisition and disposal of         Impact on the overall production, operation
                Name of company
                                                 subsidiaries during the reporting period                      and performance

Zhejiang Doer Biologics Corporation             Acquisition                                      Polyclonal antibody technology platform



                                                                                                                                               36
                                                        The Half Year Report 2021 of Huadong Medicine Co., Ltd


                                                                    International business expansion for the
High Technology Products, S.L.U.   Acquisition                      Company’s energy source aesthetic
                                                                    medicine products


IX. Structured entities controlled by the Company

□ Applicable   √ N/A


X. Research and development (R&D)

      (1) Overall situation of R&D
      With “scientific research-based, patient-centered” as the corporate philosophy, the Company
continued to increase investment in R&D, and continuously enriched its arrangements in the R&D
of innovative drug pipelines. During the reporting period, the Company invested RMB536 million
in the R&D of the pharmaceutical industry, an increase of 6.38% year on year. The R&D of the
Company mainly involved the following aspects:
      1) Continued to practice the new drug R&D model which combines independent R&D +
cooperative development + product license-in, tracked the latest international drug action
mechanism and target as well as advances in clinical application research, and accelerated the
development of innovative drugs and the cooperation on and introduction of innovative drug
projects at home and abroad.
      Completed the pipeline layout of innovative products in the fields like endocrine/metabolism,
tumor, and autoimmune and obtained the approval regarding a number of innovative drug projects
with independent intellectual property rights; covered three major drug molecular entities from all
aspects: NCE small molecules, biological macromolecules and peptides;
      2) Focused on varieties with superior clinical effect and pharmacy for special population,
accelerated the R&D of generic drugs with high technical barrier and improved new drugs (505b
(2)), and initiated key projects centering on autoimmunity, endocrine and anti-tumor fields during
the reporting period;
      3) Continued to improve the process and quality level of bulk drugs and preparations, reduced
the cost, actively developed dosage forms of on-line products, and strengthened the market
competitiveness; and
      4) Strengthened the evaluation on the comprehensive dynamic of varieties under research, and
ensured the R&D progress of key varieties under research to the greatest extent through the priority
ranking of ongoing projects and the rational allocation of R&D resources.
      (2) R&D of projects regarding major innovative drugs and biosimilars

                                                                                                               37
                                                         The Half Year Report 2021 of Huadong Medicine Co., Ltd


     The Company has drawn up a strategic plan for the development of innovative drugs for the
next five years, clearly defined the key direction and number of innovation projects for each year
during the planning period centering on the existing therapeutic fields, and proposed that no less
than 15 innovative varieties (including original new drugs, improved new drugs, innovative medical
devices and high-end aesthetic medicine products) should be established and reserved annually
during the planning period. During the reporting period, the Company actively boosted the clinical
research on innovative drugs under research and key biosimilars. In addition, the Company actively
explored and learned from the international advanced innovative drug R&D system building,
continuously optimized and adjusted its overall R&D system structure, and improved the functional
modules on the R&D of innovative projects through the introduction of high-end R&D personnel,
to achieve the objectives on the strategic planning of the Company’s innovative projects.
     (3) Progress on the clinical research of key innovative drugs, innovative medical devices
and biosimilars
     From 2020, the Company began to streamline the R&D pipeline of the innovative drug sector,
adjust the organizational structure of innovative drug R&D, and introduce high-level external R&D
personnel. The Company introduced first-in-class or best-in-class drugs at home and abroad in the
three core areas of anti-tumor, endocrine and autoimmunity. At present, the Company has
innovative drugs and key biosimilars in those three areas.
     Diabetes
     1) TTP273: The world’s first oral GLP-1 receptor agonist small-molecule innovative drug, is
currently undergoing multi-regional phase II clinical trials in the Chinese mainland and Taiwan
region. It is expected that the phase II clinical work will be completed by the end of 2021 and the
phase III trial will start in 2022;
     2) Semaglutide injection: GLP-1 receptor agonist, a product jointly developed by the Company
and its partially-owned company, Peg-Bio Biopharm Co., Ltd. (Chongqing), which is undergoing
experiments on animals. It is planned that the investigational new drug (IND) domestic clinical trial
application will be launched in 2021;
     3) Liraglutide injection: GLP-1 receptor agonist, is undergoing phase III clinical research for
indications for diabetes and weight loss in China. The phase III clinical trial on the indications for
diabetes has basically been completed, and it is expected that the application for registration will be
submitted in the third quarter of 2021. The registration regarding the indications for weight loss will
be submitted before the end of 2021; and
     4) The Company has paid attention to the latest R&D progress in the field of diabetes, and

                                                                                                            38
                                                          The Half Year Report 2021 of Huadong Medicine Co., Ltd


actively planned the global distribution of innovative drugs. It introduced the product SCO-094 of
SCOHIA PHARMA, Inc. (Japan) under the development in phase I clinical trial, which is a dual
agonist of GLP-1R and GIPR targets used for the treatment of such diseases as type 2 diabetes,
obesity and non-alcoholic steatohepatitis.
      Tumor
      1) HDM2002 (IMGN853): The world’s first ADC drug under research for FRα-positive
ovarian cancer. The clinical trials of HDM2002 (including MRCT phase III clinical and PK
bridging trials) have received approval in China, and various pre-clinical preparations are currently
being promoted as planned. The trials are expected to begin in the second half of 2021. Another
application for the single-arm clinical trial of the drug in China was approved in July 2021 and is
expected to begin in early 2022; and
      2) Mefatinib: Mefatinib for the treatment of advanced non-small cell lung cancer is under
phase III clinical trial and the enrollment of the subjects for the phase III clinical trial has been
completed. It is expected that the phase III clinical trial will end and that the application for
registration will be submitted before the end of 2021.
      Autoimmunity
      1) HDM3002 (PRV-3279): A product under research of Provention Bio (USA). The Company
introduced it for the treatment of systemic lupus erythematosus (SLE) and for preventing or
reducing the immunogenicity of gene therapy. The phase II international multi-center clinical
research of this product is underway. At present, pre-IND materials have been submitted in China;
and
      2) HDM3001 (QX001S): A biosimilar of the original drug ustekinumab (Stelara) jointly
developed by the Company and its partially-owned company Qyuns Therapeutics, used to treat
moderate-to-severe psoriasis of adults. The phase III clinical trial of the drug is underway.
      Other innovative drugs and major biosimilars
      1) HD-NP-102 (MB102, dynamic TGFR monitoring system): The renal function is evaluated
through real-time monitoring of glomerular filtration rate. With its accurate diagnosis and risk
assessment of early renal injury, the product is of ground-breaking clinical significance. The
application for carrying out the international multi-center phase III clinical trial of MB102 injection
(fluorescent tracer), class 1 new drug used in the monitoring system, has been approved by NMPA.
The drug will officially enter the clinical stage in the second half of 2021;
      2) Other varieties of biosimilars: Clinical trials of ranibizumab injection were approved in
April 2021. Insulin degludec injection and insulin aspart injection are under preclinical study; and

                                                                                                             39
                                                          The Half Year Report 2021 of Huadong Medicine Co., Ltd


     3) Arrangement of R&D of early innovative drugs: Drug screening and activity
characterization regarding oral GLP-1 innovative drugs for the treatment of type 2 diabetes,
anti-tumor projects including CDK targeted drugs and innovative drugs such as PROTAC and ADC
are underway as planned.
     (4) Progress of R&D of major generic drugs
     During the reporting period, the Company conducted earnest dynamic evaluation and combing
of the existing generic drug varieties under research, and further clarified the varieties to be focused
and prioritized. The progress regarding the key varieties is as follows:
     1) Diabetes: The production of Metformin Hydrochloride and Empagliflozin Tablets (5/500mg)
was approved in June 2021. Sitagliptin Phosphate/Metformin Hydrochloride Tablets (50/850mg)
and Canagliflozin Tablets (specifications: 0.1g, 0.3g) have been declared for production.
Pioglitazone Hydrochloride and Metformin Hydrochloride Tablets (15/850mg) is under pilot scale
production;
     2) Immunity: Tacrolimus extended-release capsules, tablets, granules and ointment are under
pilot scale production. The supplement materials of the ANDA for Tacrolimus have been submitted,
and FDA priority review has been accepted;
     3) Anti-tumor: The production of letrozole tablets was approved in May 2021. Ibrutinib
capsule is under laboratory research. Olaparib tablet is under the pilot scale production. The on-site
inspection regarding sorafenib tosylate tablets (0.2g) is pending;
     4) Antibiotics: The production of Micafungin Sodium for Injection (50mg) was approved in
June 2021.The project of BHFXG-06 was initiated. The information for ANDA application for
Caspofungin Acetate for Injection (50mg/vial) is in preparation. The ANDA regarding Caspofungin
Acetate for Injection (70mg/vial) is under process validation. The amendment of preparation and
API regarding the ANDA for Daptomycin for Injection (500mg/vial) have been completed;
     5) Digestion: The production of Omeprazole and Sodium Bicarbonate Capsule (20/1100mg)
was approved in June 2021; and
     6) Cardiovascular: The materials regarding the ANDA application for Fondaparinux Sodium
for Injection are in preparation; Macitentan Tablet (10mg) has been filed for production, and the
on-site inspection is in the preparatory stage.
     (5) Progress of patent
     The Company has attached great importance to the protection of its intellectual property rights
and application of results in recent years, and the number of patent applications and grants is
steadily increasing. The Company has applied for more than 600 patents at home and abroad over
the years, of which more than 280 were granted. Hangzhou Zhongmei Huadong Pharmaceutical Co.,

                                                                                                             40
                                                         The Half Year Report 2021 of Huadong Medicine Co., Ltd


Ltd., a wholly-owned subsidiary of the Company, is a national IP demonstration enterprise. In
November 2014, the Company passed the external audit of Zhongzhi (Beijing) Certification Co.,
Ltd., becoming one of the 147 enterprises who have firstly passed the standard implementation
certification. In 2020, the Company successfully passed the examination review on supervising the
standard implementation of corporates’ intellectual property.
     During the reporting period, the Company’s patent application and maintenance proceeded
smoothly. Zhongmei Huadong, a wholly-owned subsidiary of the Company, applied and submitted
more than 40 patents, among which more than 30 were utility patents, and 9 were authorized in
China. In May 2021, the utility patent “Enzyme for synthesizing and metabolizing inosine
monophosphate of Cordyceps sinensis (Berk.) Sacc. Hirsutella sinensis and application thereof” of
Zhongmei Huadong was awarded China Patent Excellence Award, with the patent number:
ZL201110267161.3.
     (6) Building of a R&D ecosystem
     The Company has invested, held shares in and incubated a number of domestic biotechnology
companies with leading technology. For example, it invested in Peg-Bio Biopharm featuring a
peptide technology platform, Qyuns Therapeutics, an antibody company focusing on immune
diseases, and Nuoling Biomedical Technology featuring ADC linker and coupling technology; it
incubated Huida Biotech which has a full line of toxin ingredients used to develop ADC drugs; and
it holds stakes in Doer Biologics which focuses on the development of a Polyclonal antibody
platform. Through a series of investments and acquisitions, the Company has gradually formed its
own medical R&D ecosystem. Relying on Huida Biotech’s antibody-conjugated drug toxin library
construction technology, Qyuns Therapeutics’ monoclonal antibody R&D and productive capacity,
and Nuoling Biomedical Technology’s polymer linker coupling technology, the Company has the
ability to carry out the R&D of all ADC components. Regarding R&D arrangements, the Company
follows the principle of “division of labor and cooperation, collaboration and win-win”. That is,
through cooperation, all enterprises can interact on their technologies and help each other achieve
development and innovation, further allowing the rapid improvement of the Company’s overall
R&D capability.




                                                                                                            41
                                                         The Half Year Report 2021 of Huadong Medicine Co., Ltd




XI. Risks and Countermeasures


     1. Industry policies and market risks

     At present, China has continuously deepened reform in the field of medicine and health, and

various policies have been introduced intensively. Policies such as national centralized purchasing,

generic drug consistency evaluation, two-vote system, new drug approval, control of the proportion

of hospital drugs, secondary price negotiation in hospitals, and close medical association will have a

significant impact on the R&D, production, and circulation of drugs. At the same time, with the

implementation of medical insurance fee control, the reform of payment methods, and the further

implementation of the generic drug centralized purchasing policy, some drugs will face the risk of
further price reduction.

     Countermeasures: The Company will pay close attention to, analyze and grasp major national

medicine policies and industry development trends, strengthen the layout of innovative varieties and

R&D investment through endogenous development and outward extension, reduce production and

operation risks through lean production, fully implement the international development strategy and

improve the technological quality advantages of products with international standards. It will

                                                                                                            42
                                                          The Half Year Report 2021 of Huadong Medicine Co., Ltd



continue to tap the advantageous products and subdivisions of aesthetic medicine to create new

profit points. It will vigorously expand grassroots communities and OTC markets, and increase the

coverage of primary and retail terminal markets to maintain stable growth in operations.

     2. New drug R&D risk

     New drug R&D involves a long cycle, large investment and many uncertainties. In the R&D

process, there are also risks such as shortage of high-level talents, failure to obtain registration and

approval for new drug R&D due to curative effect or safety reasons. After new drugs hit the market,

there are also risks such as market demand test, purchasing by bidding, medical insurance payment

access, and market competition for similar products. In addition, the investment in R&D will also
bring certain pressure to the realization of the Company’s current operating objectives.
     Countermeasures: The Company will continue to increase investment in new drug R&D,
optimize the innovation mechanism, improve the scientific new drug research evaluation and
decision-making system, and establish close ties with well-known R&D institutions at home and
abroad, focus on the core treatment fields, continue to enrich and optimize the product pipelines
through independent project establishment and external introduction, vigorously develop innovative
drugs and generic drugs with high technical barriers, and gradually eliminate the backward varieties
that are not competitive in the market, increase the introduction of high-level research personnel,
build a research team that covers the entire development cycle of new drugs, and strengthen the
training and encouragement of core technical personnel, and accelerate the construction of
high-standard medicine R&D centers and pilot test bases.

     3. Price reduction risk

     With the intensified competition in the medicine market and the further promotion of the

national centralized purchasing policy, domestic medicine enterprises will face the pressure of

policy-based price reduction for a long time. There will be more competitive manufacturers of
similar products, leading to the risk of failure in bidding.
     Countermeasures: Focusing on scientific R&D and technological innovation, the Company
will improve the technological quality advantages of its products with international standards,
strengthen internal management and technological upgrading, strengthen cost competitive
advantages, carry out marketing assessment and incentives and channel sinking, continue to expand
the professional promotion team of county-level markets, vigorously expand primary communities


                                                                                                             43
                                                        The Half Year Report 2021 of Huadong Medicine Co., Ltd


and OTC markets, and increase the coverage of primary and retail terminal markets to maintain stable
market growth.




                                                                                                           44
                                                                           The Half Year Report 2021 of Huadong Medicine Co., Ltd




                                        Section IV. Corporate Governance

I. Annual General Meeting and Extraordinary General Meetings convened during the
reporting period

1. Annual General Meeting convened during the current reporting period


                                                Proportion of
       Meeting                   Nature          participating        Convened Date         Disclosure Date      Disclosure Index
                                                   investors

2020 Annual General Annual General
                                                                                                               No. 2021-045;
Meeting of                 Meeting of                     59.20% May 21, 2021            May 21, 2021
                                                                                                               www.cninfo.com.cn
Shareholders               Shareholders


2. Extraordinary general meetings convened at the request of preferred shareholders with resumed voting
rights

□ Applicable     √ N/A


II. Change of directors, supervisors and senior managers

□ Applicable     √ N/A
There are no changes of directors, supervisors and senior management personnel during the reporting period (referring to 2020
annual report).


III. Profit distribution and capitalization of capital reserves plan or proposal for the current
reporting period

□ Applicable √ N/A
The Company did not plan to distribute cash dividends, send bonus shares, or convert capital reserve into share capital during the
first half of the year.


IV. The implementation of Equity Incentive Plan, Employee Stock Incentive Plan, or other
incentive plans

□ Applicable     √ N/A
No such case during the reporting period.




                                                                                                                                     45
                                                                                    The Half Year Report 2021 of Huadong Medicine Co., Ltd




                       Section V. Environmental and Social Responsibility

I. Significant environmental problems

Whether the Company and its subsidiaries are the key pollutant discharging units announced by the environmental protection
authorities
√ Yes   □No

Name of the       Name of                    Number of Distribution Concentrati Discharge                                      Approved
                               Discharge                                                                         Total                     Excessive
company or            major                      discharge of discharge         on of     standard of                            total
                                  type                                                                         discharge                    discharge
 subsidiary      pollutants                       outlets      outlets        discharge       pollutants                       discharge

Hangzhou
                                                            Front gate,
Zhongmei        Water
                              Intermittent                  866
Huadong         pollutant:                   1                            7.56            6-9              /               /               None
                              discharge                     Moganshan
Pharmaceuti PH value
                                                            Road
cal Co., Ltd.

Hangzhou
                                                            Front gate,
Zhongmei        Water
                              Intermittent                  866                                                            475.5
Huadong         pollutant::                  1                            79.6mg/l        500mg/l          25.3 tons                       None
                              discharge                     Moganshan                                                      tons/year
Pharmaceuti COD
                                                            Road
cal Co., Ltd.

Hangzhou
                Water                                       Front gate,
Zhongmei
                pollutant:    Intermittent                  866
Huadong                                      1                            0.998mg/l       35mg/l           0.317 tons      /               None
                ammonia       discharge                     Moganshan
Pharmaceuti
                nitrogen                                    Road
cal Co., Ltd.

Hangzhou                      Legal                         In the
                Solid
Zhongmei                      disposal by                   factory at
                pollutant:                                                                                 1885.19
Huadong                       entrusted      2              866           /               /                                /               None
                hazardous                                                                                  tons
Pharmaceuti                   qualified                     Moganshan
                solid waste
cal Co., Ltd.                 units                         Road

Hangzhou                      Legal                         In the
                Solid
Zhongmei                      disposal by                   factory at
                pollutant:
Huadong                       entrusted      2              866           /               /                1306.6 tons /                   None
                general
Pharmaceuti                   qualified                     Moganshan
                solid waste
cal Co., Ltd.                 units                         Road

Hangzhou
                Air                                         Roof of the
Zhongmei
                pollutant:     Organized                    boiler room                                                    17.7
Huadong                                      1                            26.5mg/ m 60mg/ m 1.27 tons                                      None
                nitrogen      emission                      in Building                                                    tons/year
Pharmaceuti
                oxide                                       No. 25
cal Co., Ltd.


                                                                                                                                                        46
                                                                       The Half Year Report 2021 of Huadong Medicine Co., Ltd


Hangzhou
                Air                             Roof of the
Zhongmei
                pollutant:   Organized          boiler room
Huadong                                     1                     3 mg/ m       50mg/ m 0.144 tons    /           None
                sulfur       emission           in Building
Pharmaceuti
                dioxide                         No. 25
cal Co., Ltd.

Hangzhou
                Air                             Roof of the
Zhongmei
                pollutant:   Organized          boiler room
Huadong                                     1                     4.6mg/ m 20mg/ m 0.221 tons         /           None
                dust and     emission           in Building
Pharmaceuti
                fume                            No. 25
cal Co., Ltd.

Huadong                                         Along
Medicine                                        National
                Water
(Xi’an)                     Intermittent       Highway
                pollutant:                  1                 8.2           6-9          /            /           None
Bohua                        discharge          310, Liuye
                PH value
Pharmaceuti                                     River,
cal Co., Ltd.                                   Huayin City

Huadong                                         Along
Medicine                                        National
                Water
(Xi’an)                     Intermittent       Highway
                pollutant:                  1                 11.22mg/l     50mg/l       0.1 tons     3 tons      None
Bohua                        discharge          310, Liuye
                COD
Pharmaceuti                                     River,
cal Co., Ltd.                                   Huayin City

Huadong                                         Along
Medicine        Water                           National
(Xi’an)        pollutant:   Intermittent       Highway
                                            1                 0.37mg/l      8mg/l        0.004 tons   0.48 tons   None
Bohua           ammonia      discharge          310, Liuye
Pharmaceuti nitrogen                            River,
cal Co., Ltd.                                   Huayin City

Huadong                                         Along
Medicine        Water                           National
(Xi’an)        pollutant:   Intermittent       Highway
                                            1                 6.26mg/l      15mg/l       0.06 tons    /           None
Bohua           total        discharge          310, Liuye
Pharmaceuti nitrogen                            River,
cal Co., Ltd.                                   Huayin City

Huadong
                             Compliant
Medicine        Solid
                             disposal by
(Xi’an)        pollutant:                      In the
                             entrusted      3                 /             /            172.06 tons /            None
Bohua           hazardous                       company
                             qualified
Pharmaceuti waste
                             units
cal Co., Ltd.

Huadong         Air          Organized          Raw
                                            1                 /                 60mg/ m /             /           None
Medicine        pollutant:   emission           medicine


                                                                                                                          47
                                                                        The Half Year Report 2021 of Huadong Medicine Co., Ltd


(Xi’an)        volatile                         No.1
Bohua           organic                          workshop
Pharmaceuti compound
cal Co., Ltd.

Huadong
Medicine        Air                              Raw
(Xi’an)        pollutant:    Organized          medicine
                                             1                /              30mg/ m /                /           None
Bohua           hydrogen      emission           No.1
Pharmaceuti chloride                             workshop
cal Co., Ltd.

Huadong
Medicine        Air                              Raw
(Xi’an)        pollutant:    Organized          medicine
                                             1                /              20mg/ m /                /           None
Bohua           hydrogen      emission           No.2
Pharmaceuti chloride                             workshop
cal Co., Ltd.

Huadong
Medicine        Air                              Raw
(Xi’an)        pollutant:    Organized          medicine
                                             1                /              20mg/ m /                /           None
Bohua           particulate   emission           No.2
Pharmaceuti matter                               workshop
cal Co., Ltd.

Huadong
Medicine        Air                              Raw
(Xi’an)        pollutant:    Organized          medicine
                                             1                /              45mg/ m /                /           None
Bohua           sulfuric acid emission           No.2
Pharmaceuti mist                                 workshop
cal Co., Ltd.

Jiangsu
                Water
Joyang                        Intermittent       9 Haidubei
                pollutant:                   1                7.95          6-9         /             /           None
Laboratorie                   discharge          Road
                PH value
s Co., Ltd.

Jiangsu
                Water
Joyang                        Intermittent       9 Haidubei                                           51.4173
                pollutant:                   1                250mg/l       500mg/l     5.83 tons                 None
Laboratorie                   discharge          Road                                                 tons/year
                COD
s Co., Ltd.

Jiangsu         Water
Joyang          pollutant:    Intermittent       9 Haidubei                                           3.6819
                                             1                1.41mg/l      35mg/l      0.0329 tons               None
Laboratorie ammonia           discharge          Road                                                 tons/year
s Co., Ltd.     nitrogen

Jiangsu         Water         Intermittent       9 Haidubei                                           24.968
                                             1                104mg/l       120mg/l     2.424 tons                None
Joyang          pollutant:    discharge          Road                                                 tons/year


                                                                                                                           48
                                                                     The Half Year Report 2021 of Huadong Medicine Co., Ltd


Laboratorie SS
s Co., Ltd.

                            Legal
Jiangsu       Solid                           In the
                            disposal by
Joyang        pollutant:                      factory at 9                              728.111     3148.7
                            entrusted     /                  /             /                                    None
Laboratorie hazardous                         Haidubei                                  tons        tons/year
                            qualified
s Co., Ltd.   solid waste                     Road
                            units

                                              Dosing
                                              section of
                                              workshop
                                              101,
                                              fermentatio
                                              n section of
                                              workshop
                                              101, dosing
                                              section of
                                              workshop
                                              104 (shared
Jiangsu       Air
                                              by 107 and
Joyang        pollutant:    Organized                                                   0.416       0.797
                                          5   108),              6.2mg/m       10mg/m                           None
Laboratorie particulate     emission                                                    tons/year   tons/year
                                              fermentatio
s Co., Ltd.   matter
                                              n section of
                                              workshop
                                              104 (shared
                                              by 107 and
                                              108), and
                                              drying
                                              section of
                                              workshop
                                              104 (shared
                                              by 107 and
                                              108)

                                              Extraction
                                              of
                                              workshop
Jiangsu       Air                             101,
Joyang        pollutant:    Organized         Extraction                                0.007       1.074
                                          3                  0.048mg/m 50mg/m                                   None
Laboratorie ethyl           emission          of                                        tons/year   tons/year
s Co., Ltd.   acetate                         workshop
                                              104, and
                                              workshop
                                              303




                                                                                                                        49
                                                                             The Half Year Report 2021 of Huadong Medicine Co., Ltd


Construction and operation of pollution prevention and control facilities


1. Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
(1) Waste water

    Name of pollution
                                                                                                                           Status of
  prevention and control      Treatment process          Processing capacity                 Time of operation
                                                                                                                           operation
         facilities

  Waste water treatment                               Original 600 tons/day; 800
                            Facultative + fluidized                                   November 1993; technical
 system of the old sewage                              tons/day after technical                                            Normal
                                     bed                                               transformation in 2007
          station                                           transformation

  Waste water treatment     Anaerobic (IC tower)+                                     December 2001; technical
 system of the new sewage facultative +CASS+ air            2,200 tons/day          transformation in 2014 (IC and         Normal
          station                  flotation                                             air flotation added)



(2) Waste gas

     Name of pollution
                                                                                    Processing                                Status of
   prevention and control                  Treatment process                                           Time of operation
                                                                                   capacity CMH                              operation
         facilities

                               Level 2 water spraying + surface cooling +
     DA010(35#-1)                                                                   15000                  2017             Normal
                                 activated carbon adsorption/desorption

     DA011(35#-2)                      Level 2 water spraying                       22000                  2013             Normal

     DA012(40#-2)              Activated carbon + horizontal spraying                6000                  2019             Stopped

     DA013(32#-1)                   Level 2 alkali liquor spraying                  22000                  2013             Stopped

                               Level 2 water spraying + surface cooling +
      DA014(36#-1)             low-temperature plasma + Level 1 water                27000                  2017             Normal
                                                spraying

     DA015(40#-1)                      Level 2 water spraying                       24200                      /            Normal

                            Two levels of alkali liquor spraying + all-in-one
                             (photocatalytic oxidation + plasma + activated
     DA016(18#-1)                                                                   16000                  2019             Normal
                            carbon) + inorganic nano catalytic deodorization
                                  equipment + Level 1 water spraying

     DA017(19#-1)                        Combustion tower                              /                   2018             Stopped

     DA018(19#-2)                        Combustion tower                              /                   2018             Stopped

                                Level 1 water spraying + photocatalytic
      DA019(3#-1)                                                                20000+52000               2019             Normal
                                                oxidation

                             Two levels of water spraying + condensation+
     DA020(36#-2)          photocatalytic oxidation + activated carbon +            10000                  2019             Normal
                               inorganic nano-catalysis + water spraying


                                                                                                                                       50
                                                                  The Half Year Report 2021 of Huadong Medicine Co., Ltd


                  Level 1 water spraying + Level 1 alkali liquor
DA021(16#-1)                                                             12000               2012           Stopped
                                     spraying

                 Level 1 water spraying + Level 1 plant oil and
DA022(16#-2)                                                             30000               2014           Stopped
                                 water spraying

                 Condensation + Level 1 alkali liquor spraying +
DA023(27#-1)                                                             15000               2009           Normal
                    all-in-one + Level 1 alkali liquor spraying

                 Level 2 alkali liquor spray + condensate tank +
DA024(33#-1)                                                             48000               2019           Stopped
                     common Level 1 alkali liquor spraying

                 Dust removal with cloth bag + high-efficiency
DA025(32#-2)                                                               /                 2017           Stopped
                                       filter

DA026(34#-1)            Level 2 alkali liquor spraying                   54000               2008           Stopped

DA027(7#-1)             Level 2 alkali liquor spraying                   26000               2015           Normal

DA028(6#-1)                Level 1 water spraying                        12200               2016           Normal

                 Level 2 alkali liquor spraying + photocatalytic
DA029(18#-2)    oxidation + activated carbon + Level 1 alkali            16000               2018           Normal
                                 liquor spraying

                  Level 1 water spraying + Level 1 alkali liquor
DA030(18#-3)                                                             5000                2017           Normal
                                     spraying

                                                                                               2009
                                                                                         (The low nitrogen
                    Low-nitrogen combustion + high-altitude
DA031(25#-2)                                                             8000            transformation     Normal
                                    emission
                                                                                           completed in
                                                                                         December 2019.)

                                                                                               2009
                                                                                         (The low nitrogen
                    Low-nitrogen combustion + high-altitude
DA032(25#-1)                                                             8000            transformation     Normal
                                    emission
                                                                                           completed in
                                                                                         December 2019.)

DA033(1#-1)                   Oil fume purifier                            /                   /            Normal

                 Two levels of water spraying + activated carbon
DA034(27#-2)                                                             15000               2011           Normal
                              adsorption/desorption

                 Photocatalytic oxidation + Level 1 alkali liquor
DA035(27#-3)                                                             22300               2016           Normal
                                     spraying

DA036(8#-1)                Level 2 water spraying                        25000               2017           Normal

                   Level 2 water spraying + surface cooling +
DA037(13#-1)                                                             25000               2017           Normal
                     activated carbon adsorption/desorption

                     Level 1 water spraying + photocatalytic
DA038(28#-1)                                                             22000               2011           Normal
                                    oxidation


                                                                                                                       51
                                                                                The Half Year Report 2021 of Huadong Medicine Co., Ltd


                                      Level 2 water spraying + common
     DA039(28#-2)                                                                      48000                  2011             Normal
                                           photocatalytic oxidation

                                Level 1 water spraying + Level 1 alkali liquor
     DA040(29#-1)                                                                      22000                  2011             Normal
                                                   spraying

     DA041(33#-2)                         Level 1 water spraying                       18600                  2012             Stopped

     DA042(10#-1)                         Level 1 water spraying                       20000                  2016             Normal

                                Level 1 alkali liquor spraying + photocatalytic
     DA043(15#-1)                                                                      25000                  2018             Normal
                                                   oxidation

                                Level 1 alkali liquor spraying + Level 1 water
     DA044(43#-1)                                                                      45000                  2014             Normal
                                                   spraying

     DA045(46#-1)                         Level 1 water spraying                       3000                   2015             Normal

     DA046(46#-2)                         Level 1 water spraying                       25000                  2015             Normal

     DA047(46#-3)                         Level 1 water spraying                       30000                  2015             Normal

     DA048(23#-1)                      Two levels of water spraying                    7000                   2019             Stopped

Note: Waste gas treatment process of 107 fermentation section: when the fermentation tank is not disinfected, the waste gas is
discharged at high altitude after level 3 alkali spray; when the fermentation tank is disinfected, the waste gas is first condensed and
then treated with level 1 alkali spray, and then discharged at high altitude.


(3) Solid waste

     Name of pollution
   prevention and control        Treatment process       Processing capacity         Time of operation             Status of operation
          facilities

                                Standardized storage           160 tons                 March 2012
                                                                                                               Standardized storage; legal
Hazardous waste warehouse
                                                                                                               disposal by qualified units
                                Standardized storage           240 tons                 March 2010

                                Standardized storage            7 tons                  March 2010
                                                                                                               Standardized storage; legal
  General solid waste yard
                                                                                                               disposal by qualified units
                                Standardized storage            30 tons                  June 2004



2. Huadong Medicine (Xi’an) Bohua Pharmaceutical Co., Ltd.
(1) Waste water

     Name of pollution
  prevention and control         Treatment process         Processing capacity             Time of operation           Status of operation
          facilities

   Waste water treatment        Ozone oxidation +
   system of the sewage       facultative + aerobic +          250 tons/day                     July 2012                   Normal
           station                     MBR



                                                                                                                                          52
                                                                                   The Half Year Report 2021 of Huadong Medicine Co., Ltd


(2) Waste gas

  Name of pollution prevention and control facilities           Treatment process            Time of operation          Status of operation

                                                                Alkali spray + dry
                                                                filter (filter cotton)
    Waste gas treatment unit of raw medicine No. 1
                                                                +UV photolysis +                October 2020                   Normal
                          workshop
                                                                 activated carbon
                                                                    adsorption

                                                              Two alkali spray + dry
    Waste gas treatment unit of raw medicine No. 2
                                                               filter +UV photolysis          November 2019                    Normal
                          workshop
                                                                + activated carbon



(3) Solid waste

     Name of pollution
   prevention and control        Treatment process         Storage capacity          Time of operation             Status of operation
          facilities

                                     Standardized                                                          Standardize storage; legal disposal
Hazardous waste warehouse                                       60 tons                  January 2012
                                       storage                                                                 by entrusted qualified units



3. Jiangsu Jiuyang Biopharm Co., Ltd.
(1) Waste water

    Name of pollution
  prevention and control                Treatment process                 Processing capacity      Time of operation      Status of operation
         facilities

                                 Air floatation tank + hydrolysis
  Waste water treatment
                                 acidification + IC tower + UASB
   system of the sewage                                                      300 tons/day             December 2014             Normal
                                   pool + A/O pool + O pool +
          station
                                  secondary sedimentation tank


(2) Waste gas

                                                                                                          Name of pollution
 Name of pollution prevention and control                                                   Processing                           Treatment
                                                          Treatment process                                prevention and
                    facilities                                                               capacity                             process
                                                                                                          control facilities

                                                    Level 1 water spray + moisture
                                                      separator + photocatalytic
 Waste gas treatment unit of the extraction
                                                     oxidation + level 2 activated            10000              2014             Normal
         section of workshop 101
                                                 carbon adsorption + high-altitude
                                                 discharge via 25m exhaust pipe


      Waste gas treatment unit of the
                                                    Level 1 water spray + moisture            20000              2019             Normal
  fermentation section of workshop 101
                                                     separator + level 2 activated


                                                                                                                                              53
                                                                              The Half Year Report 2021 of Huadong Medicine Co., Ltd


                                              carbon adsorption + high-altitude
                                               discharge via 25m exhaust pipe


                                               Level 1 water spray + moisture
 Waste gas treatment unit of the drying         separator + level 2 activated
                                                                                      22000             2017            Normal
        section of workshop 101               carbon adsorption + high-altitude
                                               discharge via 25m exhaust pipe


                                             Cyclone separator + level 1 water
 Waste gas treatment unit of the dosing
                                             spray + high-altitude discharge via       5000             2014            Normal
        section of workshop 101
                                                      15m exhaust pipe


                                               Level 1 water spray + moisture
     Waste gas treatment unit of the
                                             separator + level 2 activated carbon
    fermentation section of workshop                                                  75000             2021            Normal
                                                 adsorption + high-altitude
              104/107/108
                                               discharge via 25m exhaust pipe
                                               Level 1 water spray + moisture
                                                 separator + photocatalytic
Waste gas treatment unit of the extraction
                                                oxidation + level 2 activated
        section of workshop 104                                                       10000             2015            Normal
                                              carbon adsorption + high-altitude
                                               discharge via 25m exhaust pipe


                                             Cyclone separator + level 1 water
 Waste gas treatment unit of the dosing
                                             spray + high-altitude discharge via       5000             2015            Normal
    section of workshop 104/107/108
                                                      15m exhaust pipe
                                               Level 1 water spray + moisture
 Waste gas treatment unit of the drying
                                                separator + level 2 activated         20000             2015            Normal
    section of workshop 104/107/108
                                                     carbon adsorption
                                               Level 1 water spray + moisture
     Waste gas treatment unit of the             separator + photocatalytic
 pretreatment pool and hazardous waste          oxidation + level 2 activated         40000             2019            Normal
    warehouse of workshop 103, 303            carbon adsorption + high-altitude
                                               discharge via 25m exhaust pipe
                                               Level 1 water spray + moisture
                                                 separator + photocatalytic
Waste gas treatment unit of workshop 106        oxidation + level 2 activated
                                                                                      10000             2015            Normal
                                              carbon adsorption + high-altitude
                                               discharge via 25m exhaust pipe


                                               Level 1 water spray + moisture
                                                 separator + photocatalytic
Waste gas treatment unit of the extraction
                                                oxidation + level 2 activated         20000             2019            Normal
        section of workshop 107
                                              carbon adsorption + high-altitude
                                               discharge via 25m exhaust pipe




                                                                                                                                 54
                                                                              The Half Year Report 2021 of Huadong Medicine Co., Ltd


                                               Level 1 water spray + moisture
                                                 separator + photocatalytic
 Waste gas treatment unit of the extraction
                                                oxidation + level 2 activated
         section of workshop 108                                                      40000             2019               Normal
                                              carbon adsorption + high-altitude
                                              discharge via 25m exhaust pipe


                                                    Level 1 water spray +
Waste gas treatment unit of workshop 109      high-altitude discharge via 25m         20000             2019               Normal
                                                        exhaust pipe
                                               Level 1 water spray + moisture
Waste gas treatment unit of sewage station      separator + photocatalysis +
                                                                                      15000             2021               Normal
                       303                    high-altitude discharge via 25m
                                                        exhaust pipe



(3) Solid waste

     Name of pollution
   prevention and control       Treatment process      Processing capacity         Time of operation           Status of operation
          facilities

                                                                                                         Standardized storage; legal
Hazardous waste warehouse Standardized storage               300 tons               December 2020           disposal by entrusted
                                                                                                                 qualified units

                                                                                                        Chengdong Garbage Disposal
    Domestic waste yard       Standardized storage            3 tons                 March 2015
                                                                                                                    Station



Environmental impact assessment of construction projects and other administrative permits for

environmental protection
     1. Zhongmei Huadong completed the independent inspection and acceptance for the environmental
protection upon completion of the technical transformation project of the macromolecular medicine R&D
laboratory (pilot test), and disclosed the acceptance information in the National Environmental Protection Final
Inspection Information System for Construction Projects.
     2. All construction projects of Huadong Medicine (Xi’an) Bohua Pharmaceutical Co., Ltd. have been
declared, constructed and accepted in strict accordance with the requirements of “three simultaneous items” for
environmental protection, all of which have obtained the official approval of environmental assessment,
conforming to the requirements of environmental impact assessment of construction projects.
     On June 13, 2019, Huadong Medicine (Xi’an) Bohua Pharmaceutical Co., Ltd. obtained the approval
(W.H.P.F [2019] No.49) from Weinan Environmental Protection Bureau for the environmental impact assessment
report on domperidone, seflurane and topiramate pilot test reform projects.
     In November 2019, Huadong Medicine (Xi’an) Bohua Pharmaceutical Co., Ltd. completed the
environmental impact post assessment report and submitted it to Weinan Ecological Environment Bureau for
filing, with the filing number: W.H.P.B (2020) No.3.

                                                                                                                                     55
                                                                 The Half Year Report 2021 of Huadong Medicine Co., Ltd


     3. All construction projects of Jiangsu Jiuyang Biopharmaceutical Co., Ltd. have been declared, constructed
and accepted in strict accordance with the requirements of “three simultaneous items” for environmental
protection, all of which have obtained the official approval of environmental assessment, conforming to the
requirements of environmental impact assessment of construction projects. Jiangsu Jiuyang Biopharmaceutical
Co., Ltd. has obtained the sewage discharge permit and the discharge permit of urban sewage into the drainage
pipe network in accordance with the environmental protection requirements.


Emergency plan for sudden environmental incidents
     1. Zhongmei Huadong completed the filing with Gongshu Branch of Hangzhou Ecological Environment
Bureau on February 2, 2021.
     2. Huadong Medicine (Xi’an) Bohua Pharmaceutical Co., Ltd. prepared an Emergency Plan for Sudden
Environmental Incidents, with the filing No.61050020183022.
     3. Jiangsu Jiuyang Biopharmaceutical Co., Ltd. formulated its Emergency Plan for Sudden Environmental
Incidents which was first prepared in October 2017. The 2021 plan has been renewed and reviewed, and is being
filed.
     The Emergency Plan for Sudden Environmental Incidents of Jiangsu Jiuyang Bio-pharmaceutical Co., Ltd.
can improve the company’s ability to cope with and prevent environmental emergencies. In May 2021, the
company organized a drill for its comprehensive emergency plan for safety and environmental protection,
standardized the emergency handling of sudden environmental incidents, minimized the hazards to human health
and the environment caused by the leakage of environmental risk substances into the air, water or soil due to fire,
explosion, leakage or other unexpected emergencies, and enhanced the emergency response capability for
environmental pollution incidents.


Environmental self-monitoring scheme
     1. On December 25, 2020, Zhongmei Huadong completed the change and continuation of the pollutant
discharge permit, as well as and the revision of the self-monitoring scheme.
     2. Huadong Medicine (Xi’an) Bohua Pharmaceutical Co., Ltd. prepared the “Self-monitoring Scheme for
Pollution Sources” which was put on record in the environmental protection authorities, and all the monitoring
data was reported according to the regulations.
     3. Jiangsu Jiuyang Biopharmaceutical Co., Ltd. prepared the “Self-monitoring Scheme for Pollution Sources”
which was put on record in the environmental protection authorities.
     The scheme was prepared in accordance with the relevant national requirements for environmental protection,
and the company reported all the monitoring data every day according to the regulations.


Administrative penalties imposed for environmental issues during the reporting period
                                                                                 Impact on the
Name of company or                                                                                   Corrective measures
                     Reason for penalty    Violation       Result of penalty    production and
     subsidiary                                                                                        of the company
                                                                               operation of listed


                                                                                                                        56
                                                                         The Half Year Report 2021 of Huadong Medicine Co., Ltd


                                                                                            company

                                                                                                           The company
                                                                                                           immediately stopped
                                            The concentration of                                           discharging sewage
                                            ammonia nitrogen in                                            and re-processed the
                    Discharged
                                            the wastewater from                                            unqualified sewage.
                    industrial wastewater
                                            the general discharge                                          After the sewage
Jiangsu Jiuyang     that failed to meet
                                            outlet failed to meet A fine of 100,000   Did not constitute a reached the standard,
Biopharmaceutical   the process
                                            the treatment process yuan                significant impact   the environmental
Co., Ltd.           requirements to the
                                            requirements of                                                protection authority
                    centralized sewage
                                            Sheyang County                                                 sampled and tested
                    treatment facilities
                                            Wastewater                                                     it. After passing the
                                            Treatment Co., Ltd.                                            test, the sewage was
                                                                                                           discharged according
                                                                                                           to regulations.



Other environmental information that should be made public
/



Other information related to environmental protection
Zhongmei Huadong completes the carbon emission verification report during the period from July to August
every year according to the requirements of the superior environmental protection authorities, and reports it to the
carbon emission system of the ecological environment authority for filing.



II. Social responsibilities

      The Company actively performed corporate social responsibilities, took the initiative to
participate in social public welfare activities, and made a contribution to society with actions.
      In July 2021, many areas in Henan Province suffered from extremely heavy rainfall, which
caused severe floods and heavy casualties and property losses. Zhongmei Huadong, the Company’s
wholly-owned subsidiary, immediately donated RMB2 million in cash to the Henan Red Cross
Society to support the flood relief and the construction of the post-disaster public health service
system in the province.
      In July 2021, Zhongmei Huadong, the Company’s wholly-owned subsidiary, donated RMB1
million in cash to Zhejiang Shulan Charity Foundation to help poor patients with major diseases,
especially those who need organ transplants or have other major diseases.
      The Company actively responded to the “Connecting the Villages” activity organized by the
government, and launched targeted support projects. It formed a pair with Linqi Town, Chun’an


                                                                                                                                   57
                                                        The Half Year Report 2021 of Huadong Medicine Co., Ltd


County, Hangzhou, and provided support to boost the economic and social development of Linqi
Town through targeted poverty alleviation. From 2017 to 2020, the Company donated a total of
RMB1.2 million to the “Connecting the Villages” poverty alleviation project, and it is expected to
donate another RMB300,000 in 2021.




                                                                                                           58
                                                       The Half Year Report 2021 of Huadong Medicine Co., Ltd




                                     Section VI. Important Matters

I. Fulfilled and Unfulfilled commitments from the related committed parties such as the
Company’s actual controller, shareholders, related parties, acquirer(s), and the Company
during the current reporting period

□ Applicable    √ N/A
No such case during the reporting period.


II. Controlling shareholder’s and related parties’ occupation of non-operating funds of the
listed companies

□ Applicable    √ N/A
No such case during the reporting period.


III. External guarantees in violation of provisions

□ Applicable    √ N/A
No such case during the reporting period.


IV. Employment and dismissal of accounting firms

Whether the half year report was audited
□ Yes   √ No
The Company’s half year report was not audited.


V. Explanation given by the Board of directors and the Board of Supervisors regarding the
“non-standard auditor’s report” issued by the accounting firm for the current reporting
period

□ Applicable    √ N/A


VI. Explanation given by the Board of Directors regarding the “non-standard auditor’s
report” for the prior year

□ Applicable    √ N/A


VII. Bankruptcy reorganization

□ Applicable    √ N/A
No such case during the reporting period.



                                                                                                          59
                                                                                The Half Year Report 2021 of Huadong Medicine Co., Ltd


VIII. Litigations

Major litigation and arbitration
□ Applicable   √ N/A
No such case during the reporting period.


Other litigations
√ Applicable   □N/A

                                         Whether
                         Amount                                                                  Litigation
  Basic litigation                       estimated     Progress of         Litigation
                         involved                                                               (arbitration)      Disclosure       Disclosure
    (arbitration)                    liabilities are     litigation    (arbitration) result
                          (unit:                                                                  judgment             date           index
    information                      formed as a       (arbitration)      and impact
                      RMB10,000)                                                                 execution
                                          result

                                                                                              Some judgments
                                                                                              have taken
Summary of                                             Some cases
                                                                                              effect and are
matters that do not                                    are being       The summary of                             Not meet the
                                                                                              under execution,
meet the disclosure                                    filed, some litigation matters                             disclosure
                                                                                              some have not
standards for                783.33 No                 are under       has no material                            standards for /
                                                                                              yet taken effect,
major litigation                                       trial, and      impact on the                              major
                                                                                              some are
(arbitration)                                          some have       Company                                    litigation
                                                                                              pending, and
(domestic)                                             taken effect
                                                                                              some are in
                                                                                              progress

Summary of
matters that do not                                                    The summary of                             Not meet the
meet the disclosure                                                    litigation matters                         disclosure
                                                                                              In trial, with no
standards for                 117.6 No                 In trial        has no material                            standards for /
                                                                                              decision made
major litigation                                                       impact on the                              major
(arbitration)                                                          Company                                    litigation
(overseas)


IX. Punishment and rectification

□ Applicable   √ N/A
No such case during the reporting period.


X. Integrity of the Company and its controlling shareholder and actual controller

□ Applicable   √ N/A




                                                                                                                                                 60
                                                                                          The Half Year Report 2021 of Huadong Medicine Co., Ltd


XI. Major related transactions

1. Transactions related to daily operations

√Applicable     □N/A

                                                                                              Approve
                                                                        Related Proporti                  Whether Settleme
                                              Pricing                                            d                              Availabl
                                  Content                               transacti on in the                    it      nt
                      Type of                 principl Price of                               transacti                         e market
                                      of                                   on     amount                  exceeds method                    Date of Disclo
Related Relation related                       es for         related                            on                             prices of
                                  related                               amount       of                     the        of                   disclosu    sure
  party        ship   transacti                related transacti                              amount                            similar
                                  transacti                               (ten    similar                 approve related                      re      index
                          on                  transacti          on                             (ten                            transacti
                                      on                                thousan transacti                      d    transacti
                                                    on                                        thousan                             ons
                                                                        d yuan)     ons                   amount       on
                                                                                              d yuan)

                                              Market
                                              price
                                              determi
          Subsidia
                                              ned        by
          ry of the
Grandph                                       the
          Compan                                                                                                    Cash,                              http://
arma                  Drug        Drug        Compan
          y’s                                                Market                                                banker’s Market April             www.c
(China)               purchas purchas y’s                              3,831.33 0.33%        7,500       No
          controlli                                           price                                                 acceptan price          21, 2021 ninfo.c
Co.,                  e           e           related
          ng                                                                                                        ce bill                            om.cn
Ltd.                                          transacti
          sharehol
                                              on
          der
                                              decision
                                              -making
                                              process

                                              Market
                                              price
                                              determi
Hangzh
                                              ned        by
ou
          Joint                               the
Jiuyuan                                                                                                             Cash,                              http://
          venture Drug            Drug        Compan
Gene                                                          Market                                                banker’s Market April             www.c
          of      the purchas purchas y’s                              3,006.94 0.26%        4,500       No
Enginee                                                       price                                                 acceptan price          21, 2021 ninfo.c
          Compan e                e           related
ring                                                                                                                ce bill                            om.cn
          y                                   transacti
Co.,
                                              on
Ltd.
                                              decision
                                              -making
                                              process

Sichuan Subsidia                              Market                                                                Cash,                              http://
                      Drug        Drug
Yuanda ry of the                              price           Market                                                banker’s Market April             www.c
                      purchas purchas                                   2,468.59 0.21%        6,500       No
Shuyang Compan                                determi price                                                         acceptan price          21, 2021 ninfo.c
                      e           e
Pharmac y’s                                  ned        by                                                         ce bill                            om.cn


                                                                                                                                                               61
                                                                                The Half Year Report 2021 of Huadong Medicine Co., Ltd


eutical    controlli                     the
Co.,       ng                            Compan
Ltd.       sharehol                      y’s
           der                           related
                                         transacti
                                         on
                                         decision
                                         -making
                                         process

                                         Market
                                         price
                                         determi
           Subsidia
Beijing                                  ned     by
           ry of the
Grand                                    the
           Compan                                                                                  Cash,                      http://
Johamu                 Drug    Drug      Compan
           y’s                                       Market                                       banker’s Market April     www.c
Pharmac                purchas purchas y’s                    1,110.83 0.10%    4,000    No
           controlli                                  price                                        acceptan price    21, 2021 ninfo.c
eutical                e       e         related
           ng                                                                                      ce bill                    om.cn
Co.,                                     transacti
           sharehol
Ltd.                                     on
           der
                                         decision
                                         -making
                                         process

                                         Market
                                         price
                                         determi
Wuhan Subsidia
                                         ned     by
Grand      ry of the
                                         the
Pharmac Compan                                                                                     Cash,                      http://
                       Drug    Drug      Compan
eutical    y’s                                       Market                                       banker’s Market April     www.c
                       purchas purchas y’s                    1,037.95 0.09%    2,000    No
Group      controlli                                  price                                        acceptan price    21, 2021 ninfo.c
                       e       e         related
Sales      ng                                                                                      ce bill                    om.cn
                                         transacti
Co.,       sharehol
                                         on
Ltd.       der
                                         decision
                                         -making
                                         process

           Subsidia                      Market
Hangzh
           ry of the                     price
ou
           Compan                        determi                                                   Cash,                      http://
Grand                  Drug    Drug
           y’s                          ned     by Market                                         banker’s Market April     www.c
Biologic               purchas purchas                         920.86   0.08%    2,000    No
           controlli                     the          price                                        acceptan price    21, 2021 ninfo.c
Pharmac                e       e
           ng                            Compan                                                    ce bill                    om.cn
eutical
           sharehol                      y’s
Inc
           der                           related



                                                                                                                                    62
                                                                                The Half Year Report 2021 of Huadong Medicine Co., Ltd


                                         transacti
                                         on
                                         decision
                                         -making
                                         process

                                         Market
                                         price
                                         determi
           Subsidia
                                         ned     by
Penglai ry of the
                                         the
Nuokan Compan                                                                                      Cash,                      http://
                       Drug    Drug      Compan
g          y’s                                       Market                                       banker’s Market April     www.c
                       purchas purchas y’s                    880.23   0.08%    3,000    No
Pharmac controlli                                     price                                        acceptan price    21, 2021 ninfo.c
                       e       e         related
eutical    ng                                                                                      ce bill                    om.cn
                                         transacti
Co. Ltd. sharehol
                                         on
           der
                                         decision
                                         -making
                                         process

                                         Market
                                         price
                                         determi
Yunnan Subsidia
                                         ned     by
Leiyuns ry of the
                                         the
hang       Compan                                                                                  Cash,                      http://
                       Drug    Drug      Compan
Lixiang y’s                                          Market                                       banker’s Market April     www.c
                       purchas purchas y’s                    850.27   0.07%    2,000    No
Pharmac controlli                                     price                                        acceptan price    21, 2021 ninfo.c
                       e       e         related
eutical    ng                                                                                      ce bill                    om.cn
                                         transacti
Co.,       sharehol
                                         on
Ltd.       der
                                         decision
                                         -making
                                         process

                                         Market
                                         price
           Subsidia                      determi
Shangha
           ry of the                     ned     by
i
           Compan                        the                                                       Cash,                      http://
Xudong                 Drug    Drug
           y’s                          Compan Market                                             banker’s Market April     www.c
Haipu                  purchas purchas                         240.72   0.02%    500      No
           controlli                     y’s         price                                        acceptan price    21, 2021 ninfo.c
Pharmac                e       e
           ng                            related                                                   ce bill                    om.cn
eutical
           sharehol                      transacti
Co., Ltd
           der                           on
                                         decision
                                         -making



                                                                                                                                    63
                                                                              The Half Year Report 2021 of Huadong Medicine Co., Ltd


                                       process

                                       Market
                                       price
                                       determi
          Subsidia
                                       ned     by
Leiyuns ry of the
                                       the
hang      Compan                                                                                 Cash,                          http://
                      Drug    Drug     Compan
Pharmac y’s                                        Market                                       banker’s Market April         www.c
                      purchas purchas y’s                   230.9    0.02%    500      No
eutical   controlli                                 price                                        acceptan price      21, 2021 ninfo.c
                      e       e        related
Group     ng                                                                                     ce bill                        om.cn
                                       transacti
Co. Ltd. sharehol
                                       on
          der
                                       decision
                                       -making
                                       process

                                       Market
                                       price
                                       determi
Shenyan Subsidia
                                       ned     by
g Yaoda ry of the
                                       the
Leiyuns Compan                                                                                   Cash,                          http://
                      Drug    Drug     Compan
hang      y’s                                      Market                                       banker’s Market April         www.c
                      purchas purchas y’s                   221.82   0.02%    700      No
Pharmac controlli                                   price                                        acceptan price      21, 2021 ninfo.c
                      e       e        related
eutical   ng                                                                                     ce bill                        om.cn
                                       transacti
Co.,      sharehol
                                       on
Ltd.      der
                                       decision
                                       -making
                                       process

                                       Market
                                       price
                                       determi
Guangd Subsidia
                                       ned     by
ong       ry of the
                                       the
Leiyuns Compan                                                                                   Cash,                          http://
                      Drug    Drug     Compan
hang      y’s                                      Market                                       banker’s Market April         www.c
                      purchas purchas y’s                   206.18   0.02%    350      No
Pharmac controlli                                   price                                        acceptan price      21, 2021 ninfo.c
                      e       e        related
eutical   ng                                                                                     ce bill                        om.cn
                                       transacti
Co.,      sharehol
                                       on
Ltd.      der
                                       decision
                                       -making
                                       process

Xi'an     Subsidia Drug       Drug     Market                                                    Cash,                          http://
                                                    Market                                                   Market April
Yuanda ry of the purchas purchas price                       104.13   0.01%    300      No       banker’s                      www.c
                                                    price                                                    price   21, 2021
new       Compan e            e        determi                                                   acceptan                       ninfo.c


                                                                                                                                      64
                                                                             The Half Year Report 2021 of Huadong Medicine Co., Ltd


Beilin    y’s                         ned     by                                               ce bill                    om.cn
Pharmac controlli                      the
eutical   ng                           Compan
Co., Ltd sharehol                      y’s
          der                          related
                                       transacti
                                       on
                                       decision
                                       -making
                                       process

                                       Market
                                       price
                                       determi
Changsh Subsidia
                                       ned     by
u         ry of the
                                       the
Leiyuns Compan                                                                                  Cash,                      http://
                      Drug    Drug     Compan
hang      y’s                                      Market                                      banker’s Market April     www.c
                      purchas purchas y’s                   70.47   0.01%    200      No
Pharmac controlli                                   price                                       acceptan price    21, 2021 ninfo.c
                      e       e        related
eutical   ng                                                                                    ce bill                    om.cn
                                       transacti
Co.,      sharehol
                                       on
Ltd.      der
                                       decision
                                       -making
                                       process

                                       Market
                                       price
                                       determi
Changc Subsidia
                                       ned     by
hun       ry of the
                                       the
Leiyuns Compan                                                                                  Cash,                      http://
                      Drug    Drug     Compan
hang      y’s                                      Market                                      banker’s Market April     www.c
                      purchas purchas y’s                   68.51   0.01%    150      No
Pharmac controlli                                   price                                       acceptan price    21, 2021 ninfo.c
                      e       e        related
eutical   ng                                                                                    ce bill                    om.cn
                                       transacti
Co.,      sharehol
                                       on
Ltd.      der
                                       decision
                                       -making
                                       process

          Subsidia                     Market
Beijing ry of the                      price
                                                                                                Cash,                      http://
Huajin    Compan Drug         Drug     determi
                                                    Market                                      banker’s Market April     www.c
Pharmac y’s          purchas purchas ned      by            28.1    0.00%    100      No
                                                    price                                       acceptan price    21, 2021 ninfo.c
eutical   controlli e         e        the
                                                                                                ce bill                    om.cn
Co., Ltd ng                            Compan
          sharehol                     y’s



                                                                                                                                 65
                                                                             The Half Year Report 2021 of Huadong Medicine Co., Ltd


          der                          related
                                       transacti
                                       on
                                       decision
                                       -making
                                       process

                                       Market
Hangzh
                                       price
ou
                                       determi
Huadon Subsidia
                                       ned     by
g         ry of the
                                       the
Medicin Compan                                                                                  Cash,                      http://
                      Drug    Drug     Compan
e Group y’s                                        Market                                      banker’s Market April     www.c
                      purchas purchas y’s                   24.82   0.00%    150      No
Guizhou second                                      price                                       acceptan price    21, 2021 ninfo.c
                      e       e        related
TCM       largest                                                                               ce bill                    om.cn
                                       transacti
Develop sharehol
                                       on
ment      der
                                       decision
Co.,
                                       -making
Ltd.
                                       process

                                       Market
                                       price
                                       determi
          Subsidia
                                       ned     by
Xi'an     ry of the
                                       the
Yuanda Compan                                                                                   Cash,                      http://
                      Drug    Drug     Compan
Detian    y’s                                      Market                                      banker’s Market April     www.c
                      purchas purchas y’s                   5.41    0.00%             Yes
Pharmac controlli                                   price                                       acceptan price    21, 2021 ninfo.c
                      e       e        related
eutical   ng                                                                                    ce bill                    om.cn
                                       transacti
Co., Ltd sharehol
                                       on
          der
                                       decision
                                       -making
                                       process

                                       Market
Grandph                                price
          Subsidia
arma                                   determi
          ry of the
Huangs                                 ned     by
          Compan                                                                                Cash,                      http://
hi                                     the
          y’s        Drug    Drug                  Market                                      banker’s Market April     www.c
Feiyun                                 Compan                3.29    0.00%             Yes
          controlli sales     sales                 price                                       acceptan price    21, 2021 ninfo.c
Pharmac                                y’s
          ng                                                                                    ce bill                    om.cn
eutical                                related
          sharehol
Co.,                                   transacti
          der
Ltd.                                   on
                                       decision



                                                                                                                                 66
                                                                             The Half Year Report 2021 of Huadong Medicine Co., Ltd


                                      -making
                                      process

                                      Market
                                      price
                                      determi
Hangzh                                ned     by
ou                                    the
           Shareho                                                                              Cash,                      http://
Junlan                                Compan
           lding       Drug   Drug                 Market                                       banker’s Market April     www.c
Pharmac                               y’s                  4,526.18 0.26%    14,000   No
           enterpris sales    sales                price                                        acceptan price    21, 2021 ninfo.c
eutical                               related
           e                                                                                    ce bill                    om.cn
Trading                               transacti
Co. Ltd.                              on
                                      decision
                                      -making
                                      process

                                      Market
                                      price
                                      determi
           Subsidia
                                      ned     by
Leiyuns ry of the
                                      the
hang       Compan                                                                               Cash,                      http://
                                      Compan
Pharmac y’s           Drug   Drug                 Market                                       banker’s Market April     www.c
                                      y’s                  251.55   0.01%    450      No
eutical    controlli sales    sales                price                                        acceptan price    21, 2021 ninfo.c
                                      related
Group      ng                                                                                   ce bill                    om.cn
                                      transacti
Co. Ltd. sharehol
                                      on
           der
                                      decision
                                      -making
                                      process

                                      Market
                                      price
                                      determi
Guangd Subsidia
                                      ned     by
ong        ry of the
                                      the
Leiyuns Compan                                                                                  Cash,                      http://
                                      Compan
hang       y’s        Drug   Drug                 Market                                       banker’s Market April     www.c
                                      y’s                  36.34    0.00%    400      No
Pharmac controlli sales       sales                price                                        acceptan price    21, 2021 ninfo.c
                                      related
eutical    ng                                                                                   ce bill                    om.cn
                                      transacti
Co.,       sharehol
                                      on
Ltd.       der
                                      decision
                                      -making
                                      process

Yunnan Subsidia Drug          Drug    Market Market                                             Cash,     Market April     http://
                                                            66.06    0.00%    250      No
Leiyuns ry of the sales       sales   price        price                                        banker’s price   21, 2021 www.c


                                                                                                                                 67
                                                                             The Half Year Report 2021 of Huadong Medicine Co., Ltd


hang      Compan                        determi                                                 acceptan                   ninfo.c
Lixiang y’s                            ned     by                                              ce bill                    om.cn
Pharmac controlli                       the
eutical   ng                            Compan
Co.,      sharehol                      y’s
Ltd.      der                           related
                                        transacti
                                        on
                                        decision
                                        -making
                                        process

                                        Market
                                        price
                                        determi
Changc Subsidia
                                        ned     by
hun       ry of the
                                        the
Leiyuns Compan                                                                                  Cash,                      http://
                                        Compan
hang      y’s          Drug    Drug                 Market                                     banker’s Market April     www.c
                                        y’s                  5.69   0.00%             Yes
Pharmac controlli sales         sales                price                                      acceptan price    21, 2021 ninfo.c
                                        related
eutical   ng                                                                                    ce bill                    om.cn
                                        transacti
Co.,      sharehol
                                        on
Ltd.      der
                                        decision
                                        -making
                                        process

                                        Market
                                        price
                                        determi
Changsh Subsidia
                                        ned     by
u         ry of the
                                        the
Leiyuns Compan                                                                                  Cash,                      http://
                                        Compan
hang      y’s          Drug    Drug                 Market                                     banker’s Market April     www.c
                                        y’s                  8.58   0.00%             Yes
Pharmac controlli sales         sales                price                                      acceptan price    21, 2021 ninfo.c
                                        related
eutical   ng                                                                                    ce bill                    om.cn
                                        transacti
Co.,      sharehol
                                        on
Ltd.      der
                                        decision
                                        -making
                                        process

Hangzh                                  Market
          Joint
ou                                      price                                                   Cash,                      http://
          venture
Jiuyuan                 Drug    Drug    determi Market                                          banker’s Market April     www.c
          of      the                                         0.66   0.00%    600      No
Gene                    sales   sales   ned     by price                                        acceptan price    21, 2021 ninfo.c
          Compan
Enginee                                 the                                                     ce bill                    om.cn
          y
ring                                    Compan



                                                                                                                                 68
                                                                                The Half Year Report 2021 of Huadong Medicine Co., Ltd


Co.,                                     y’s
Ltd.                                     related
                                         transacti
                                         on
                                         decision
                                         -making
                                         process

                                         Market
                                         price
                                         determi
Hangzh
                                         ned     by
ou
           Joint                         the
Tangyan                                                                                            Cash,                      http://
           venture                       Compan
gyuan                    Drug    Drug                 Market                                       banker’s Market April     www.c
           of      the                   y’s                  462.48   0.03%    1,200    No
Pharmac                  sales   sales                price                                        acceptan price    21, 2021 ninfo.c
           Compan                        related
eutical                                                                                            ce bill                    om.cn
           y                             transacti
Co.,
                                         on
Ltd.
                                         decision
                                         -making
                                         process

                                         Market
                                         price
                                         determi
           Subsidia
Hangzh                                   ned     by
           ry of the
ou                                       the
           Compan                                                                                  Cash,                      http://
Grand                                    Compan
           y’s          Drug    Drug                 Market                                       banker’s Market April     www.c
Biologic                                 y’s                  74.1     0.00%    150      No
           controlli sales       sales                price                                        acceptan price    21, 2021 ninfo.c
Pharmac                                  related
           ng                                                                                      ce bill                    om.cn
eutical                                  transacti
           sharehol
Inc.                                     on
           der
                                         decision
                                         -making
                                         process

                                         Market
           Subsidia                      price
Grand      ry of the                     determi
Resourc Compan                           ned     by                                                Cash,                      http://
es         y’s          Drug    Drug    the          Market                                       banker’s Market April     www.c
                                                               5.65     0.00%             Yes
Group      controlli sales       sales   Compan price                                              acceptan price    21, 2021 ninfo.c
Co.,       ng                            y’s                                                      ce bill                    om.cn
Ltd.       sharehol                      related
           der                           transacti
                                         on



                                                                                                                                    69
                                                                                  The Half Year Report 2021 of Huadong Medicine Co., Ltd


                                            decision
                                            -making
                                            process

                                            Market
                                            price
                                            determi
Hangzh
                                            ned     by
ou
            Joint                           the
Jiuyuan                                                                                              Cash,                      http://
            venture                         Compan
Gene                      House    House                 Market                                      banker’s Market April     www.c
            of      the                     y’s                  6.42    0.00%    5        Yes
Enginee                   rental   rental                price                                       acceptan price    21, 2021 ninfo.c
            Compan                          related
ring                                                                                                 ce bill                    om.cn
            y                               transacti
Co.,
                                            on
Ltd.
                                            decision
                                            -making
                                            process

                                            Market
                                            price
                                            determi
            Subsidia
                                            ned     by
Beijing ry of the
                                            the
Yanhuan Compan                                                                                       Cash,                      http://
                                            Compan
g      Real y’s          House    House                 Market                                      banker’s Market April     www.c
                                            y’s                  43.09   0.00%             Yes
Estate      controlli leasing leasing                    price                                       acceptan price    21, 2021 ninfo.c
                                            related
Co.,        ng                                                                                       ce bill                    om.cn
                                            transacti
Ltd.        sharehol
                                            on
            der
                                            decision
                                            -making
                                            process

                                            Market
                                            price
                                            determi
Hangzh
            The                             ned     by
ou
            Compan                          the
Huadon                                                                                               Cash,                      http://
            y’s                            Compan
g                         House    House                 Market                                      banker’s Market April     www.c
            second                          y’s                  10.86   0.00%    25       No
Medicin                   leasing leasing                price                                       acceptan price    21, 2021 ninfo.c
            largest                         related
e Group                                                                                              ce bill                    om.cn
            sharehol                        transacti
Co.,
            der                             on
Ltd.
                                            decision
                                            -making
                                            process

Hangzh Subsidia Technol Technol Market Market 8.08                        0.00%             Yes      Cash,     Market April     http://


                                                                                                                                      70
                                                                                 The Half Year Report 2021 of Huadong Medicine Co., Ltd


ou        ry of the ogy         ogy       price        price                                        banker’s price   21, 2021 www.c
Grand     Compan Develop Develop determi                                                            acceptan                   ninfo.c
Biologic y’s         ment      ment      ned     by                                                ce bill                    om.cn
Pharmac controlli Service Service the
eutical   ng                              Compan
Inc.      sharehol                        y’s
          der                             related
                                          transacti
                                          on
                                          decision
                                          -making
                                          process

                                          Market
                                          price
                                          determi
          Subsidia
                                          ned     by
Penglai ry of the
                                          the
Nuokan Compan                                                                                       Cash,                      http://
                                          Compan
g         y’s        Agency Agency                    Market                                       banker’s Market April     www.c
                                          y’s                  794.75   0.07%             Yes
Pharmac controlli Service Service                      price                                        acceptan price    21, 2021 ninfo.c
                                          related
eutical   ng                                                                                        ce bill                    om.cn
                                          transacti
Co. Ltd. sharehol
                                          on
          der
                                          decision
                                          -making
                                          process

                                          Market
                                          price
                                          determi
          Subsidia
Sichuan                                   ned     by
          ry of the
Yuanda                Transpo Transpo the
          Compan                                                                                    Cash,                      http://
Shuyang               rt        rt        Compan
          y’s                                         Market                                       banker’s Market April     www.c
Pharmac               warehou warehou y’s                      18.5     0.00%             Yes
          controlli                                    price                                        acceptan price    21, 2021 ninfo.c
eutical               sing      sing      related
          ng                                                                                        ce bill                    om.cn
Co.,                  service   service   transacti
          sharehol
Ltd.                                      on
          der
                                          decision
                                          -making
                                          process

Beijing Subsidia                          Market
                                                                                                    Cash,                      http://
Yuanda ry of the Property Property price
                                                       Market                                       banker’s Market April     www.c
Chuang Compan manage manage determi                             9.64     0.00%             Yes
                                                       price                                        acceptan price    21, 2021 ninfo.c
xin       y’s        ment fee ment fee ned       by
                                                                                                    ce bill                    om.cn
Property controlli                        the



                                                                                                                                     71
                                                                                       The Half Year Report 2021 of Huadong Medicine Co., Ltd


Manage ng                                     Compan
ment           sharehol                       y’s
Co.,           der                            related
Ltd.                                          transacti
                                              on
                                              decision
                                              -making
                                              process

                                              Market
                                              price
                                              determi
Beijing Subsidia
                                              ned     by
Haiwan ry of the
                                              the
Banshan Compan                                                                                                  Cash,                            http://
                                              Compan
Hotel          y’s       conferen conferen                Market                                               banker’s Market April           www.c
                                              y’s                  9.08       0.00%               Yes
Manage controlli ce fee           ce fee                   price                                                acceptan price       21, 2021 ninfo.c
                                              related
ment           ng                                                                                               ce bill                          om.cn
                                              transacti
Co.,           sharehol
                                              on
Ltd.           der
                                              decision
                                              -making
                                              process

                                                                    21,649.0
Total                                         --           --                  --       51,530     --           --        --         --          --
                                                                    6

Details of bulk sales returns                 N/A

Actual         performance     during   the
reporting period where the total
amount of daily related transactions N/A
is estimated by category for the
current period (if any)

Reasons for the large difference
between the transaction price and the N/A
market reference price (if applicable)


2. Related transactions involving the acquisition or sale of assets and shares

□ Applicable         √ N/A
No such case during the reporting period.


3. Related transactions of joint external investment

√ Applicable         □N/A

       Joint            Related    Name of investee Main business               Registered       Total assets        Net assets of        Net profits of



                                                                                                                                                           72
                                                                              The Half Year Report 2021 of Huadong Medicine Co., Ltd


  investors       relations                          of investee        capital of      of investee   investee (unit:   investee (unit:
                                                                         investee         (unit:      RMB10,000)        RMB10,000)
                                                                                        RMB10,000)

               Yuanda
               Investment
               Management
               and Fuguang
               Chengdu are
               subsidiaries
               of Beijing
               Yuanda
               Huachuang
Shanghai       Investment
Yuanda         Co., Ltd., the
Investment     controlling
Management shareholder
Co., Ltd.,     of China
Fuguang        Grand
Chengdu        Enterprises,
                                                   General
Equity         Inc. (the
                                                   projects:
Investment     controlling
                                                   Equity
Management shareholder          Hangzhou
                                                   investment;
Co., Ltd.,     of the           Fuguang
                                                   venture capital
Hangzhou       Company).        Hongxin Equity                       200 million yuan      7,900.37          7,900.37            -99.63
                                                   investment
High-Tech      According to Investment
                                                   (investment in
Venture        the provisions Partnership (L.P.)
                                                   unlisted
Capital        of Rules
                                                   companies
Management Governing
                                                   only)
Co., Ltd., and the Listing of
Hangzhou       Shares on
Heda           Shenzhen
Industrial     Stock
Fund           Exchange and
Investment     other relevant
Co., Ltd.      laws and
               regulations,
               Yuanda
               Investment
               Management,
               Fuguang
               Chengdu and
               the Company
               constitute
               related


                                                                                                                                      73
                                                                           The Half Year Report 2021 of Huadong Medicine Co., Ltd


              parties.

              Since
              Fuguang
              Chengdu, the
              managing
              partner and
              fund manager
              of Fuguang
              Hongxin, and
              Yuanda
              Investment
              Management,
              one of
              Fuguang
              Hongxin’s
              limited
              partner, are
              subsidiaries
              of Yuanda
                                                 Development,
Hangzhou      Huachuang,
                                                 transfer,
Fuguang       the               Nuoling
                                                 consulting and
Hongxin       controlling       Biomedical
                                                 services         4.981729 million
Equity        shareholder       Technology                                             7,537.97         7,443.61        -534.41
                                                 regarding        yuan
Investment    of China          (Beijing) Co.,
                                                 biological and
Partnership   Grand             Ltd.
                                                 medical
(L.P.)        Enterprises,
                                                 technologies
              Inc. (the
              controlling
              shareholder
              of the
              Company),
              and the
              Company is a
              limited
              partner of
              Fuguang
              Hongxin,
              Fuguang
              Hongxin and
              the Company
              constitute
              related parties
              in accordance
              with the


                                                                                                                              74
                                                                             The Half Year Report 2021 of Huadong Medicine Co., Ltd


               provisions of
               Rules
               Governing
               the Listing of
               Shares on
               Shenzhen
               Stock
               Exchange and
               other relevant
               laws and
               regulations.
                                1. In order to further increase the integration of industry and finance and industrial innovation, build
                                an incubation and introduction platform for diversified high-quality R&D and innovation projects,
                                and quickly enrich the Company’s core product pipelines, the Company signed the Partnership
                                Agreement of Hangzhou Fuguang Hongxin Equity Investment Partnership (L.P.) with Shanghai
                                Yuanda Investment Management Co., Ltd., Fuguang Chengdu Equity Investment Management Co.,
                                Ltd., Hangzhou High-Tech Venture Capital Management Co., Ltd., and Hangzhou Heda Industrial
                                Fund Investment Co., Ltd., jointly establishing “Hangzhou Fuguang Hongxin Equity Investment
                                Partnership (L.P.)” on January 7, 2021. The Pharmaceutical Industry Fund was established with a total
                                scale of RMB200 million, of which RMB98 million is contributed by the Company with its own
                                funds and the Company is a limited partner of the Pharmaceutical Industry Fund. For details, please
                                refer to No. 2021-002 Announcement on Participation in Investment in the Establishment of
                                Pharmaceutical Industry Investment Fund and Related Party Transactions issued by the Company on
                                January 7, 2021.
                                2. As of April 6, 2021, the Pharmaceutical Industry Fund completed the initial fund raising, finished

Progress of major ongoing       the industrial and commercial registration procedures, and it was successfully filed with AMAC on

projects (if any) of the        April 2, 2021. For details, please refer to No. 2021-016 Announcement on the Progress of

investee                        Participation in Investment in the Establishment of Pharmaceutical Industry Investment Fund issued
                                by the Company on April 6, 2021.
                                3. Zhongmei Huadong, a wholly-owned subsidiary of the Company, and Hangzhou Fuguang Hongxin
                                Equity Investment Partnership (L.P.) jointly contributed a total of RMB35 million to increase the
                                capital of Nuoling Biomedical Technology (Beijing) Co., Ltd. and subscribed for the newly increased
                                registered capital of RMB520,479 of Nuoling Biomedical Technology, which corresponds to
                                10.4478% of its equity after the completion of the financing. Specifically, Zhongmei Huadong
                                invested RMB15 million and subscribed for Nuoling Biomedical Technology’s newly registered
                                capital of RMB223,062, while Fuguang Hongxin invested RMB20 million and subscribed for
                                RMB297,417. Upon completion of the transaction, Zhongmei Huadong held 4.4776% of the equity of
                                Nuoling Biomedical Technology, while Fuguang Hongxin held 5.9702%. On April 19, 2021, all
                                existing shareholders of Nuoling Biomedical Technology signed a Capital Increase Agreement and a
                                Shareholders Agreement with Zhongmei Huadong and Fuguang Hongxin. For details, please refer to
                                No. 2021-020 Announcement on Joint External Investment and Related Party Transactions with the
                                Pharmaceutical Industry Investment Fund issued by the Company on April 19, 2021. Note 1

Note 1: Related inquiries on the disclosure website of interim reports on major related party transactions

      Title of provisional announcement              Disclosure date of provisional            Disclosure website of provisional


                                                                                                                                      75
                                                                             The Half Year Report 2021 of Huadong Medicine Co., Ltd


                                                           announcement                               announcement

Announcement on Participation in Investment
    in the Establishment of Pharmaceutical
                                                          January 08, 2021                      http://www.cninfo.com.cn
 Industry Investment Fund and Related Party
                 Transactions

       Announcement on the Progress of
       Participation in Investment in the
                                                           April 07, 2021                       http://www.cninfo.com.cn
   Establishment of Pharmaceutical Industry
                Investment Fund

 Announcement on Joint External Investment
    and Related Party Transactions with the                April 20, 2021                       http://www.cninfo.com.cn
   Pharmaceutical Industry Investment Fund




4. Associated claim and debt transactions

□ Applicable   √N/A
No such case during the reporting period.


5. Deals with related financial companies and financial companies controlled by the company

□ Applicable   √N/A
There are no deposits, loans, credits, or other financial services between the company and the financial company that has an affiliated
relationship, and the financial company controlled by the company and the affiliated party.


6. Other major related transactions

□ Applicable   √N/A
No such case during the reporting period.


XII. Major contracts and their fulfilment

1. Entrustment, contracting and leasing

(1) Entrustment

□ Applicable   √N/A
No such case during the reporting period.


 (2) Contracting

□ Applicable   √N/A
No such case during the reporting period.


                                                                                                                                    76
                                                                                       The Half Year Report 2021 of Huadong Medicine Co., Ltd


 (3) Leasing

□ Applicable     √N/A
No such case during the reporting period.


2. Important guarantees

√ Applicable    □ N/A
                                                                                                                  Unit: RMB ten thousand yuan

                       External guarantees of the Company and its subsidiaries (excluding guarantees for subsidiaries)

                Disclosure
                                                                                                       Counter
                date of the                                                                                                             Guarante
                                                                                                       -guarant
                announcem                      Actual date     Actual                                                                    e for a
 guaranteed                    Guarantee                                     Type of      Collateral     ee       Period of Fulfilled
                ent related                           of     guaranteed                                                                  related
   party                          Cap                                       guarantee      (if any)    situatio guarantee     or not
                   to the                      occurrence      amount                                                                   party or
                                                                                                        n (if
                 guarantee                                                                                                                   not
                                                                                                        any)
                    Cap

       /               /            /                 /           /                /          /           /           /         /             /

Total amount of external                                     Total actual amount of
guarantees approved                                          external guarantees
                                           /                                                                         /
during the reporting                                         during the reporting
period (A1)                                                  period (A2)


Total amount of
                                                             Total actual balance of
approved external
                                                             external guarantees at
guarantees at the end of                   /                                                                         /
                                                             the end of the reporting
the reporting period
                                                             period (A4)
(A3)


                                                  The Company’s guarantees for its subsidiaries

                Disclosure
                                                                                                       Counter
                date of the                                                                                                             Guarante
                                                                                                       -guarant
                announcem                      Actual date     Actual                                                                    e for a
 guaranteed                    Guarantee                                     Type of      Collateral     ee       Period of Fulfilled
                ent related                           of     guaranteed                                                                  related
   party                          Cap                                       guarantee      (if any)    situatio guarantee     or not
                   to the                      occurrence      amount                                                                   party or
                                                                                                        n (if
                 guarantee                                                                                                                   not
                                                                                                        any)
                    Cap

Hangzhou
Zhongmei                                                                   Joint
                April 21,                      June 01,
Huadong                            80,000                         27,652 liability                                One year No           No
                2021                           2021
Pharmaceut                                                                 guarantee
ical Co.,



                                                                                                                                                   77
                                                                 The Half Year Report 2021 of Huadong Medicine Co., Ltd


Ltd.

Huadong
                                                     Joint
Ningbo      April 21,            June 01,
                        50,000                  533 liability                  Yes     One year No          No
Medicine    2021                 2021
                                                     guarantee
Co., Ltd.

Huadong
                                                     Joint
Ningbo      April 28,            December
                        50,000                 2,009 liability                 Yes     One year No          No
Medicine    2020                 18, 2020
                                                     guarantee
Co., Ltd.

Huadong
                                                     Joint
Ningbo      April 28,            November
                        50,000                 1,591 liability                 Yes     One year No          No
Medicine    2020                 20, 2020
                                                     guarantee
Co., Ltd.

Huadong
                                                     Joint
Ningbo      April 28,            October 23,
                        50,000                 1,030 liability                 Yes     One year No          No
Medicine    2020                 2020
                                                     guarantee
Co., Ltd.

Huadong
                                                     Joint
Ningbo      April 28,            October 28,
                        50,000                  375 liability                  Yes     One year No          No
Medicine    2020                 2020
                                                     guarantee
Co., Ltd.

Huadong
                                                     Joint
Ningbo      April 28,            October 21,
                        50,000                  995 liability                  Yes     One year No          No
Medicine    2020                 2020
                                                     guarantee
Co., Ltd.

Huadong
                                                     Joint
Ningbo      April 28,            October 14,
                        50,000                  995 liability                  Yes     One year No          No
Medicine    2020                 2020
                                                     guarantee
Co., Ltd.

Huadong
                                                     Joint
Ningbo      April 28,            September
                        50,000                  255 liability                  Yes     One year No          No
Medicine    2020                 23, 2020
                                                     guarantee
Co., Ltd.

Huadong
                                                     Joint
Ningbo      April 28,            September
                        50,000                  675 liability                  Yes     One year No          No
Medicine    2020                 04, 2020
                                                     guarantee
Co., Ltd.

Huadong
                                                     Joint
Ningbo      April 28,            September
                        50,000                  855 liability                  Yes     One year No          No
Medicine    2020                 25, 2020
                                                     guarantee
Co., Ltd.



                                                                                                                    78
                                                               The Half Year Report 2021 of Huadong Medicine Co., Ltd


Huadong
                                                   Joint
Ningbo       April 28,            February
                         50,000              1,702 liability                 Yes     One year No          No
Medicine     2020                 03, 2021
                                                   guarantee
Co., Ltd.

Huadong
                                                   Joint
Ningbo       April 28,            June 28,
                         50,000              1,200 liability                 Yes     One year No          No
Medicine     2020                 2020
                                                   guarantee
Co., Ltd.

Huadong
                                                   Joint
Ningbo       April 28,            June 28,
                         50,000               800 liability                  Yes     One year No          No
Medicine     2020                 2020
                                                   guarantee
Co., Ltd.

Huadong
                                                   Joint
Ningbo       April 28,            July 02,
                         50,000              1,000 liability                 Yes     One year No          No
Medicine     2020                 2020
                                                   guarantee
Co., Ltd.

Huadong
                                                   Joint
Ningbo       April 28,            July 02,
                         50,000              1,000 liability                 Yes     One year No          No
Medicine     2020                 2020
                                                   guarantee
Co., Ltd.

Huadong
                                                   Joint
Medicine     April 21,
                         24,000                  0 liability                         One year No          No
Wenzhou      2021
                                                   guarantee
Co., Ltd.

Hangzhou
Huadong                                            Joint
             April 21,            May 31,
Pharmacy                  5,000              2,300 liability                         One year No          No
             2021                 2021
Chain Co.,                                         guarantee
Ltd.

Huadong
Medicine
(Xi’an)                                           Joint
             April 21,
Bohua                     5,000                  0 liability                         One year No          No
             2021
Pharmaceut                                         guarantee
ical Co.,
Ltd.

Jiangsu
                                                   Joint
Jiuyang      April 21,
                          7,000                  0 liability                         One year No          No
Biopharm     2021
                                                   guarantee
Co., Ltd.

Huadong      April 21,   15,000                    Joint                             One year No          No



                                                                                                                  79
                                                                The Half Year Report 2021 of Huadong Medicine Co., Ltd


Medicine      2021                                  liability
Ningbo                                              guarantee
Sales Co.,
Ltd.

Huadong
                                                    Joint
Medicine      April 21,
                          19,000                  0 liability                         One year No          No
Huzhou        2021
                                                    guarantee
Co., Ltd.

Huadong
                                                    Joint
Medicine      April 21,
                          18,000                 12 liability                         One year No          No
Shaoxing      2021
                                                    guarantee
Co., Ltd.

Huadong
Medicine
Supply
                                                    Joint
Chain         April 21,
                           6,000                  0 liability                         One year No          No
Manageme 2021
                                                    guarantee
nt
(Hangzhou)
Co., Ltd.

Huadong
Medicine
Supply                                              Joint
              April 19,
Chain                     20,000                  0 liability                         Ten years No         No
              2019
Manageme                                            guarantee
nt (JinHua)
Co., Ltd.

Huadong
                                                    Joint
Medicine      April 21,            May 31,
                          15,000              6,000 liability                         One year No          No
Lishui Co., 2021                   2021
                                                    guarantee
Ltd.

Huadong
                                                    Joint
Medicine      April 21,            May 11,
                          15,000              2,900 liability                         One year No          No
Lishui Co., 2021                   2021
                                                    guarantee
Ltd.

Huadong
Medicine
                                                    Joint
(Hangzhou) April 21,
                           3,200                  0 liability                         One year No          No
Biological    2021
                                                    guarantee
Products
Co., Ltd.

Hangzhou      April 21,   70,000 June 01,    25,162 Joint                             One year No          No


                                                                                                                   80
                                                                                       The Half Year Report 2021 of Huadong Medicine Co., Ltd


Zhongmei      2021                       2021                              liability
Huadong                                                                    guarantee
Pharmaceut
ical
Jiangdong
Co., Ltd.

Huadong
                                                                           Joint
Medicine      April 21,
                                12,000                                     liability                             One year No           No
Jinhua Co., 2021
                                                                           guarantee
Ltd.

Huadong
Medicine                                                                   Joint
              April 21,
Cunde                           12,000                               0 liability                                 One year No           No
              2021
(Zhoushan)                                                                 guarantee
Co., Ltd.

Huadong
                                                                           Joint
Medicine      April 21,
                                 5,500                               0 liability                                 One year No           No
Daishan       2021
                                                                           guarantee
Co., Ltd.

Sinclair                                                                   Joint
              September                  April 01,                                                               three
Pharma                          15,000                          9,586 liability                                              No        No
              15, 2020                   2021                                                                    years
Limited                                                                    guarantee

Sinclair                                                                   Joint
              November                   May 01,                                                                 three
Pharma                          40,000                        17,429 liability                                               No        No
              23, 2018                   2020                                                                    years
Limited                                                                    guarantee

Sinclair                                                                   Joint
              March 16,                  April 01,                                                               three
Pharma                          50,050                        35,824 liability                                               No        No
              2021                       2021                                                                    years
Limited                                                                    guarantee

Total guarantee cap for                                  Total actual guarantee
subsidiaries approved                                    amount      for
                                            396,750                                                                                     111,659
during the reporting                                     subsidiaries during the
period (B1)                                              reporting period (B2)

Total    approved                                        Total actual guarantee
guarantee cap for                                        balance     for
                                            471,750                                                                                     141,880
subsidiaries at the end of                               subsidiaries at the end of
the reporting period (B3)                                the reporting period (B4)

                                                     Subsidiariesguarantee for subsidiaries

              Disclosure                                                                              Counter                          Guarante
                                         Actual date        Actual
guaranteed date of the       Guarantee                                       Type of      Collateral -guarant Period of Fulfilled       e for a
                                                of        guaranteed
   party      announcem        Cap                                          guarantee      (if any)     ee       guarantee    or not    related
                                         occurrence         amount
              ent related                                                                             situatio                         party or



                                                                                                                                                  81
                                                                                     The Half Year Report 2021 of Huadong Medicine Co., Ltd


                 to the                                                                              n (if                           not
               guarantee                                                                             any)
                     Cap

Hangzhou
Zhongmei
Huadong                                                                  Joint
              April 21,
Pharmaceut                        20,000                                 liability                           One year No        No
              2021
ical                                                                     guarantee
Jiangdong
Co., Ltd.

Total   guarantee cap for                                Total actual guarantee
subsidiaries approved                                    amount    for
                                                20,000                                                                                     0
during the reporting                                     subsidiaries during the
period (C1)                                              reporting period (C2)

Total   approved                                         Total actual guarantee
guarantee cap for                                        balance   for
                                                20,000                                                                                     0
subsidiaries at the end of                               subsidiaries at the end of
the reporting period (C3)                                the reporting period (C4)

                Total amount of the Company’s guarantees (i.e. the sum of the above-mentioned 3 kinds of guarantees)

                                                         Total actual     guarantee
Total guarantees cap approved
                                                         amount during the
during the reporting period                    416,750                                                                            111,659
                                                         reporting period
(A1+B1+C1)
                                                         (A2+B2+C2)

                                                         Total actual guarantee
Total   approved guarantee cap
                                                         balance   at the end of
at the end of the reporting period             491,750                                                                            141,880
                                                         the reporting period
(A3+B3+C3)
                                                         (A4+B4+C4)

Proportion of the actual guarantee amount (i.e.
                                                                                                                                     9.11%
A4+B4+C4) in the Company’s net assets

Including:

Balance of guarantees for shareholders, actual
                                                                                                                                           /
controllers and their related parties (D)

Amount of debt guarantees provided directly or
indirectly for the entities with a liability-to asset                                                                             112,000
ratio over 70% (E)

The total amount of guarantees exceeds 50% of
                                                                                                                                           /
the net assets (F)

Total guarantee amount of the above-mentioned
                                                                                                                                  112,000
three kineds of guarantees (D+E+F)

For the unexpired guarantee, a guarantee liability                                                                                         /



                                                                                                                                           82
                                                                          The Half Year Report 2021 of Huadong Medicine Co., Ltd


has occurred or there may be a joint liability for
satisfaction during the reporting period (if any)

Note of external guarantees in violation of
                                                                                                                              /
prescribed procedures (if any)


3. Entrusted finances

□ Applicable   √N/A
No such case during the reporting period.


4. Daily significant contracts

□ Applicable   √N/A


5. Other significant contracts

□ Applicable   √N/A
No such case during the reporting period.


XIII. Other major events

□ Applicable   √N/A
During the reporting period, the company did not have other major matters that need to be explained.


XIV. Major events of subsidiaries

□ Applicable   √N/A




                                                                                                                             83
                                                                                  The Half Year Report 2021 of Huadong Medicine Co., Ltd




                           Section VII. Share Change and Shareholders

I. Changes in Share Capital

1. Table of Changes in share capital

                                                                                                                                        Unit: share

                               Before the change                       Change in the period (+/-)                            After the change

                                                                                   Capital
                              Number of                  New          Bonus        reserve                                  Number      Proportio
                                            Proportion                                           Other       Subtotal
                               shares                    shares       share       conversio                                 of shares       n
                                                                                      n

I. Shares subject to
                                 47,745         0.00%             0           0              0           0              0     47,745       0.00%
conditional restriction

1. Shares held by the state             0       0.00%             0           0              0           0              0           0      0.00%

2. Shares held by
                                        0       0.00%             0           0              0           0              0           0      0.00%
state-owned corporations

3. Shares held by other
                                 47,745         0.00%             0           0              0           0              0     47,745       0.00%
domestic investors

Including: held by
                                        0       0.00%             0           0              0           0              0           0      0.00%
domestic corporations

           held by domestic
                                 47,745         0.00%             0           0              0           0              0     47,745       0.00%
natural persons

4. Shares held by overseas
                                        0       0.00%             0           0              0           0              0           0      0.00%
investors

Including: held by
                                        0       0.00%             0           0              0           0              0           0      0.00%
overseas corporations

        held by overseas
                                        0       0.00%             0           0              0           0              0           0      0.00%
natural persons

II. Shares without            1,749,761,                                                                                    1,749,761
                                             100.00%              0           0              0           0              0                100.00%
restriction                         803                                                                                          ,803

                              1,749,761,                                                                                    1,749,761
1. RMB ordinary shares                       100.00%              0           0              0           0              0                100.00%
                                    803                                                                                          ,803

2. Domestically listed
                                        0       0.00%             0           0              0           0              0           0      0.00%
foreign shares

3. Foreign shares listed
                                        0       0.00%             0           0              0           0              0           0      0.00%
overseas



                                                                                                                                                84
                                                                                       The Half Year Report 2021 of Huadong Medicine Co., Ltd


4. Others                               0       0.00%               0              0            0             0        0          0       0.00%

                               1,749,809,                                                                                  1,749,809
III. Total number of shares                   100.00%               0              0            0             0        0               100.00%
                                      548                                                                                       ,548

Reasons for the changes in share capital
□ Applicable   √N/A
Approval for changes in share capital
□ Applicable   √N/A
Transfer of shares
□ Applicable   √N/A
Progress of share repurchase
□ Applicable   √N/A
Progress of reducing repurchased shares through centralized bidding
□ Applicable   √N/A
Effects   of changes in share capital on the basic earnings per share, diluted earnings per share for the most recent year and the most
recent period, the net assets per share attributable to the Company’s shareholders of common shares and other financial indicators
□ Applicable   √N/A
Other disclosures the Company deems necessary or required by securities regulatory authorities
□ Applicable   √N/A


2. Changes in restricted shares

□ Applicable   √N/A


II. Issuance and listing of securities

□ Applicable   √N/A


III. Total number of shareholders and their shareholdings

                                                                                                                                       Unit: share

                                                                         Total number of preference
Total number of common                                                   shareholders with restoration of
shareholderss at the end of the                             194,208 the voting rights at the end of                                            0
reporting period                                                         the reporting period (if any) (see
                                                                         Note 8)

                     Particulars about shareholders with a shareholding ratio over 5% or the Top 10 shareholders

                                                         Total                          The     The number        Pledged, marked or frozen
                                                                    Changes
                                            Share-      common                     number of of common
    Name of              Nature of                                      in the
                                            holding     shares                     common        shares held
  shareholder           shareholder                                 reporting                                     Status          Amount
                                             ratio    held at the                      shares       without
                                                                        period
                                                      end of the                   held with        trading


                                                                                                                                               85
                                                                           The Half Year Report 2021 of Huadong Medicine Co., Ltd


                                                reporting                  trading       restriction
                                                 period                   restriction
                                                                              s

                    Domestic
China Grand                                     730,938,1
                    non-state-owned    41.77%                 0                      0 730,938,157 Pledged          220,450,000
Enterprises, Inc.                                      57
                    corporation

Hangzhou
Huadong             State-owned                 284,000,0
                                       16.23%                 5,380,000              0 284,000,000
Medicine Group corporation                             00
Co., Ltd.

Hong Kong
Securities          Overseas                    36,743,86 -1,555,75
                                       2.10%                                         0   36,743,863
Clearing            corporation                           32
Company Ltd.

China Securities Domestic
                                                22,186,81
Finance Co.,        non-state-owned    1.27%                  0                      0   22,186,818
                                                          8
Ltd.                corporation

National Social
Security Fund       Others             0.45% 7,926,311 0                             0     7,926,311
Portfolio 602

                    domestic natural
# Yang Yushan                          0.29% 5,000,000 5,000,000                     0     5,000,000
                    persons

Industrial and
Commercial
Bank of China
— CUAM
3-year Closed
Operation
Strategy
                    Others             0.28% 4,835,665 4,835,665                     0     4,835,665
Placement
Flexible
Allocation
Mixed
Securities
Investment
Fund (LOF)

Hua Life
Insurance Co.,
                    Others             0.22% 3,780,104 3,780,104                     0     3,780,104
Ltd. — own
funds

#Chen               domestic natural   0.21% 3,744,388 -20,000                       0     3,744,388



                                                                                                                              86
                                                                              The Half Year Report 2021 of Huadong Medicine Co., Ltd


Shaoming          persons

National Social
                                                                 -3,999,77
Security Fund     Others                       0.17% 3,000,000                        0     3,000,000
                                                                 3
Portfolio 503

Strategic investors or general
corporations become the top 10
                                         N/A
shareholders due to the placement
of new shares (if any) (see Note 3)

Explanation on associated
relationships or concerted actions       The Company does not know whether the above-mentioned shareholders are related parties or
among the above-mentioned                whether they are acting-in-concert parties with one another.
shareholders

Description about above-mentioned
shareholders’ entrusting/being
                                         N/A
entrusted with and waiving voting
rights

Special instructions for the
existence of special repurchase
                                         N/A
accounts among the top 10
shareholders (if any) (see Note 11)

                               Shareholding of the top 10 shareholders without trading restriction conditions

                                          Number of the trading unrestricted stocks held at the                 Type of stocks
         Name of shareholder
                                                         end of the Report Period                   Type of stocks          Amount

                                                                                                   RMB ordinary
China Grand Enterprises, Inc.                                                        730,938,157                             730,938,157
                                                                                                   stocks

Hangzhou Huadong Medicine                                                                          RMB ordinary
                                                                                     284,000,000                             284,000,000
Group Co., Ltd.                                                                                    stocks

Hong Kong Securities Clearing                                                                      RMB ordinary
                                                                                      36,743,863                                 36,743,863
Company Ltd.                                                                                       stocks

                                                                                                   RMB ordinary
China Securities Finance Co., Ltd.                                                    22,186,818                                 22,186,818
                                                                                                   stocks

National Social Security Fund                                                                      RMB ordinary
                                                                                       7,926,311                                  7,926,311
Portfolio 602                                                                                      stocks

                                                                                                   RMB ordinary
# Yang Yushan                                                                          5,000,000                                  5,000,000
                                                                                                   stocks

Industrial and Commercial Bank of
China — CUAM 3-year Closed
                                                                                                   RMB ordinary
Operation Strategy Placement                                                           4,835,665                                  4,835,665
                                                                                                   stocks
Flexible Allocation Mixed
Securities Investment Fund (LOF)


                                                                                                                                         87
                                                                            The Half Year Report 2021 of Huadong Medicine Co., Ltd


Hua Life Insurance Co., Ltd. —                                                                  RMB ordinary
                                                                                     3,780,104                               3,780,104
own funds                                                                                        stocks

                                                                                                 RMB ordinary
#Chen Shaoming                                                                       3,744,388                               3,744,388
                                                                                                 stocks

National Social Security Fund                                                                    RMB ordinary
                                                                                     3,000,000                               3,000,000
Portfolio 503                                                                                    stocks

Description of the related
relationship or concerted action
between the top 10 common
shareholders of unrestricted shares, The Company does not know whether the above-mentioned shareholders are related parties or
and between the top 10 common         whether they are acting-in-concert parties with one another.
shareholders of unrestricted shares
and the top 10 common
shareholders

                                      The second major shareholder of the Company, Hangzhou Huadong Medicine Group Co.,
                                      Ltd., holds 288,000,000 shares of the Company, accounting for 16.46% of the Company’s
Description of the participation in   total capitalization. As of the end of the reporting period, 4,000,000 shares thereof were
margin trading business of the top    subject to refinancing securities lending transactions in China Securities Finance Corporation
10 common shareholders (if any)       Limited. As of the end of the reporting period, Yang Yushan, the sixth shareholder among the
(see Note 4)                          Company’s Top 10 common shareholders, held 5,000,000 shares of the Company through
                                      securities margin accounts, and Chen Shaoming, the ninth shareholder, held 3,651,388 shares
                                      of the Company in the same manner.

Whether the Company’s Top 10 common shareholders or the Top 10 common shareholders without trading restriction have carried
out any agreement to repurchase transaction during the reporting period
□ Yes   √ No
No such case during the reporting period.


IV. Changes in shareholding of directors, supervisors and senior managers

□ Applicable    √N/A
No such case during the reporting period. For details, please refer to the 2020 Annual Report.


V. Changes in controlling shareholders or actual controllers

Change of controlling shareholder during the reporting period
□ Applicable    √N/A
No such case during the reporting period.
Change of actual controller during the reporting period
□ Applicable    √N/A
No such case during the reporting period.




                                                                                                                                       88
                                                        The Half Year Report 2021 of Huadong Medicine Co., Ltd




                                     Section VIII. Preferred Shares

□ Applicable   √N/A
No such case during the reporting period.




                                                                                                           89
                                             The Half Year Report 2021 of Huadong Medicine Co., Ltd




                        Section IX. Information about Bonds

□ Applicable   √N/A




                                                                                                90
                                                                            The Half Year Report 2021 of Huadong Medicine Co., Ltd




                                           Section X. Financial Report

I. Audit report

Whether the half year report was audited
□ Yes   √ No
The Company’s half year report was not audited.


II. Financial statements

The currency unit of statements in the financial notes is: RMB yuan.


1. Consolidated balance sheet

Prepared by: Huadong Medicine Co., Ltd.
                                                           June 30, 2021
                                                                                                                  Unit: RMB yuan

                    Item                                June 30, 2021                             December 31, 2020

Current assets:

     Cahs and bank balances                                            3,269,314,047.58                         3,198,080,997.82

     Settlement reserve

     Lending to other banks and other
financial institutions

     Financial assets for trade

     Derivative financial assets

     Notes receivable

     Accounts receivable                                               6,871,300,450.79                         6,137,675,568.82

     Accounts receivable for financing                                  530,122,144.99                            828,659,217.25

     Prepayments                                                        213,421,350.99                            250,916,482.07

     Premiums receivable

     Reinsurance accounts receivable

     Reinsurance contract reserve
receivable

     Other receivables                                                  114,697,517.74                             87,269,489.82

         Including: Interests receivable                                  6,326,425.78

                  Dividends receivable                                      832,286.37                              4,195,666.37



                                                                                                                               91
                                                  The Half Year Report 2021 of Huadong Medicine Co., Ltd


       Financial assets purchased for
resale

       Inventories                           4,130,364,327.93                         4,067,635,254.80

       Contract assets

       Assets held for sale

       Non-current assets due within one
year

       Other current assets                    44,928,681.66                             85,654,691.58

Total current assets                        15,174,148,521.68                        14,655,891,702.16

Non-current assets:

       Loans and prepayments issuance

       Debt investments

       Other debt investments

       Long-term receivables

       Long-term equity investments           947,007,338.50                            850,072,053.02

       Other equity instrument
                                              235,756,138.76                            225,453,120.05
investments

       Other non-current financial assets

       Real estate properties for
                                               17,191,977.46                             17,792,735.95
investment

       Fixed assets                          2,668,749,549.01                         2,420,366,582.92

       Constructions in progress             2,000,163,547.28                         2,240,201,926.65

       Biological assets for production

       Oil & gas assets

       Right-of-use assets                    128,934,858.91

       Intangible assets                     1,645,727,476.51                         1,463,242,463.99

       Development expenditures

       Goodwill                              2,100,106,651.09                         1,469,617,262.10

       Long-term unamortized expenses           11,043,633.03                             8,811,339.43

       Deferred tax assets                    151,508,607.37                            137,829,774.40

       Other non-current assets              1,027,839,790.27                           712,069,194.08

Total non-current assets                    10,934,029,568.19                         9,545,456,452.59

Total assets                                26,108,178,089.87                        24,201,348,154.75

Current liabilities:

       Short-term borrowing                  1,386,401,620.12                         1,416,932,884.87



                                                                                                     92
                                               The Half Year Report 2021 of Huadong Medicine Co., Ltd


     Borrowing from the central bank

     Borrowing from other banks and
other financial institutions

     Financial liabilities for trade

     Derivative financial liabilities

     Notes payable                         979,859,751.59                            554,336,058.71

     Accounts payable                     4,018,087,903.17                         3,947,044,331.68

     Receipts in Advance                     2,002,944.53                                951,926.56

     Contract liabilities                   53,923,017.30                             94,384,629.77

     Financial assets sold for
repurchase

     Absorbing deposits and due from
banks

     Receipts for buying and selling
securities as proxy

     Receipts for underwriting
securities as proxy

     Payroll payable                       116,950,830.93                            152,106,819.91

     Taxes payable                         623,460,837.87                            571,792,475.80

     Other payables                       1,764,290,228.84                         1,817,529,820.99

        Including: Interests payable

                Dividends payable              224,219.60                                224,219.60

     Handling fees and commissions
payable

     Reinsurance accounts payable

     Liabilities held for sale

     Non-current liabilities due within
                                            43,273,480.68                             67,813,886.68
one year

     Other current liabilities               6,752,043.58                             10,786,034.37

Total current liabilities                 8,995,002,658.61                         8,633,678,869.34

Non-current liabilities:

     Insurance policy reserve

     Long-term borrowing                   477,876,860.08                            151,611,367.86

     Bonds payable

        Including: Preferred shares

                Perpetual bonds


                                                                                                  93
                                                                 The Half Year Report 2021 of Huadong Medicine Co., Ltd


     Lease liabilities                                        82,245,770.91

     Long-term payables                                      157,449,847.67                             26,812,354.90

     Long-term employee benefits
payable

     Provisions                                               38,277,744.27                             39,467,829.23

     Deferred income                                          86,144,877.82                             81,628,032.54

     Deferred tax liabilities                                 83,108,397.29                             88,738,187.41

     Other non-current liabilities

Total non-current liabilities                                925,103,498.04                            388,257,771.94

Total liabilities                                           9,920,106,156.65                         9,021,936,641.28

Owners’ Equity:

     Share capital                                          1,749,809,548.00                         1,749,809,548.00

     Other equity instruments

        Including: Preferred shares

                Perpetual bonds

     Capital reserves                                       2,158,080,661.07                         2,158,080,661.07

     Less: Treasury shares

     Other comprehensive income                               44,251,842.19                             -2,191,069.45

     Special reserve

     Surplus reserves                                        861,680,578.42                            861,680,578.42

     General risk reserve

     Retained earnings                                     10,753,451,519.08                         9,852,441,590.56

Total owners’ equity attributable to
                                                           15,567,274,148.76                        14,619,821,308.60
owner of the Company

     Minority interest                                       620,797,784.46                            559,590,204.87

Total owners’ equity                                      16,188,071,933.22                        15,179,411,513.47

Total liabilities & owners’ equity                        26,108,178,089.87                        24,201,348,154.75


Legal representative: Lv Liang


Person in charge of accounting work: Lv Liang


Person in charge of the Accounting Department: Qiu Renbo


2. Balance sheet of the parent company

                                                                                                       Unit: RMB yuan


                                                                                                                    94
                                                              The Half Year Report 2021 of Huadong Medicine Co., Ltd


                      Item                  June 30, 2021                           December 31, 2020

Current assets:

       Cash and bank balances                          1,500,810,612.41                           1,889,264,142.30

       Financial assets for trade

       Derivative financial assets

       Notes receivable

       Accounts receivable                             3,572,579,601.70                           3,287,882,027.51

       Accounts receivable for financing                231,103,545.66                              214,871,707.01

       Prepayments                                          54,030,047.36                           121,268,106.62

       Other receivables                                863,943,656.30                              798,152,353.96

         Including: Interests receivable                     3,810,555.56

                  Dividends receivable                                                                3,363,380.00

       Inventories                                     1,875,097,391.72                           1,845,977,070.46

       Contract assets

       Assets held for sale

       Non-current assets due within one
year

       Other current assets                                    14,830.80

Total current assets                                   8,097,579,685.95                           8,157,415,407.86

Non-current assets:

       Debt investments

       Other debt investments

       Long-term receivables

       Long-term equity investments                    4,925,884,087.36                           4,847,172,288.65

       Other equity instrument
                                                            94,312,742.49                            94,312,742.49
investments

       Other non-current financial assets

       Real estate properties for
                                                             7,892,460.22                             8,125,576.54
investment

       Fixed assets                                     156,295,538.13                              159,486,234.04

       Constructions in progress                             2,016,101.54                               342,161.41

       Biological assets for production

       Oil & gas assets

       Right-of-use assets                                  11,446,169.18

       Intangible assets                                    52,496,891.26                            56,448,575.54


                                                                                                                 95
                                                The Half Year Report 2021 of Huadong Medicine Co., Ltd


     Development expenditures

     Goodwill

     Long-term unamortized expenses             486,793.30                                645,902.07

     Deferred tax assets                     50,432,935.67                             45,918,388.57

     Other non-current assets               137,966,017.50                             96,882,664.08

Total non-current assets                   5,439,229,736.65                         5,309,334,533.39

Total assets                              13,536,809,422.60                        13,466,749,941.25

Current liabilities:

     Short-term borrowing                   610,340,666.97                            930,813,369.36

     Financial liabilities for trade

     Derivative financial liabilities

     Notes payable                          201,919,106.24                            180,042,270.63

     Accounts payable                      2,476,104,386.33                         2,421,476,904.57

     Receipts in advance

     Contract liabilities                    19,475,506.65                             32,577,236.92

     Payroll payable                           2,907,977.80                             8,530,961.48

     Taxes payable                           73,709,247.43                            154,676,067.87

     Other payables                         200,923,749.27                            518,390,330.44

        Including: Interests payable

                 Dividends payable              224,219.60                                224,219.60

     Liabilities held for sale

     Non-current liabilities due within
one year

     Other current liabilities                 2,484,687.36                             4,273,258.99

Total current liabilities                  3,587,865,328.05                         4,250,780,400.26

Non-current liabilities:

     Long-term borrowing

     Bonds payable

        Including: Preferred shares

                 Perpetual bonds

     Lease liabilities                         9,417,965.84

     Long-term payables

     Long-term employee benefits
payable

     Provision


                                                                                                   96
                                                          The Half Year Report 2021 of Huadong Medicine Co., Ltd


     Deferred income                                   39,415,973.49                              40,698,910.95

     Deferred tax liabilities                          10,888,106.00                              10,888,106.00

     Other non-current liabilities

Total non-current liabilities                          59,722,045.33                              51,587,016.95

Total liabilities                                   3,647,587,373.38                           4,302,367,417.21

Owners’ Equity:

     Share capital                                  1,749,809,548.00                           1,749,809,548.00

     Other equity instruments

        Including: Preferred shares

                Perpetual bonds

     Capital reserves                               2,168,451,528.01                           2,168,451,528.01

     Less: Treasury shares

     Other comprehensive income                          3,051,311.29                              3,051,311.29

     Special reserve

     Surplus reserves                                 939,536,337.86                            939,536,337.86

     Retained earnings                              5,028,373,324.06                           4,303,533,798.88

Total owners’ equity                               9,889,222,049.22                           9,164,382,524.04

Total liabilities & owners’ equity                13,536,809,422.60                         13,466,749,941.25


3. Consolidated income statement

                                                                                                 Unit: RMB yuan

                     Item             Current period in 2021                   Previous period in 2020

I. Total operating income                           17,179,437,902.61                        16,660,934,157.64

     Including: Operating revenue                   17,179,437,902.61                        16,660,934,157.64

              Interests received

              Premiums earned

              Handling fees and
commissions received

II. Total operating cost                            15,638,788,710.40                        14,896,020,510.59

     Including: Operating cost                      11,589,419,896.59                        10,681,089,643.50

              Interests paid

              Handling fees and
commissions paid

              Surrender value




                                                                                                             97
                                                   The Half Year Report 2021 of Huadong Medicine Co., Ltd


              Net payment of insurance
claims

              Net appropriation of policy
reserve

              Policy dividends paid

              Reinsurance expenses

              Business taxes and
                                                88,585,385.20                            101,439,816.68
surcharges

              Selling expenses                2,978,753,751.45                         3,109,911,383.02

              Administrative expenses          534,683,411.33                            506,362,613.35

              Research and
                                               437,556,684.96                            479,685,981.21
Development(R&D) expenses

              Financial expenses                 9,789,580.87                             17,531,072.80

                Including: Interests
                                                37,214,555.56                             47,068,116.52
expenses

                        Interests income        38,453,252.17                             30,675,897.56

     Add: Other income                         137,364,653.52                             93,032,855.48

           Investment income (Losses are
                                                -54,458,950.28                           -10,002,163.90
indicated by “-”)

           Including: Investment gains
(losses) in associated enterprise and           -22,852,478.03                            -3,173,963.23
joint-venture enterprise

                Gains on the
derecognition of financial assets
measured at amortized cost

           Gains on exchange (Losses are
indicated by “-”)

           Gains on net exposure hedging
(Losses are indicated by “-”)

           Gains on changes in fair value
(Losses are indicated by “-”)

           Credit impairment losses
                                                -38,263,673.24                           -29,841,283.63
(Losses are indicated by “-”)

           Impairment losses of assets
                                                 3,054,806.20
(Losses are indicated by “-”)

           Gains on assets disposal
                                                   182,307.80                            301,166,257.18
(Losses are indicated by “-”)

III. Operating profit (Losses are indicated   1,588,528,336.21                         2,119,269,312.18


                                                                                                      98
                                                     The Half Year Report 2021 of Huadong Medicine Co., Ltd


by “-”)

         Add: Non-operating income                   834,874.23                             10,190,295.80

         Less: Non-operating expenses              6,126,908.04                             20,122,066.85

IV. Total profit (Total losses are indicated
                                                1,583,236,302.40                         2,109,337,541.13
by “-”)

         Less: Income tax expenses               240,728,486.55                            334,125,800.82

V. Net profit (Net losses are indicated by
                                                1,342,507,815.85                         1,775,211,740.31
“-”)

   (I) Classification by continuous
operations

         1. Net profit from continued
operations (Net losses are indicated by         1,342,507,815.85                         1,775,211,740.31
“-”)

         2. Net profit from terminational
operations (Net losses are indicated by
“-”)

   (II) Classification by attribution of
ownership

         1. Net profit attributable to owners
                                                1,300,346,324.85                         1,731,184,721.25
of the parent company

         2. Profit or loss attributable to
                                                  42,161,491.00                             44,027,019.06
minority shareholders

VI. Other comprehensive income, net of
                                                  49,562,711.35                             38,749,338.23
income tax

   Other comprehensive income
attributable to owners of the parent              49,562,711.35                             38,749,338.23
company, net of tax

         (I) Other comprehensive income that
                                                  15,091,655.18                                217,909.39
cannot be reclassified into gains/losses

                 1.Changes in remeasurement
on the defined benefit plan

                 2. Other comprehensive
income that cannot be reclassified into
gains/losses under equity method

                 3. Changes in fair value of
                                                  15,091,655.18                                217,909.39
other equity instrument investments

                 4. Changes in fair value of
credit risk of the enterprise

                 5. Others


                                                                                                        99
                                                                              The Half Year Report 2021 of Huadong Medicine Co., Ltd


     (II) Other comprehensive income to
                                                                            34,471,056.17                             38,531,428.84
be reclassified into gains/losses

             1. Other comprehensive
income that can be reclassified into
gains/losses under equity method

             2. Changes in fair value of
other debt investments

             3. Amount of financial assets
reclassified into other comprehensive
income

             4. Credit impairment reserve
of other debt investments

             5. Cash flow hedging reserve

             6. Exchange differences
arising on conversion of financial
                                                                            34,471,056.17                             38,531,428.84
statements denominated in foreign
currencies

             7. Others

  Net amount after tax of other
comprehensive income attributable to
minority shareholders

VII. Total comprehensive income                                       1,392,070,527.20                             1,813,961,078.54

     Total comprehensive income
attributable to owners of the parent                                  1,349,909,036.20                             1,769,934,059.48
company

     Total comprehensive income
                                                                            42,161,491.00                             44,027,019.06
attributable to minority shareholders

VIII. Earnings per share (EPS):

     (I) Basic EPS                                                                0.7431                                      0.9894

     (II) Diluted EPS                                                             0.7431                                      0.9894

As for enterprise merger under the same control in the current period, the net profit generated by the merged party before the merger
is 0.00 yuan, and that generated during the previous period is 0.00 yuan.


Legal representative: Lv Liang


Person in charge of accounting work: Lv Liang


Person in charge of the Accounting Department: Qiu Renbo




                                                                                                                                  100
                                                                The Half Year Report 2021 of Huadong Medicine Co., Ltd


4. Income statement of the parent company

                                                                                                      Unit: RMB yuan

                      Item                 Current period in 2021                   Previous period in 2020

I. Total operating income                                 8,825,456,287.77                          7,916,714,385.48

     Less: Total operating cost                           8,358,026,557.10                          7,486,315,469.35

           Business taxes and surcharges                       8,620,356.90                            12,247,764.43

           Selling expenses                                 183,609,392.52                            156,652,760.76

           Administrative expenses                           84,417,643.06                             69,866,518.00

           Research and Development
(R&D) expenses

           Financial expenses                                  3,945,113.42                            17,433,290.41

              Including: Interests
                                                             28,654,116.50                             37,898,542.00
expenses

                       Interests income                      25,469,215.21                             19,437,282.41

     Add: Other income                                         3,491,044.84                            10,042,695.77

           Investment income (Losses
                                                          1,013,064,044.10                          1,167,513,101.57
are indicated by “-”)

           Including: Investment gains
(losses) in associated enterprise and                           -488,201.29
joint-venture enterprise

                Gains on the
derecognition of financial assets
measured at amortized cost (Losses are
indicated by “-”)

           Gains on net exposure
hedging (Losses are indicated by “-”)

           Gains from changes in fair
values (Losses are indicated by “-”)

           Credit impairment losses
                                                             -37,061,514.45                            25,531,116.40
(Losses are indicated by “-”)

           Impairment gains (losses) of
assets (Losses are indicated by “-”)

           Asset disposal income
                                                                    -24,172.29                                -6,556.33
(Losses are indicated by “-”)

II. Operating profit (Losses are
                                                          1,166,306,626.97                          1,377,278,939.94
indicated by “-”)

     Add: Non-operating income                                       3,934.06                           4,902,319.33



                                                                                                                    101
                                                   The Half Year Report 2021 of Huadong Medicine Co., Ltd


         Less: Non-operating expenses              232,283.92                              6,681,349.13

III. Total profit (Total losses are
                                              1,166,078,277.11                         1,375,499,910.14
indicated by “-”)

         Less: Income tax expenses              38,782,555.89                             53,781,016.19

IV. Net profit (Net losses are indicated
                                              1,127,295,721.22                         1,321,718,893.95
by “-”)

         (I) Net profit from continuous
operations (Net losses are indicated by       1,127,295,721.22                         1,321,718,893.95
“-”)

         (II) Net profit from discontinued
operations (Net losses are indicated by
“-”)

V. Other comprehensive income, net of
income tax

         (I) Other comprehensive income
that cannot be reclassified into
gains/losses

                1. Changes in
remeasurement on the defined benefit
plan

                2. Other comprehensive
income that cannot be reclassified into
gains/losses under equity method

                3. Changes in fair value of
other equity instrument investments

                4. Changes in fair value of
credit risk of the enterprise

                5. Others

          (II) Other comprehensive income
to be reclassified into gains/losses

                1. Other comprehensive
income that can be reclassified into
gains/losses under equity method

                2. Changes in fair value of
other debt investments

                3. Amount of financial
assets reclassified into other
comprehensive income

                4. Credit impairment


                                                                                                     102
                                                                 The Half Year Report 2021 of Huadong Medicine Co., Ltd


reserve of other debt investments

               5. Cash flow hedging
reserve

               6. Exchange differences
from translation of foreign currency
financial statements

               7. Others

VI. Total comprehensive income                             1,127,295,721.22                          1,321,718,893.95

VII. Earnings per share (EPS):

     (I) Basic EPS

     (II) Diluted EPS


5. Consolidated cash flow statement

                                                                                                       Unit: RMB yuan

                    Item                    Current period in 2021                   Previous period in 2020

I. Cash flows from operating activities:

     Cash received from sale of goods
                                                          19,260,978,489.19                         17,305,533,832.79
or rendering of services

     Net increase in customer deposits
and due from banks

     Net increase in borrowing from the
central bank

     Net increase in borrowing from
other financial institutions

     Cash from the premium of the
original insurance policy

     Net cash from reinsurance

     Net increase in deposits and
investment of the insured

     Cash from interests, handling fees
and commissions

     Net increase in borrowing from
other banks and other financial
institutions

     Net increase in funds for
repurchase

     Net cash received for buying and



                                                                                                                   103
                                                 The Half Year Report 2021 of Huadong Medicine Co., Ltd


selling securities as proxy

     Receipts of tax refunds                    1,862,175.25                            15,546,329.17

     Other cash receipts to operating
                                             320,057,319.74                            510,015,283.23
activities

Sub-total of Cash inflows from
                                           19,582,897,984.18                        17,831,095,445.19
operating activities

     Cash payments for goods
                                           12,667,873,491.42                        11,048,841,667.18
purchased and services received

     Net increase in customer loans and
prepayments

     Net increase in deposits of central
bank and due from banks

     Cash payments for original
insurance claims

     Net increase in lending to other
banks and other financial institutions

     Cash payments for interests,
handling fees and commissions

     Cash payments for policy
dividends

     Cash payments to and on behalf of
                                            1,324,178,305.24                         1,139,977,576.42
employees

     Payments of various types of taxes     1,022,924,459.48                         1,417,914,481.02

     Other cash payments in relation to
                                            2,829,409,355.93                         2,968,819,053.28
operating activities

Sub-total of cash outflows for operating
                                           17,844,385,612.07                        16,575,552,777.90
activities

Net cash flow from operating activities     1,738,512,372.11                         1,255,542,667.29

II. Cash flows from investing activities

     Cash receipts from recovery of
investments

     Cash receipts from investment
                                                4,281,616.49                               900,000.00
income

     Net cash from disposal of fixed
assets, intangible assets and other              407,737.22                            347,790,583.31
long-term assets

     Net cash from disposal of
subsidiaries and other business units



                                                                                                   104
                                                 The Half Year Report 2021 of Huadong Medicine Co., Ltd


     Other cash receipts in relation to
                                               4,788,636.47
investing activities

Sub-total of cash inflows from investing
                                               9,477,990.18                            348,690,583.31
activities

     Cash payments for purchase and
construction of fixed assets, intangible     403,137,637.26                            522,164,019.70
assets and other long-term assets

     Cash payments for investment            120,706,000.00                             70,535,000.00

     Net increase in pledge loans

     Net cash paid for acquisition of
                                             756,550,801.75                            130,000,000.00
subsidiaries and other business units

     Other cash payments in relation to
                                              26,127,840.41
investing activities

Sub-total of cash outflows for investing
                                           1,306,522,279.42                            722,699,019.70
activities

Net cash flow from investing activities    -1,297,044,289.24                          -374,008,436.39

III. Cash flows from financing
activities:

     Cash receipts from capital
contributions

     Including: Cash receipts from
capital contributions from minority
owners of subsidiaries

     Cash from borrowing                   1,421,047,085.43                          1,681,800,534.35

     Other cash receipts in relation to
                                                                                       340,000,000.00
financing activities

Sub-total of cash inflows from
                                           1,421,047,085.43                          2,021,800,534.35
financing activities

     Cash repayment of borrowings          1,309,701,912.43                          1,851,002,797.43

     Cash payments for distribution of
dividends or profits or settlement of        472,827,211.26                            605,214,724.28
interest expenses

     Including: Dividends and profits
paid by subsidiaries to minority                                                        49,000,000.00
shareholders

     Other cash payments in relation to
                                               5,424,076.04                            308,940,044.54
financing activities

Sub-total of cash outflows from            1,787,953,199.73                          2,765,157,566.25



                                                                                                   105
                                                                 The Half Year Report 2021 of Huadong Medicine Co., Ltd


financing activities

Net cash flows from financing activities                    -366,906,114.30                           -743,357,031.90

IV. Effect of foreign exchange rate
                                                                 -423,905.66                            40,923,061.58
changes on Cash and Cash Equivalents

V. Net increase in cash and cash
                                                              74,138,062.91                            179,100,260.58
equivalents

     Add: Opening balance of cash and
                                                           3,157,407,073.26                          2,231,771,546.50
cash equivalents

VI. Closing balance of cash and cash
                                                           3,231,545,136.17                          2,410,871,807.08
equivalents


6. Cash flow statement of the parent company

                                                                                                       Unit: RMB yuan

                   Item                     Current period in 2021                   Previous period in 2020

I. Cash flows from operating activities:

     Cash receipts from the sale of
                                                           9,547,450,716.13                          8,598,969,576.40
goods and the rendering of services

     Receipts of tax refund

     Other cash receipts in relation to
                                                             257,412,395.37                            325,891,677.56
operating activities

Sub-total of cash inflows from
                                                            9,804,863,111.50                         8,924,861,253.96
operating activities

     Cash payments for goods acquired
                                                           9,463,890,457.11                          8,095,291,298.89
and services received

     Cash payments to and on behalf of
                                                             131,308,524.66                            123,512,245.38
employees

     Payments of various types of
                                                             199,085,236.17                            120,889,907.22
taxes

     Other cash payments in relation to
                                                             440,569,707.04                            375,568,357.02
operating activities

Sub-total of cash outflows for operating
                                                          10,234,853,924.98                          8,715,261,808.51
activities

Net cash flow from operating activities                     -429,990,813.48                            209,599,445.45

II. Cash flows from investing activities

     Cash receipts from recovery of
investments

     Cash receipts from investment                         1,003,363,380.00                            601,000,000.00



                                                                                                                   106
                                                 The Half Year Report 2021 of Huadong Medicine Co., Ltd


income

     Net cash receipts from disposal of
fixed assets, intangible assets and other        237,307.57                                 45,538.08
long-term assets

     Net cash from disposal of
subsidiaries and other business units

     Other cash receipts in relation to
                                             289,814,850.52                            691,791,772.13
investing activities

Sub-total of cash inflows from investing
                                            1,293,415,538.09                         1,292,837,310.21
activities

     Cash payments for purchase and
construction of fixed assets, intangible      23,188,911.97                             13,910,582.10
assets and other long-term assets

     Cash payments for investment             79,200,000.00                             74,281,870.80

     Net cash paid for acquisition of
subsidiaries and other business units

     Other cash payments in relation to
                                             360,086,340.00                            549,000,000.00
investing activities

Sub-total of cash outflows for investing
                                             462,475,251.97                            637,192,452.90
activities

Net cash flows from investing activities     830,940,286.12                            655,644,857.31

III. Cash flows from financing
activities:

     Cash receipts from absorbing
investments

     Cash receipts from borrowing            559,345,278.50                          1,040,651,082.42

     Other cash receipts in relation to
                                            1,012,500,000.00                           673,000,000.00
financing activities

Sub-total of cash inflows from
                                            1,571,845,278.50                         1,713,651,082.42
financing activities

     Cash repayments of borrowings           879,341,384.32                          1,165,656,610.43

     Cash payments for distribution of
dividends or profits or settlement of        456,826,281.28                            545,718,585.88
interest expenses

     Other cash payments in relation to
                                            1,025,043,198.88                           434,406,787.51
financing activities

Sub-total of cash outflows
                                            2,361,210,864.48                         2,145,781,983.82
fromfinancing activities



                                                                                                   107
                                                                                    The Half Year Report 2021 of Huadong Medicine Co., Ltd


Net cash flow from financing activities                                        -789,365,585.98                           -432,130,901.40

IV. Effect of foreign exchange rate
                                                                                    -37,416.55                                1,987,917.74
changes on Cahs and Cash Equivalents

V. Net increase in cash and cash
                                                                               -388,453,529.89                              435,101,319.10
equivalents

     Add: Opening balance of cash and
                                                                              1,889,254,142.30                              893,929,724.56
cash equivalents

VI. Closing balance of cash and cash
                                                                              1,500,800,612.41                          1,329,031,043.66
equivalents


7. Consolidated statement of changes in owners’ Equity

Amount in the current period
                                                                                                                            Unit: RMB yuan

                                                                  Amount for the first half of 2021

                                                Ownership interest attributable to the parent company

                                 Other equity                       Other                                                             Total
                                                                                                                            Minori
                                  instruments                Less: compr                                                             owners
      Item           Share                                                    Specia Surplu Genera Undist                     ty
                                                   Capital Treasu ehensi                                                   hip
                               Prefe Perpe
                     capita                                                     l    l risk ributed Others Total interes
                                                                                        s
                                                                                                                         interes
                                rred tual Other reserve ry      ve
                                                                                                                    t
                       l                                            reserve reserve reserve profit
                                                       shares incom                                                         t
                               share bond s
                                  s    s                         e

I. Balance at the 1,749
                                                    2,158,                           861,68           9,852,       14,619 559,59 15,179
end of the            ,809,                                         -2,191,
                                                    080,66                            0,578.          441,59        ,821,3 0,204. ,411,5
period of the        548.0                                          069.45
                                                      1.07                                  42          0.56        08.60          87 13.47
prior year                 0

     Add:
changes in
accounting
policies

             Error
correction in the
prior periods


Merger of
enterprises
under the same
control


Others


                                                                                                                                         108
                                              The Half Year Report 2021 of Huadong Medicine Co., Ltd


II. Balance at     1,749
                           2,158,              861,68          9,852,        14,619 559,59 15,179
the beginning of ,809,              -2,191,
                           080,66               0,578.        441,59          ,821,3 0,204. ,411,5
the period of the 548.0             069.45
                             1.07                  42           0.56          08.60      87 13.47
current year          0

III. Amount of
change in the
                                    46,442                    901,00         947,45 61,207 1,008,
current period
                                    ,911.6                     9,928.         2,840. ,579.5 660,41
(Decreases are
                                         4                        52             16       9     9.75
indicated by
“-”)

(I) Total                           49,562                     1,300,         1,349, 42,161 1,392,
comprehensive                       ,711.3                    346,32         909,03 ,491.0 070,52
income                                   5                      4.85           6.20       0     7.20

(II) Capital
contributed by                                                                        19,046 19,046
owners and                                                                            ,088.5 ,088.5
capital                                                                                   9       9
decreases

1. Common
shares invested
by owners

2. Capital
invested by
holders of other
equity
instruments

3. Amount of
share-based
payment
included in
ownership
interest

                                                                                      19,046 19,046
4. Others                                                                             ,088.5 ,088.5
                                                                                          9       9

                                                              -402,4         -402,4           -402,4
(III) Profit
                                                              56,196         56,196           56,196
distribution
                                                                  .04           .04              .04

1. Withdrawal
of surplus
reserve



                                                                                                 109
                              The Half Year Report 2021 of Huadong Medicine Co., Ltd


2. Withdrawal
of general risk
reserve

3. Distribution                               -402,4         -402,4         -402,4
to owners (or                                 56,196         56,196         56,196
shareholders)                                     .04           .04            .04

4. Others

(IV) Internal
conversion of       -3,119,                    3,119,
ownership           799.71                    799.71
interest

1. Capital (or
share capital)
increase from
capital reserve
conversion

2. Capital (or
share capital)
increase from
surplus reserve
conversion

3. Recovery of
losses by
surplus reserve

4. Retained
earnings from
transfer of
changes in the
defined benefit
plan

5. Retained
earnings from
                    -3,119,                    3,119,
transfer of other
                    799.71                    799.71
comprehensive
income

6. Others

(V) Special
reserve

1. Withdrawal
in the current
period


                                                                                110
                                                                                      The Half Year Report 2021 of Huadong Medicine Co., Ltd


2. Use in the
current period

(VI) Others

                     1,749
IV. Balance at                                      2,158,           44,251             861,68             10,753         15,567 620,79 16,188
                      ,809,
the end of the                                     080,66             ,842.1             0,578.            ,451,5         ,274,1 7,784. ,071,9
                     548.0
current period                                        1.07                  9                 42            19.08          48.76         46 33.22
                           0

Amount in the previous period
                                                                                                                                   Unit: RMB yuan

                                                                   Amount for the first half of 2020

                                              Ownership interest attributable to the parent company

                                 Other equity                       Other
                                                                                                                                              Total
                                    instruments              Less: compr                                                          Minorit
      Item                                                                                                                                   owners
                     Share                                                     Specia Surplu Genera Undist
                                                  Capital Treasu ehensi                                                              y
                               Prefe Perp                                                                                                      hip
                     capita                                                       l      s         l risk ributed Others Total
                                                                                                                                  interest
                               rred etual Other reserve       ry      ve
                                                                                                                                             interest
                       l                                                       reserve reserve reserve profit
                               share bond     s              shares incom
                                s       s                              e

I. Balance at        1,749
                                                   2,158,           22,792             710,35             7,668,        12,309               12,866,
the end of the        ,809,                                                                                                       557,146
                                                  080,66            ,488.8             9,967.            434,64          ,477,3              624,239
period of the        548.0                                                                                                        ,931.87
                                                     1.07                  0                 51             2.62         08.00                    .87
prior year                 0

     Add:
Changes in
accounting
policies

             Error
correction in
the prior
periods


Merger of
enterprises
under the same
control


Others

II. Balance at       1,749
                                                   2,158,           22,792             710,35             7,668,        12,309               12,866,
the beginning         ,809,                                                                                                       557,146
                                                  080,66            ,488.8             9,967.            434,64          ,477,3              624,239
of the period of 548.0                                                                                                            ,931.87
                                                     1.07                  0                 51             2.62         08.00                    .87
the current year           0


                                                                                                                                                     111
                                     The Half Year Report 2021 of Huadong Medicine Co., Ltd


III. Amount of
change in the
                            38,749                  1,241,         1,279,             1,272,4
current period     -218,6                                                   -7,285,
                            ,338.2                  238,04        768,76              83,594.
(Decreases are     23.93                                                    167.82
                                3                     7.81           2.11                 29
indicated by
“-”)

(I) Total                   38,749                  1,731,         1,769,             1,813,9
                                                                            44,027,
comprehensive               ,338.2                  184,72        934,05              61,078.
                                                                            019.06
income                          3                     1.25           9.48                 54

(II) Capital
contributed by
owners and
capital
decreases

1. Common
shares invested
by owners

2. Capital
invested by
holders of other
equity
instruments

3. Amount of
share-based
payment
included in
ownership
interest

4. Others

                                                    -489,9         -489,9             -538,94
(III) Profit                                                                -49,000
                                                    46,673        46,673              6,673.4
distribution                                                                ,000.00
                                                       .44            .44                  4

1. Withdrawal
of surplus
reserve

2. Withdrawal
of general risk
reserve

3. Distribution                                     -489,9         -489,9             -538,94
                                                                            -49,000
to owners (or                                       46,673        46,673              6,673.4
                                                                            ,000.00
shareholders)                                          .44            .44                  4


                                                                                          112
                           The Half Year Report 2021 of Huadong Medicine Co., Ltd


4. Others

(IV) Internal
conversion of
ownership
interest

1. Capital (or
share capital)
increase from
capital reserve
conversion

2. Capital (or
share capital)
increase from
surplus reserve
conversion

3. Recovery of
losses by
surplus reserve

4. Retained
earnings from
transfer of
changes in the
defined benefit
plan

5. Retained
earnings from
transfer of
other
comprehensive
income

6. Others

(V) Special
reserve

1. Withdrawal
in the current
period

2. Use in the
current period

                  -218,6                                 -218,6 -2,312, -2,530,
(VI) Others
                  23.93                                   23.93 186.88 810.81




                                                                             113
                                                                                       The Half Year Report 2021 of Huadong Medicine Co., Ltd


                      1,749
IV. Balance at                                      2,157,            61,541            710,35             8,909,         13,589             14,139,
                      ,809,                                                                                                        549,861
the end of the                                      862,03            ,827.0            9,967.             672,69         ,246,0             107,834
                      548.0                                                                                                        ,764.05
current period                                           7.14                3              51               0.43          70.11                 .16
                         0


8. Statement of changes in ownership interest of the parent company

Amount in the current period
                                                                                                                                    Unit: RMB yuan

                                                                     Amount for the first half of 2021

                                          Other equity
                                                                                       Other
                                          instruments                       Less:                                     Undistr                Total
       Item            Share                                    Capital               compreh Special       Surplus
                                   Preferr Perpet                          Treasury                                   ibuted    Others ownership
                       capital                                  reserve               ensive     reserve    reserve
                                     ed       ual   Others                  shares                                    profit             interest
                                                                                      income
                                   shares bonds

I. Balance at the 1,749,8                                                                                             4,303,5
                                                                2,168,45              3,051,31 939,536,                                 9,164,382,
end of the period 09,548.                                                                                             33,798.
                                                                1,528.01                 1.29     337.86                                      524.04
of the prior year             00                                                                                          88

     Add:
Changes in
accounting
policies

            Error
correction in the
prior periods

            Others

II. Balance at the
                       1,749,8                                                                                        4,303,5
beginning of the                                                2,168,45              3,051,31 939,536,                                 9,164,382,
                       09,548.                                                                                        33,798.
period of the                                                   1,528.01                 1.29     337.86                                      524.04
                              00                                                                                          88
current year

III. Amount of
change in the                                                                                                         724,83
                                                                                                                                         724,839,5
current period                                                                                                        9,525.1
                                                                                                                                               25.18
(Decreases are                                                                                                             8
indicated by “-”)

(I) Total                                                                                                             1,127,2
                                                                                                                                        1,127,295,
comprehensive                                                                                                         95,721.
                                                                                                                                              721.22
income                                                                                                                    22

(II) Capital
contributed by
owners and


                                                                                                                                                     114
                     The Half Year Report 2021 of Huadong Medicine Co., Ltd


capital decreases

1. Common
shares invested
by owners

2. Capital
invested by
holders of other
equity
instruments

3. Amount of
share-based
payment
included in
ownership
interest

4. Others

                                              -402,45
(III) Profit                                                   -402,456,1
                                              6,196.0
distribution                                                        96.04
                                                    4

1. Withdrawal of
surplus reserve

2. Distribution to                            -402,45
                                                               -402,456,1
owners (or                                    6,196.0
                                                                    96.04
shareholders)                                       4

3. Others

(IV) Internal
conversion of
ownership
interest

1. Capital (or
share capital)
increase from
capital reserve
conversion

2. Capital (or
share capital)
increase from
surplus reserve
conversion

3. Recovery of
losses by surplus


                                                                       115
                                                                                  The Half Year Report 2021 of Huadong Medicine Co., Ltd


reserve

4. Retained
earnings from
transfer of
changes in the
defined benefit
plan

5. Retained
earnings from
transfer of other
comprehensive
income

6. Others

(V) Special
reserve

1. Withdrawal in
the current
period

2. Use in the
current period

(VI) Others

IV. Balance at       1,749,8                                                                                    5,028,3
                                                          2,168,45              3,051,31 939,536,                                      9,889,222,
the end of the       09,548.                                                                                    73,324.
                                                          1,528.01                     1.29   337.86                                      049.22
current period            00                                                                                            06

Amount in the previous period
                                                                                                                                  Unit: RMB yuan

                                                                  Amount for the first half of 2020

                                     Other equity
                                                                             Other
                                     instruments                    Less:                                   Undistrib                   Total
       Item         Share                               Capital              compre     Special   Surplus
                              Preferr Perpet                       Treasur                                    uted           Others   ownership
                    capital                             reserve              hensive    reserve   reserve
                                ed       ual   Others             y shares                                   profit                    interest
                                                                             income
                              shares bonds

I. Balance at the
                    1,749,                              2,168,4
end of the                                                                   847,526              788,215 3,431,594                   8,138,919,3
                    809,54                              51,528.
period of the                                                                    .06              ,726.95     ,974.14                      03.16
                      8.00                                   01
prior year

       Add:
Changes in
accounting
policies


                                                                                                                                                  116
                                             The Half Year Report 2021 of Huadong Medicine Co., Ltd


             Error
correction in
the prior
periods


Others

II. Balance at
                     1,749,   2,168,4
the beginning                           847,526          788,215 3,431,594            8,138,919,3
                     809,54   51,528.
of the period of                            .06           ,726.95     ,974.14               03.16
                       8.00       01
the current year

III. Amount of
change in the
current period                                                      831,772,2          831,772,22
(Decreases are                                                         20.51                 0.51
indicated by
“-”)

(I) Total
                                                                    1,321,718         1,321,718,8
comprehensive
                                                                      ,893.95               93.95
income

(II) Capital
contributed by
owners and
capital
decreases

1. Common
shares invested
by owners

2. Capital
invested by
holders of other
equity
instruments

3. Amount of
share-based
payment
included in
ownership
interest

4. Others

(III) Profit                                                        -489,946,         -489,946,67
distribution                                                          673.44                 3.44


                                                                                               117
                    The Half Year Report 2021 of Huadong Medicine Co., Ltd


1. Withdrawal
of surplus
reserve

2. Distribution
                                         -489,946,           -489,946,67
to owners (or
                                            673.44                  3.44
shareholders)

3. Others

(IV) Internal
conversion of
ownership
interest

1. Capital (or
share capital)
increase from
capital reserve
conversion

2. Capital (or
share capital)
increase from
surplus reserve
conversion

3. Recovery of
losses by
surplus reserve

4. Retained
earnings from
transfer of
changes in the
defined benefit
plan

5. Retained
earnings from
transfer of other
comprehensive
income

6. Others

(V) Special
reserve

1. Withdrawal
in the current
period


                                                                      118
                                         The Half Year Report 2021 of Huadong Medicine Co., Ltd


2. Use in the
current period

(VI) Others

IV. Balance at   1,749,   2,168,4
                                    847,526          788,215 4,263,367            8,970,691,5
the end of the   809,54   51,528.
                                        .06           ,726.95   ,194.65                 23.67
current period     8.00       01




                                                   Huadong Medicine Co., Ltd.

                                              Chairman of the Board: Lv Liang


                                                                       August 10, 2021




                                                                                           119